10/1873

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: 9-30-2003
Art Unit: 1654 Phone Number 308-3975 Serial Number: 10/072,419
Mail Box and Bldg/Room Location: CM1-11D13/CM1-9807 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Compositions And Methods For Promoting Lipid Mobilization In Humans

Inventors (please provide full names): B. Schacter, L. Schacter

Earliest Priority Filing Date: 2-7-2002 CORE

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search SEQ ID NO: 4 (ELNFSTGW) in STN, in the U.S. patent application sequence database (pending, issued, and published), and in Genesey/Swissprot/PIR.

Thank you.

JR

STAFF USE ONLY Point of Contact: Alexandra Waclawiw Technical Info. Specialist CM1 6A02 Tel: 308-4491

Searcher: _____
Searcher Phone #: _____
Searcher Location: A
Date Searcher Picked Up: 10-2-03
Date Completed: 10-2-03
Searcher Prep & Review Time: _____
Clerical Prep Time: _____
Online Time: _____

PT ... (illegible)

Type of Search

NA Sequence (#) _____
AA Sequence (#) 1
Structure (#) _____
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN ✓ $
Dialog _____
Questel/Orbit _____
Dr. Links _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify): compugen

```
$%^STN;HighlightOn=  ***;HighlightOff=***  ;
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:57:07 ON 02 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 OCT 2003  HIGHEST RN 596788-60-2
DICTIONARY FILE UPDATES:   1 OCT 2003  HIGHEST RN 596788-60-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d que l1
L1            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ELNFSTGW/SQSP


=> d l1 sqide 1-2

L1   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   577987-91-8  REGISTRY
CN   Glycine, L-.alpha.-glutamyl-L-leucyl-L-asparaginyl-L-phenylalanyl-L-seryl-
     L-threonylglycyl-L-tryptophylglycyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   36: PN: WO03066080 SEQID: 36 unclaimed sequence
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  10

SEQ      1 ELNFSTGWGG
           ========
HITS AT:   1-8
MF   C48 H66 N12 O16
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL

Absolute stereochemistry.


/ Structure 1 in file .gra /


**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              1 REFERENCES IN FILE CA (1907 TO DATE)
```

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS on STN
RN 149924-80-1 REGISTRY
CN Chromatophorotropin, red-pigment-concentrating (Pandalus borealis)
1-L-glutamic acid-6-L-threonine-8-L-tryptophan- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4: PN: WO03066080 SEQID: 4 unclaimed sequence
CN Protein (Schistocerca gregaria adipokinetic hormone II)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8

SEQ 1 ELNFSTGW
========
HITS AT: 1-8
MF C44 H60 N10 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

/ Structure 2 in file .gra /

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil hcpalus
'HCPALUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:57:20 ON 02 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Oct 2003 VOL 139 ISS 14
FILE LAST UPDATED: 1 Oct 2003 (20031001/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

```
=> d que nos l2
L1             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ELNFSTGW/SQSP
L2             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1


=> d .ca l2 1-2

L2   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:633493  HCAPLUS
DOCUMENT NUMBER:          139:173813
TITLE:                    Insect adipokinetic hormone peptide compositions and
                          methods for promoting lipid mobilization, glycogen
                          mobilization, or both, in humans, and screening
                          methods
INVENTOR(S):              Schacter, Bernice Z.; Schacter, Lee P.
PATENT ASSIGNEE(S):       BLM Group, USA
SOURCE:                   PCT Int. Appl., 82 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ----------------  ----  --------      ---------------  --------
     WO 2003066080      A1   20030814      WO 2003-US3800   20030207
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
             ML, MR, NE, SN, TD, TG
     US 2003162717      A1   20030828      US 2002-72419    20020207
PRIORITY APPLN. INFO.:                  US 2002-72419    A  20020207
OTHER SOURCE(S):          MARPAT 139:173813
AB   The invention provides methods of using polypeptide compds. based on the
     structures of insect peptides of the adipokinetic hormone family in humans
     for a variety of purposes, including mobilization of lipids and glycogen,
     inhibition of protein, lipid, and RNA synthesis, and enhancement of muscle
     contractility.  The compns. and methods are useful e.g. for modulating
     human body wt., inducing wt. loss, and alleviating glycogen storage
     disorders.  The invention also includes screening methods for identifying
     other compds. having similar activities in humans.
IC   ICM  A61K038-03
     ICS  A61K038-10; C07K007-06; C07K007-08; G01N033-68
CC   1-10 (Pharmacology)
     Section cross-reference(s): 12, 63
IT   22006-64-0, .alpha.1-13-Corticotropin   123466-63-7, Melanin-concentrating
     hormone (human reduced)   ***149924-80-1***     577986-95-9   577986-98-2
     577987-01-0   577987-06-5   577987-09-8   577987-16-7   577987-19-0
     577987-22-5   577987-25-8   577987-28-1   577987-31-6   577987-36-1
     577987-39-4   577987-44-1   577987-47-4   577987-52-1   577987-55-4
```

577987-58-7 577987-65-6 577987-68-9 577987-72-5 577987-75-8
577987-80-5 577987-83-8 577987-86-1 ***577987-91-8***
577987-94-1 577987-99-6 577988-02-4
RL: PRP (Properties)
(unclaimed sequence; insect adipokinetic hormone peptide compns. and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans, and screening methods)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:599933 HCAPLUS
DOCUMENT NUMBER: 119:199933
TITLE: AKH biosynthesis: transcriptional and translational control of two co-localized prohormones
AUTHOR(S): Fischer-Lougheed, Jacqueline; O'Shea, Michael; Cornish, Ian; Losberger, Christophe; Roulet, Emmanuelle; Schulz-Aellen, Marie Francoise
CORPORATE SOURCE: Sch. Biol. Sci., Univ. Sussex, Brighton, BN1 9QG, UK
SOURCE: Journal of Experimental Biology (1993), 177, 223-41
CODEN: JEBIAM; ISSN: 0022-0949
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The neurosecretory cells of the locust corpora cardiaca (CC) express w co-localized transcripts which are translated into the 2 preprohormones required in adipokinetic hormone I (AKH I) and AKH II biosynthesis. At different stages of postembryonic development, the relative amts. of the 2 transcripts (AKH I mRNA andAKH II mRNA) change in parallel with the relative rates of synthesis of proAKH I and proAKH II. Differential regulation of transcript expression, however, cannot account for the changes in neuropeptide ratios seen during postembryonic development. Comparison of in vivo and in vitro translation shows that protein synthesis in vivo is biased towards the translation of AKH I mRNA by a factor of .apprx.2.6. This factor appears to be const. during postembryonic development and is required to produce the obsd. developmental changes in neuropeptide ratios. Both transcriptional and translational mechanisms are therefore necessary to alter neuropeptide ratios in the CC. The mechanisms can account for the developmentally changing pattern of peptide expression. Regulation of neuropeptide ratios indicates that signalling functions can be attributed to the precise configuration of peptide cocktails.
CC 12-3 (Nonmammalian Biochemistry)
Section cross-reference(s): 3, 6
IT 130002-73-2, Protein (Schistocerca gregaria prepro-adipokinetic hormone I) 130093-13-9, Protein (Schistocerca gregaria prepro-adipokinetic hormone I C-terminal .alpha.-chain) ***149924-80-1*** , Protein (Schistocerca gregaria adipokinetic hormone II) 149924-81-2, Protein (Schistocerca gregaria adipokinetic hormone I) 150295-31-1, Protein (Schistocerca gregaria prepro-adipokinetic hormone II C-terminal .beta.-chain) 150679-74-6 150679-75-7, Protein (Schistocerca gregaria pro-adipokinetic hormone II) 150679-76-8, Protein (Schistocerca gregaria pro-adipokinetic hormone I)
RL: BIOL (Biological study)
(amino acid sequence and mRNA for, in development)

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 2, 2003, 08:40:01 ; Search time 83 Seconds
(without alignments)
15.299 Million cell updates/sec

Title: US-10-072-419-4
Perfect score: 47
Sequence: 1 ELNFSTGW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,

and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	38	80.9	10	20	AAY31073	Non-crosslinked pr
2	36	76.6	525	21	AAY51354	Protein b5pp with
3	36	76.6	525	22	AAB46810	P. patens delta6-d
4	36	76.6	525	23	ABG73602	P. patens D6 desat
5	36	76.6	525	23	ABG73607	P. patens delta6 d
6	36	76.6	525	23	ABG73609	P. patens delta6 d
7	36	76.6	525	23	ABB98277	Physcomitrella pat
8	35	74.5	102	22	AAO01790	Human polypeptide
9	35	74.5	183	22	AAE10429	Human matrix metal
10	35	74.5	206	21	AAY70007	Human Protease and
11	35	74.5	291	19	AAW52352	Bacillus subtilis
12	35	74.5	376	22	AAB48499	Staphylococcus aur
13	34	72.3	41	22	ABG52099	Human liver peptid
14	34	72.3	41	22	ABB32027	Peptide #4678 enco
15	34	72.3	41	22	ABB37277	Peptide #4783 enco
16	34	72.3	41	22	ABB22566	Protein #4565 enco
17	34	72.3	41	22	AAM57979	Human brain expres
18	34	72.3	41	22	AAM70409	Human bone marrow
19	34	72.3	41	22	AAM18246	Peptide #4680 enco
20	34	72.3	41	22	AAM30739	Peptide #4776 enco
21	34	72.3	41	22	AAM05858	Peptide #4540 enco
22	34	72.3	41	23	ABG40048	Human peptide enco
23	34	72.3	77	22	AAU60312	Propionibacterium
24	34	72.3	156	21	AAG33838	Arabidopsis thalia
25	34	72.3	157	22	ABG18088	Novel human diagno
26	34	72.3	804	22	AAB69038	Streptomyces sp. c
27	34	72.3	858	22	AAG64427	Chimeric CBD-fused
28	34	72.3	1297	22	AAB62491	P. chrysogenum ABC
29	33	70.2	90	23	ABP35217	Human ORF4190 prot
30	33	70.2	90	23	ABP05423	Human ORFX protein
31	33	70.2	333	22	ABG16843	Novel human diagno
32	33	70.2	380	23	ABP38985	Staphylococcus epi
33	33	70.2	417	21	AAG09076	Arabidopsis thalia
34	33	70.2	422	21	AAG09075	Arabidopsis thalia
35	33	70.2	425	21	AAG09074	Arabidopsis thalia
36	33	70.2	472	22	AAB79087	Corynebacterium gl
37	33	70.2	472	22	AAB79088	Corynebacterium gl
38	33	70.2	474	22	AAB67963	Amino acid sequenc
39	33	70.2	482	18	AAW22943	Barley alanine ami
40	33	70.2	482	22	AAB85486	Barley AlaAT prote
41	33	70.2	701	22	ABG25139	Novel human diagno
42	33	70.2	706	22	AAG92603	C glutamicum prote
43	33	70.2	2008	18	AAW22016	Utrophin truncated
44	33	70.2	2013	22	AAB67964	Amino acid sequenc
45	33	70.2	3433	18	AAW22017	Utrophin. Homo sa
46	32.5	69.1	990	16	AAR84660	Chondroitinase II.
47	32.5	69.1	990	16	AAR77460	Chondroitinase-II.
48	32.5	69.1	990	19	AAW37786	Amino acid sequenc
49	32.5	69.1	990	19	AAW39746	P. vulgaris chondr
50	32.5	69.1	990	20	AAW90075	P. vulgaris chondr

51	32.5	69.1	1013	15	AAR62535	P. vulgaris chondr
52	32.5	69.1	1013	18	AAW09398	Proteus vulgaris c
53	32	68.1	53	22	AAU50425	Propionibacterium
54	32	68.1	55	21	AAG01803	Human secreted pro
55	32	68.1	55	22	AAM87298	Human immune/haema
56	32	68.1	72	23	AAU83509	Novel human ion ch
57	32	68.1	75	22	AAO08089	Human polypeptide
58	32	68.1	94	21	AAG56966	Arabidopsis thalia
59	32	68.1	110	22	AAU48245	Propionibacterium
60	32	68.1	115	21	AAG56965	Arabidopsis thalia
61	32	68.1	115	22	AAU62328	Propionibacterium
62	32	68.1	128	22	AAE07023	Human heavy chain
63	32	68.1	148	22	AAM23509	Murine EST encoded
64	32	68.1	208	22	AAU17087	Novel signal trans
65	32	68.1	208	22	AAU17513	Novel signal trans
66	32	68.1	219	22	AAB63432	Human breast cance
67	32	68.1	233	21	AAB41888	Human ORFX ORF1652
68	32	68.1	236	20	AAY03141	Heparin sulphate 6
69	32	68.1	236	20	AAY03142	Heparin sulphate 6
70	32	68.1	255	22	ABG18084	Novel human diagno
71	32	68.1	272	24	ABR38888	Surface exposed im
72	32	68.1	272	24	ABP57985	Outer membrane ass
73	32	68.1	283	22	AAM24140	Murine EST encoded
74	32	68.1	290	23	ABP43902	PAC97K10 protein.
75	32	68.1	324	22	AAB92699	Human protein sequ
76	32	68.1	382	22	AAB93973	Human protein sequ
77	32	68.1	401	20	AAY03143	Heparin sulphate 6
78	32	68.1	401	20	AAY03144	Heparin sulphate 6
79	32	68.1	401	21	AAY83903	Mouse HS6ST3 prote
80	32	68.1	401	24	AAO26607	Human 6-OST-1 prot
81	32	68.1	410	20	AAY03140	Heparin sulphate 6
82	32	68.1	410	21	AAB41787	Human ORFX ORF1551
83	32	68.1	410	21	AAY83900	Human HS6ST1 prote
84	32	68.1	438	23	ABB89683	Human polypeptide
85	32	68.1	459	22	AAB93310	Human protein sequ
86	32	68.1	459	23	ABB06194	Human HS6ST2v prot
87	32	68.1	459	23	AAE14449	Human drug metabol
88	32	68.1	460	24	ABP71362	Human AK polypepti
89	32	68.1	462	22	AAB94993	Human protein sequ
90	32	68.1	465	22	AAB88474	Human membrane or
91	32	68.1	465	24	AAO26608	Human 6-OST-2A pro
92	32	68.1	469	24	ABP71364	Mouse H6ST-3 prote
93	32	68.1	470	21	AAY83902	Mouse HS6ST2 prote
94	32	68.1	471	24	AAO26610	Human 6-OST-3 prot
95	32	68.1	499	23	AAE21048	Human drug metabol
96	32	68.1	499	23	ABB06195	Human HS6ST2 prote
97	32	68.1	504	24	AAO26609	Human 6-OST-2B pro
98	32	68.1	506	21	AAY83901	Mouse HS6ST1 prote
99	32	68.1	506	24	ABP71363	Mouse H6ST-2 prote
100	32	68.1	508	23	AAE21053	Human drug metabol

ALIGNMENTS

RESULT 1
AAY31073

ID AAY31073 standard; peptide; 10 AA.
XX
AC AAY31073;
XX
DT 21-OCT-1999 (first entry)
XX
DE Non-crosslinked protein particle peptide 122.
XX
KW Non-crosslinked protein particle; diagnostic; therapy; monodisperse;
KW albumin; haemoglobin; nanometer; micrometer; clearance.
XX
OS Synthetic.
XX
FH Key   Location/Qualifiers
FT Modified-site   1
FT   /note= "pyroglutamic acid"
FT Modified-site   10
FT   /note= "C-terminal amide"
XX
PN US5945033-A.
XX
PD 31-AUG-1999.
XX
PF 12-NOV-1996;   96US-0747137.
XX
PR 14-MAR-1994;   94US-0212546.
PR 15-JAN-1991;   91US-0641720.
PR 13-OCT-1992;   92US-0959560.
PR 01-JUN-1993;   93US-0069831.
PR 12-NOV-1996;   96US-0747137.
XX
PA (HEMO-) HEMOSPHERE INC.
XX
PI Yen RCK;
XX
DR WPI; 1999-508153/42.
XX
PT Non-crosslinked protein particles for therapeutic and diagnostic use
XX
PS Example 22; Column 103-104; 65pp; English.
XX
CC This invention describes a novel aqueous suspension of monodisperse
CC particles on non-crosslinked, non-denatured albumin (50-5000 nm) which
CC is stable against dissolving upon dilution with an alcohol-free aqueous
CC medium. The method involves (a) forming an aqueous solution containing
CC albumin and hemoglobin and (b) treating the aqueous solution with an
CC alcohol to cause the solution to become turbid. The particles are useful
CC as agents for in vivo administration, either of their own administration
CC or as a vehicle for other therapeutic or diagnostic agents. The method
CC permits the formation of albumin and hemoglobin particles in the
CC nanometer and micrometer size range, in a form closer to their natural
CC form than the forms of the prior art. The particles therefore constitute
CC a more closely controlled agent for in vivo administration, with greater
CC ease of clearance from the body after their period of usefulness.
CC AAY30952-Y31135 represent peptides used in the method of the invention.
XX
SQ Sequence   10 AA;

```
  Query Match             80.9%;  Score 38;  DB 20;  Length 10;
  Best Local Similarity   75.0%;  Pred. No. 0.64;
  Matches    6;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 ELNFSTGW 8
              |:||| ||
Db          1 EVNFSPGW 8



Search completed: October  2, 2003, 08:50:39
Job time : 86 secs

                                GenCore version 5.1.6
                          Copyright (c) 1993 - 2003  Compugen Ltd.


OM protein - protein search, using sw model

Run on:          October  2, 2003, 08:49:12 ; Search time 29 Seconds
                                             (without alignments)
                                             11.672 Million cell updates/sec

Title:           US-10-072-419-4
Perfect score:   47
Sequence:        1 ELNFSTGW 8

Scoring table:   BLOSUM62
                 Gapop 10.0 , Gapext 0.5

Searched:        328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters:      328717

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 100 summaries

Database :        Issued_Patents_AA:*
                1:  /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
                2:  /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
                3:  /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
                4:  /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
                5:  /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
                6:  /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

     Pred. No. is the number of results predicted by chance to have a
     score greater than or equal to the score of the result being printed,
     and is derived by analysis of the total score distribution.

                                   SUMMARIES

                    %
Result            Query
```

No.	Score	Match	Length	DB	ID	Description
1	35	74.5	376	4	US-09-564-954-2	Sequence 2, Appli
2	34	72.3	339	4	US-09-252-991A-29085	Sequence 29085, A
3	33	70.2	10	2	US-08-747-137-122	Sequence 122, App
4	33	70.2	300	4	US-09-091-501B-11	Sequence 11, Appl
5	33	70.2	300	4	US-09-091-501B-12	Sequence 12, Appl
6	33	70.2	300	4	US-09-091-501B-13	Sequence 13, Appl
7	33	70.2	380	4	US-09-134-001C-3830	Sequence 3830, Ap
8	33	70.2	2008	4	US-09-091-501B-8	Sequence 8, Appli
9	33	70.2	3433	4	US-09-091-501B-10	Sequence 10, Appl
10	32.5	69.1	990	1	US-08-232-540-2	Sequence 2, Appli
11	32.5	69.1	990	1	US-08-428-949A-2	Sequence 2, Appli
12	32.5	69.1	990	1	US-08-428-948A-2	Sequence 2, Appli
13	32.5	69.1	990	2	US-08-428-946-2	Sequence 2, Appli
14	32.5	69.1	990	5	PCT-US95-04656-2	Sequence 2, Appli
15	32.5	69.1	1013	1	US-08-233-008A-8	Sequence 8, Appli
16	32	68.1	91	3	US-08-851-843A-220	Sequence 220, App
17	32	68.1	91	3	US-08-974-549A-339	Sequence 339, App
18	32	68.1	91	3	US-08-854-050-220	Sequence 220, App
19	32	68.1	91	4	US-09-430-323-220	Sequence 220, App
20	32	68.1	434	4	US-09-252-991A-18011	Sequence 18011, A
21	32	68.1	820	4	US-09-252-991A-25454	Sequence 25454, A
22	31	66.0	241	4	US-09-328-352-5020	Sequence 5020, Ap
23	31	66.0	265	4	US-09-742-693-30	Sequence 30, Appl
24	31	66.0	389	4	US-09-328-352-7099	Sequence 7099, Ap
25	31	66.0	535	3	US-08-813-574-2	Sequence 2, Appli
26	31	66.0	997	4	US-09-252-991A-30799	Sequence 30799, A
27	31	66.0	2710	1	US-08-480-604A-6	Sequence 6, Appli
28	31	66.0	2710	2	US-08-405-496A-6	Sequence 6, Appli
29	31	66.0	2710	3	US-08-915-136-6	Sequence 6, Appli
30	31	66.0	2710	4	US-08-957-310-6	Sequence 6, Appli
31	31	66.0	2710	4	US-10-011-366-6	Sequence 6, Appli
32	31	66.0	2864	4	US-08-469-260A-394	Sequence 394, App
33	31	66.0	2864	4	US-08-488-446-394	Sequence 394, App
34	31	66.0	2864	4	US-08-467-344A-394	Sequence 394, App
35	30	63.8	38	2	US-08-867-087B-44	Sequence 44, Appl
36	30	63.8	133	4	US-09-072-596-283	Sequence 283, App
37	30	63.8	200	4	US-09-252-991A-26936	Sequence 26936, A
38	30	63.8	211	4	US-09-252-991A-30029	Sequence 30029, A
39	30	63.8	307	2	US-08-782-760-6	Sequence 6, Appli
40	30	63.8	307	5	PCT-US96-00995-6	Sequence 6, Appli
41	30	63.8	396	1	US-07-649-591B-4	Sequence 4, Appli
42	30	63.8	396	1	US-08-277-540-4	Sequence 4, Appli
43	30	63.8	396	1	US-08-430-787A-4	Sequence 4, Appli
44	30	63.8	518	4	US-09-134-001C-4348	Sequence 4348, Ap
45	30	63.8	607	1	US-07-959-943-7	Sequence 7, Appli
46	30	63.8	607	1	US-07-879-617A-12	Sequence 12, Appl
47	30	63.8	607	1	US-08-753-985-12	Sequence 12, Appl
48	30	63.8	630	1	US-07-959-943-9	Sequence 9, Appli
49	30	63.8	630	1	US-07-959-943-11	Sequence 11, Appl
50	30	63.8	807	4	US-09-177-650-3	Sequence 3, Appli
51	30	63.8	866	2	US-08-483-101-4	Sequence 4, Appli
52	30	63.8	1711	2	US-08-342-930-2	Sequence 2, Appli
53	30	63.8	1881	4	US-09-233-086-3	Sequence 3, Appli
54	29	61.7	39	2	US-08-867-087B-42	Sequence 42, Appl
55	29	61.7	40	2	US-08-867-087B-43	Sequence 43, Appl

56	29	61.7	126	4	US-09-554-765-7	Sequence 7, Appli
57	29	61.7	147	4	US-09-554-765-10	Sequence 10, Appl
58	29	61.7	189	1	US-08-709-912-13	Sequence 13, Appl
59	29	61.7	189	2	US-09-047-370-13	Sequence 13, Appl
60	29	61.7	235	4	US-09-328-352-6859	Sequence 6859, Ap
61	29	61.7	250	2	US-08-867-087B-13	Sequence 13, Appl
62	29	61.7	261	4	US-09-252-991A-33140	Sequence 33140, A
63	29	61.7	263	2	US-08-206-790A-23	Sequence 23, Appl
64	29	61.7	263	4	US-09-311-784A-28	Sequence 28, Appl
65	29	61.7	263	5	PCT-US95-02943-23	Sequence 23, Appl
66	29	61.7	302	4	US-09-585-858-54	Sequence 54, Appl
67	29	61.7	303	3	US-08-818-112-92	Sequence 92, Appl
68	29	61.7	303	4	US-08-818-111-93	Sequence 93, Appl
69	29	61.7	303	4	US-09-056-556-92	Sequence 92, Appl
70	29	61.7	303	4	US-09-072-596-93	Sequence 93, Appl
71	29	61.7	306	1	US-08-696-139-4	Sequence 4, Appli
72	29	61.7	310	4	US-09-328-352-5485	Sequence 5485, Ap
73	29	61.7	312	1	US-08-525-505A-4	Sequence 4, Appli
74	29	61.7	314	1	US-08-525-505A-2	Sequence 2, Appli
75	29	61.7	321	4	US-09-252-991A-26066	Sequence 26066, A
76	29	61.7	329	4	US-09-011-769A-51	Sequence 51, Appl
77	29	61.7	331	4	US-09-252-991A-28430	Sequence 28430, A
78	29	61.7	346	2	US-07-952-853-24	Sequence 24, Appl
79	29	61.7	346	2	US-08-914-848-24	Sequence 24, Appl
80	29	61.7	349	4	US-09-011-769A-47	Sequence 47, Appl
81	29	61.7	349	4	US-09-011-769A-60	Sequence 60, Appl
82	29	61.7	349	4	US-09-011-769A-64	Sequence 64, Appl
83	29	61.7	367	4	US-09-328-352-7478	Sequence 7478, Ap
84	29	61.7	372	4	US-09-252-991A-18963	Sequence 18963, A
85	29	61.7	383	3	US-09-357-251-26	Sequence 26, Appl
86	29	61.7	404	1	US-08-696-139-2	Sequence 2, Appli
87	29	61.7	409	4	US-09-554-765-14	Sequence 14, Appl
88	29	61.7	415	2	US-08-860-882A-57	Sequence 57, Appl
89	29	61.7	415	4	US-09-011-769A-39	Sequence 39, Appl
90	29	61.7	424	4	US-09-011-769A-56	Sequence 56, Appl
91	29	61.7	432	3	US-09-306-595C-8	Sequence 8, Appli
92	29	61.7	432	4	US-09-925-388-8	Sequence 8, Appli
93	29	61.7	477	4	US-09-328-352-6549	Sequence 6549, Ap
94	29	61.7	489	4	US-09-328-352-5088	Sequence 5088, Ap
95	29	61.7	538	4	US-09-252-991A-23060	Sequence 23060, A
96	29	61.7	549	4	US-09-107-532A-7304	Sequence 7304, Ap
97	29	61.7	558	4	US-09-328-352-5987	Sequence 5987, Ap
98	29	61.7	580	1	US-08-309-512-6	Sequence 6, Appli
99	29	61.7	580	5	PCT-US92-08756A-6	Sequence 6, Appli
100	29	61.7	613	3	US-09-171-945-113	Sequence 113, App

ALIGNMENTS

RESULT 1
US-09-564-954-2
; Sequence 2, Application US/09564954
; Patent No. 6406889
; GENERAL INFORMATION:
; APPLICANT: Bae, Weonhye
; APPLICANT: Van Horn, Stephanie

```
;  APPLICANT:  Warren, Richard L.
;  APPLICANT:  Biswas, Sanjoy
;  APPLICANT:  Throup, John P.
;  APPLICANT:  Burnham, Martin K. R.
;  TITLE OF INVENTION:  509HK
;  FILE REFERENCE:  GM10220HK
;  CURRENT APPLICATION NUMBER: US/09/564,954
;  CURRENT FILING DATE:  2000-05-04
;  PRIOR APPLICATION NUMBER:  US 60/132,935
;  PRIOR FILING DATE:  1999-05-06
;  NUMBER OF SEQ ID NOS:  2
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 376
;   TYPE: PRT
;   ORGANISM: Staphylococcus aureus
US-09-564-954-2

  Query Match             74.5%;  Score 35;  DB 4;  Length 376;
  Best Local Similarity   83.3%;  Pred. No. 43;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 NFSTGW 8
              ||:|||
Db         45 NFTTGW 50



RESULT 3
US-08-747-137-122
; Sequence 122, Application US/08747137
; Patent No. 5945033
;  GENERAL INFORMATION:
;    APPLICANT:  YEN, Richard C.K.
;    TITLE OF INVENTION:  NON-CROSSLINKED PROTEIN PARTICLES FOR
;    TITLE OF INVENTION:  THERAPEUTIC AND DIAGNOSTIC USE
;    NUMBER OF SEQUENCES:  184
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/747,137
;      FILING DATE:  12-NOV-1996
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/212,546
;      FILING DATE:  14-MAR-1994
;    PRIOR APPLICATION DATA:
```

```
;       APPLICATION NUMBER:  US 08/069,831
;       FILING DATE:  01-JUN-1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/959,560
;       FILING DATE:  13-OCT-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/641,720
;       FILING DATE:  15-JAN-1991
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Apple, Randolph T.
;       REGISTRATION NUMBER:  36,429
;       REFERENCE/DOCKET NUMBER:  016197-000840US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-576-0200
;   INFORMATION FOR SEQ ID NO:  122:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10 amino acids
;       TYPE:  amino acid
;       STRANDEDNESS:  not relevant
;       TOPOLOGY:  not relevant
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  1
;       OTHER INFORMATION:  /product= "p-Glu"
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  10
;       OTHER INFORMATION:  /product= "Thr-Amide"
US-08-747-137-122

  Query Match             70.2%;  Score 33;  DB 2;  Length 10;
  Best Local Similarity   71.4%;  Pred. No. 2.4;
  Matches    5;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 LNFSTGW 8
              :||| ||
Db          2 VNFSPGW 8


Search completed: October  2, 2003, 08:54:13
Job time : 32 secs

                          GenCore version 5.1.6
                 Copyright (c) 1993 - 2003  Compugen Ltd.


OM protein - protein search, using sw model

Run on:         October  2, 2003, 08:47:57 ; Search time 39 Seconds
                                            (without alignments)
                                            19.727 Million cell updates/sec

Title:          US-10-072-419-4
Perfect score:  47
Sequence:       1 ELNFSTGW 8

Scoring table:  BLOSUM62
```

Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : PIR_76:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	44	93.6	61	1	AKLQS2	adipokinetic hormo
2	44	93.6	61	1	B34913	adipokinetic hormo
3	41	87.2	8	2	A28004	adipokinetic hormo
4	39	83.0	61	1	AKLQL2	adipokinetic hormo
5	38	80.9	8	2	A61348	red pigment-concen
6	38	80.9	110	1	JN0761	red pigment-concen
7	38	80.9	282	2	T29279	hypothetical prote
8	38	80.9	371	2	T24853	hypothetical prote
9	36	76.6	315	2	T25171	hypothetical prote
10	36	76.6	331	2	T28948	hypothetical prote
11	36	76.6	341	2	T21400	hypothetical prote
12	36	76.6	346	2	T24567	hypothetical prote
13	36	76.6	346	2	T24568	hypothetical prote
14	35	74.5	10	2	A60421	hypertrehalosemic
15	35	74.5	10	2	S08997	hypertrehalosemic
16	35	74.5	10	2	S08998	hypertrehalosemic
17	35	74.5	10	2	A26381	hypertrehalosemic
18	35	74.5	301	2	A88931	protein R11G11.15
19	35	74.5	336	2	T34162	hypothetical prote
20	35	74.5	349	2	S74499	phosphoglycerate m
21	35	74.5	370	2	H89971	hypothetical prote
22	35	74.5	747	2	H82943	hypothetical prote
23	35	74.5	915	2	T21773	hypothetical prote
24	35	74.5	927	2	T21772	hypothetical prote
25	34	72.3	10	2	A31571	hypertrehalosemic/
26	34	72.3	42	2	C39853	alkanal monooxygen
27	34	72.3	108	2	T29281	hypothetical prote
28	34	72.3	287	2	T29280	hypothetical prote
29	34	72.3	339	2	A83539	hypothetical prote

30	34	72.3	346	1	JH0387	alkanal monooxygen
31	34	72.3	354	2	JQ0413	alkanal monooxygen
32	34	72.3	412	2	T40295	fructosyl amine -
33	34	72.3	465	2	T16618	hypothetical prote
34	34	72.3	1090	2	C86450	F5D14.27 protein -
35	33	70.2	168	2	T17790	hypothetical prote
36	33	70.2	276	2	T50896	hypothetical membr
37	33	70.2	294	2	JQ0798	nucleoside-specifi
38	33	70.2	294	2	H90686	nucleoside-specifi
39	33	70.2	294	2	D85537	hypothetical prote
40	33	70.2	396	2	AH3375	serine-type D-Ala-
41	33	70.2	420	2	T06000	aspartic proteinas
42	33	70.2	438	2	T04800	CDP-diacylglycerol
43	33	70.2	482	2	S42535	alanine transamina
44	33	70.2	521	2	T11710	probable amino aci
45	33	70.2	522	2	T39281	ars binding protei
46	33	70.2	538	2	S65764	chitinase (EC 3.2.
47	33	70.2	559	2	C72732	probable medium-ch
48	33	70.2	591	1	SYBYKT	lysine-tRNA ligase
49	33	70.2	627	2	S67257	proline transport
50	33	70.2	682	2	F81332	probable periplasm
51	33	70.2	3433	1	S28381	utrophin - human
52	32	68.1	8	2	A43976	hypertrehalosemic
53	32	68.1	8	2	B43976	hypertrehalosemic
54	32	68.1	8	2	S55310	adipokinetic hormo
55	32	68.1	8	2	A58620	adipokinetic hormo
56	32	68.1	8	2	A05169	neuropeptide M-I -
57	32	68.1	82	2	E82754	hypothetical prote
58	32	68.1	110	2	S26167	capsid assembly pr
59	32	68.1	115	2	T36887	hypothetical prote
60	32	68.1	214	2	T11966	lipoate biosynthes
61	32	68.1	339	2	AC2153	hypothetical prote
62	32	68.1	364	2	A82860	DNA replication an
63	32	68.1	366	2	T21166	hypothetical prote
64	32	68.1	374	2	G88955	protein K04F1.6 [i
65	32	68.1	402	2	C97132	hypothetical prote
66	32	68.1	429	2	AI2611	Sun protein [impor
67	32	68.1	429	2	G97393	sun-family protein
68	32	68.1	430	2	H83178	conserved hypothet
69	32	68.1	445	2	C69233	lysyl endopeptidas
70	32	68.1	446	2	H90507	amino acid transpo
71	32	68.1	477	2	F82200	cytochrome-c oxida
72	32	68.1	551	2	H95301	FixN3 cytochrome c
73	32	68.1	631	2	T33559	hypothetical prote
74	32	68.1	660	2	D91176	heme utilization/t
75	32	68.1	660	2	E86022	outer membrane hem
76	32	68.1	714	2	T32386	hypothetical prote
77	32	68.1	785	2	T00474	hypothetical prote
78	32	68.1	813	2	A40601	ferripyoverdine re
79	32	68.1	815	2	H83345	ferripyoverdine re
80	32	68.1	868	2	T25716	hypothetical prote
81	32	68.1	1024	2	T30868	RhoA-binding prote
82	32	68.1	1117	2	C91286	hypothetical prote
83	32	68.1	1117	2	G86127	hypothetical prote
84	32	68.1	1121	2	T25715	hypothetical prote
85	32	68.1	1418	2	D75281	ribonucleoside-dip
86	32	68.1	1475	2	A60026	cell communication

87	32	68.1	2123	2	S55089	probable acetyl-Co
88	32	68.1	2326	2	T29140	hypothetical prote
89	32	68.1	2489	2	S59782	probable membrane
90	31	66.0	8	2	S21663	neuropeptide - flo
91	31	66.0	104	2	H69261	hypothetical prote
92	31	66.0	171	2	E97074	probable acetyltra
93	31	66.0	176	2	E95274	hypothetical prote
94	31	66.0	190	2	B84989	50S ribosomal prot
95	31	66.0	211	2	S43214	phosphoglycerate m
96	31	66.0	229	2	AE1350	phosphoglyceromuta
97	31	66.0	229	2	AH1720	phosphoglyceromuta
98	31	66.0	287	2	AD1388	conserved hypothet
99	31	66.0	287	2	AF1763	conserved hypothet
100	31	66.0	315	2	E83064	hypothetical prote

ALIGNMENTS

RESULT 1
AKLQS2
adipokinetic hormone II precursor - desert locust
N;Alternate names: adipokinetic hormone II precursor-related peptide;
adipokinetic hormone precursor-related peptide beta chain; APRP beta chain; Scg-AKH-II
N;Contains: adipokinetic hormone II; adipokinetic hormone-associated peptide II
C;Species: Schistocerca gregaria (desert locust)
C;Date: 31-Mar-1988 #sequence_revision 14-Nov-1997 #text_change 20-Mar-1998
C;Accession: A58662; A44822; A25204; A24241
R;Fischer-Lougheed, J.; O'Shea, M.; Cornish, I.; Losberger, C.; Roulet, E.; Schulz-Aellen, M.F.
J. Exp. Biol. 177, 223-241, 1993
A;Title: AKH biosynthesis: transcriptional and translational control of two co-localised prohormones.
A;Reference number: A58662
A;Accession: A58662
A;Molecule type: mRNA
A;Residues: 1-61 <FIS>
R;Hekimi, S.; Fischer-Lougheed, J.; O'Shea, M.
J. Neurosci. 11, 3246-3256, 1991
A;Title: Regulation of neuropeptide stoichiometry in neurosecretory cells.
A;Reference number: A44822; MUID:92044772; PMID:1941082
A;Accession: A44822
A;Molecule type: protein
A;Residues: 'E',24-45,'T',47-61 <HEK>
A;Experimental source: neurosecretory cells, corpora cardiaca
A;Note: sequence extracted from NCBI backbone (NCBIP:63239)
R;Siegert, K.; Morgan, P.; Mordue, W.
Biol. Chem. Hoppe-Seyler 366, 723-727, 1985
A;Title: Primary structures of locust adipokinetic hormones II.
A;Reference number: A90692; MUID:86050918; PMID:4063072
A;Accession: A25204
A;Molecule type: protein
A;Residues: 23-30 <SIE>
R;Gade, G.; Goldsworthy, G.J.; Schaffer, M.H.; Cook, J.C.; Rinehart Jr., K.L.
Biochem. Biophys. Res. Commun. 134, 723-730, 1986

A;Title: Sequence analyses of adipokinetic hormones II from corpora cardiaca of Schistocerca nitans, Schistocerca gregaria, and Locusta migratoria by fast atom bombardment mass spectrometry.
A;Reference number: A24241; MUID:86130555; PMID:3947348
A;Accession: A24241
A;Molecule type: protein
A;Residues: 'E',24-30 <GAD>
C;Complex: forms disulfide linked homodimers; disulfide linked heterodimers form between adipokinetic hormone-associated peptides I and II
C;Function:
A;Description: hormone, released from the corpora cardiaca after the beginning of flight, causes release of diglycerides from the fat body and then stimulates the flight muscles to use diglycerides as an energy source
C;Superfamily: adipokinetic hormone
C;Keywords: amidated carboxyl end; corpora cardiaca; heterodimer; homodimer; hormone; neuropeptide; pyroglutamic acid
F;1-22/Domain: signal sequence #status predicted <SIG>
F;23-30/Product: adipokinetic hormone II #status experimental <MAT1>
F;34-61/Product: adipokinetic hormone-associated peptide II #status experimental <MAT2>
F;23/Modified site: pyrrolidone carboxylic acid (Gln) (in mature form) #status experimental
F;30/Modified site: amidated carboxyl end (Trp) (amide in mature form from following glycine) #status experimental
F;59/Disulfide bonds: interchain (partial) #status experimental
F;59/Disulfide bonds: interchain (to adipokinetic hormone-associated peptide I 59) (partial) #status experimental

  Query Match 93.6%; Score 44; DB 1; Length 61;
  Best Local Similarity 87.5%; Pred. No. 0.095;
  Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 ELNFSTGW 8
              :|||||||
Db         23 QLNFSTGW 30
```

RESULT 3
A28004
adipokinetic hormone G - two-spotted cricket
N;Alternate names: AKH-G
C;Species: Gryllus bimaculatus (two-spotted cricket)
C;Date: 30-Jun-1989 #sequence_revision 24-Oct-1997 #text_change 24-Oct-1997
C;Accession: A28004
R;Gaede, G.; Rinehart, K.L.
Biochem. Biophys. Res. Commun. 149, 908-914, 1987
A;Title: Primary sequence analysis by fast atom bombardment mass spectrometry of a peptide with adipokinetic activity from the corpora cardiaca of the cricket Gryllus bimaculatus.
A;Reference number: A28004; MUID:88106553; PMID:3426616
A;Accession: A28004
A;Molecule type: protein
A;Residues: 1-8 <GAE>
A;Note: the amino-terminal residue forms pyrrolidone carboxylic acid; therefore, we have shown it as Gln
C;Superfamily: adipokinetic hormone

C;Keywords: amidated carboxyl end; corpora cardiaca; hormone; neuropeptide;
pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;8/Modified site: amidated carboxyl end (Trp) #status experimental

  Query Match   87.2%; Score 41; DB 2; Length 8;
  Best Local Similarity   75.0%; Pred. No. 2.8e+05;
  Matches   6; Conservative   2; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 ELNFSTGW 8
              ::||||||
Db          1 QVNFSTGW 8
```

Search completed: October 2, 2003, 08:53:39
Job time : 44 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 08:40:31 ; Search time 23 Seconds
(without alignments)
16.357 Million cell updates/sec

Title: US-10-072-419-4
Perfect score: 47
Sequence: 1 ELNFSTGW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : SwissProt_41:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	44	93.6	39	1	AKH2_SCHGR	P35808 schistocerc

2	44	93.6	61	1	AKH2_SCHNI	P35807 schistocerc
3	41	87.2	8	1	AKHG_GRYBI	P14086 gryllus bim
4	39	83.0	61	1	AKH2_LOCMI	P08379 locusta mig
5	38	80.9	8	1	RPCH_PANBO	P08939 pandalus bo
6	38	80.9	109	1	RPCH_CALSI	Q23757 callinectes
7	38	80.9	110	1	RPCH_CARMA	Q26324 carcinus ma
8	35	74.5	10	1	HTF_NAUCI	P10939 nauphoeta c
9	35	74.5	72	1	HTF_BLADI	Q17128 blaberus di
10	35	74.5	747	1	Y030_UREPA	Q9prb5 ureaplasma
11	34	72.3	10	1	HTF_HELZE	P16353 heliothis z
12	34	72.3	346	1	LUXA_PHOPO	P24113 photobacter
13	34	72.3	354	1	LXA1_PHOLE	P09140 photobacter
14	33	70.2	214	1	LAZA_SCHAM	P49291 schistocerc
15	33	70.2	294	1	TSX_ECOLI	P22786 escherichia
16	33	70.2	482	1	ALA2_HORVU	P52894 hordeum vul
17	33	70.2	521	1	YCV4_SCHPO	O74543 schizosacch
18	33	70.2	522	1	ABP1_SCHPO	P49777 schizosacch
19	33	70.2	590	1	SYKC_YEAST	P15180 saccharomyc
20	33	70.2	627	1	PUT4_YEAST	P15380 saccharomyc
21	33	70.2	3433	1	UTRO_HUMAN	P46939 homo sapien
22	32	68.1	8	1	HTF_TENMO	P25419 tenebrio mo
23	32	68.1	110	1	Y12M_BPT4	Q00305 bacteriopha
24	32	68.1	214	1	LIPB_CYACA	O19898 cyanidium c
25	32	68.1	232	1	GPMA_BUCBP	Q89aj4 buchnera ap
26	32	68.1	364	1	RECF_XYLFA	Q9phe1 xylella fas
27	32	68.1	593	1	TARA_HUMAN	Q9h2d6 homo sapien
28	32	68.1	815	1	FPVA_PSEAE	P48632 pseudomonas
29	32	68.1	1024	1	RIP3_MOUSE	P97434 mus musculu
30	32	68.1	1029	1	RIP3_RAT	Q9ere6 rattus norv
31	32	68.1	1475	1	TRA2_CAEEL	P34709 caenorhabdi
32	32	68.1	2273	1	HFA1_YEAST	P32874 saccharomyc
33	31	66.0	104	1	Y096_ARCFU	O30140 archaeoglob
34	31	66.0	178	1	RL6_BUCAI	P57576 buchnera ap
35	31	66.0	211	1	PMGY_SCHPO	P36623 schizosacch
36	31	66.0	229	1	GPMA_LISIN	Q929g8 listeria in
37	31	66.0	229	1	GPMA_LISMO	Q8y571 listeria mo
38	31	66.0	321	1	ABNA_ASPNG	P42256 aspergillus
39	31	66.0	338	1	YP79_CAEEL	Q09439 caenorhabdi
40	31	66.0	463	1	VNFK_ANAVA	Q57302 anabaena va
41	31	66.0	494	1	G6PD_ACTAC	P77809 actinobacil
42	31	66.0	494	1	G6PD_HAEIN	P44311 haemophilus
43	31	66.0	512	1	EMRY_ECOLI	P52600 escherichia
44	31	66.0	513	1	PDI_HORVU	P80284 hordeum vul
45	31	66.0	513	1	PDI_MAIZE	P52588 zea mays (m
46	31	66.0	515	1	PDI_WHEAT	P52589 triticum ae
47	31	66.0	517	1	GUNA_CLOLO	P54937 clostridium
48	31	66.0	676	1	HMUR_YERPE	Q56989 yersinia pe
49	31	66.0	677	1	VGP_EBORE	Q66799 ebola virus
50	31	66.0	677	1	VGP_EBORS	Q89853 ebola virus
51	31	66.0	900	1	SYA_SULSO	P96041 sulfolobus
52	31	66.0	958	1	HIG_DROME	Q09101 drosophila
53	31	66.0	1699	1	POLN_LORDV	P54634 lordsdale v
54	31	66.0	1704	1	CED7_CAEEL	P34358 caenorhabdi
55	31	66.0	2280	1	COAC_SCHPO	P78820 schizosacch
56	31	66.0	2710	1	TOXA_CLODI	P16154 clostridium
57	31	66.0	3680	1	DMD_CANFA	O97592 canis famil
58	31	66.0	3685	1	DMD_HUMAN	P11532 homo sapien

59	30	63.8	54	1	ATP8_ASTPE	Q33822 asterina pe
60	30	63.8	108	1	YGGL_ECOLI	P38521 escherichia
61	30	63.8	121	1	RNPA_COXBU	P45648 coxiella bu
62	30	63.8	157	1	MENG_MYCTU	P96224 mycobacteri
63	30	63.8	192	1	SODF_BORPE	P37369 bordetella
64	30	63.8	192	1	SODF_ECOLI	P09157 escherichia
65	30	63.8	192	1	SODF_SALTY	P40726 salmonella
66	30	63.8	213	1	YE54_HAEIN	P44202 haemophilus
67	30	63.8	234	1	GU33_RAT	P35896 rattus norv
68	30	63.8	248	1	PAAC_ECOLI	P76079 escherichia
69	30	63.8	249	1	GPMA_MYCTU	Q11140 mycobacteri
70	30	63.8	251	1	GPMA_TREPA	P96121 treponema p
71	30	63.8	252	1	AGL6_ARATH	P29386 arabidopsis
72	30	63.8	290	1	YPHB_ECOLI	P76584 escherichia
73	30	63.8	312	1	GU27_RAT	P34987 rattus norv
74	30	63.8	401	1	CBPB_PIG	P09955 sus scrofa
75	30	63.8	415	1	CBPB_RAT	P19223 rattus norv
76	30	63.8	460	1	YS85_MYCTU	Q10809 mycobacteri
77	30	63.8	467	1	POF9_SCHPO	O74381 schizosacch
78	30	63.8	476	1	OSTA_YEAST	P41543 saccharomyc
79	30	63.8	477	1	YZ64_SYNY3	P73436 synechocyst
80	30	63.8	481	1	SYP_CLOST	Q914q8 clostridium
81	30	63.8	511	1	DHAY_YEAST	P32872 saccharomyc
82	30	63.8	630	1	S6A4_BOVIN	Q9xt49 bos taurus
83	30	63.8	630	1	S6A4_CAVPO	O35899 cavia porce
84	30	63.8	630	1	S6A4_HUMAN	P31645 homo sapien
85	30	63.8	630	1	S6A4_MACMU	Q9myx0 macaca mula
86	30	63.8	630	1	S6A4_MOUSE	Q60857 mus musculu
87	30	63.8	630	1	S6A4_RAT	P31652 rattus norv
88	30	63.8	636	1	FET3_YEAST	P38993 saccharomyc
89	30	63.8	670	1	SSM4_SCHPO	O42667 schizosacch
90	30	63.8	1336	1	MAM1_SCHPO	P78966 schizosacch
91	30	63.8	1441	1	VGLM_BUNSH	P04875 bunyavirus
92	30	63.8	1456	1	MANR_HUMAN	P22897 homo sapien
93	30	63.8	1658	1	ITN2_MOUSE	Q9z0r6 mus musculu
94	30	63.8	1711	1	PTPO_RAT	Q64612 rattus norv
95	30	63.8	1927	1	LPH_HUMAN	P09848 homo sapien
96	30	63.8	2493	1	YBA4_YEAST	P35194 saccharomyc
97	30	63.8	3343	1	YOG7_CAEEL	P34616 caenorhabdi
98	30	63.8	4590	1	FATH_HUMAN	Q14517 homo sapien
99	29	61.7	8	1	AKH_TABAT	P14595 tabanus atr
100	29	61.7	8	1	HTF1_PERAM	P04548 periplaneta

ALIGNMENTS

RESULT 1
AKH2_SCHGR
ID AKH2_SCHGR STANDARD; PRT; 39 AA.
AC P35808; P08378;
DT 01-AUG-1988 (Rel. 08, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Adipokinetic hormone II precursor [Contains: Adipokinetic hormone II
DE (AKH-II); Adipokinetic hormone precursor-related peptide beta chain
DE (APRP-beta)].

```
OS   Schistocerca gregaria (Desert locust).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Orthopteroidea; Orthoptera; Caelifera; Acridomorpha;
OC   Acridoidea; Acrididae; Cyrtacanthacridinae; Schistocerca.
OX   NCBI_TaxID=7010;
RN   [1]
RP   SEQUENCE, AND PROCESSING.
RX   MEDLINE=92044772; PubMed=1941082;
RA   Hekimi S., Fischer-Lougheed J., O'Shea M.;
RT   "Regulation of neuropeptide stoichiometry in neurosecretory cells.";
RL   J. Neurosci. 11:3246-3256(1991).
RN   [2]
RP   SEQUENCE OF 1-8.
RX   MEDLINE=86050918; PubMed=4063072;
RA   Siegert K., Morgan P., Mordue W.;
RT   "Primary structures of locust adipokinetic hormones II.";
RL   Biol. Chem. Hoppe-Seyler 366:723-727(1985).
CC   -!- FUNCTION: THIS HORMONE, RELEASED FROM CELLS IN THE CORPORA
CC       CARDIACA AFTER THE BEGINNING OF FLIGHT, CAUSES RELEASE OF
CC       DIGLYCERIDES FROM THE FAT BODY AND THEN STIMULATES THE FLIGHT
CC       MUSCLES TO USE THESE DIGLYCERIDES AS AN ENERGY SOURCE.
CC   -!- SUBUNIT: ADIPOKINETIC HORMONE PRECURSOR-RELATED PEPTIDE (APRP)
CC       CAN FORM THREE TYPE OF DISULFIDE-BOND DIMERS: P1 (ALPHA-ALPHA),
CC       P2 (ALPHA-BETA), AND P3 (BETA-BETA).
CC   -!- SIMILARITY: BELONGS TO THE AKH / HRTH / RPCH FAMILY.
DR   InterPro; IPR002047; AKH.
DR   PROSITE; PS00256; AKH; 1.
KW   Neuropeptide; Amidation; Flight; Cleavage on pair of basic residues;
KW   Pyrrolidone carboxylic acid.
FT   PEPTIDE       1      8       ADIPOKINETIC HORMONE II.
FT   PEPTIDE      12     39       ADIPOKINETIC HORMONE PRECURSOR-RELATED
FT                                 PEPTIDE BETA CHAIN.
FT   MOD_RES       1      1       PYRROLIDONE CARBOXYLIC ACID.
FT   MOD_RES       8      8       AMIDATION (G-9 PROVIDE AMIDE GROUP).
FT   DISULFID     37     37       INTERCHAIN.
SQ   SEQUENCE   39 AA;  4371 MW;  DB80C45CE57310C3 CRC64;

  Query Match             93.6%;  Score 44;  DB 1;  Length 39;
  Best Local Similarity   87.5%;  Pred. No. 0.042;
  Matches    7;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ELNFSTGW 8
              :|||||||
Db          1 QLNFSTGW 8


RESULT 3
AKHG_GRYBI
ID   AKHG_GRYBI     STANDARD;      PRT;     8 AA.
AC   P14086;
DT   01-JAN-1990 (Rel. 13, Created)
DT   01-FEB-1994 (Rel. 28, Last sequence update)
DT   28-FEB-2003 (Rel. 41, Last annotation update)
DE   Adipokinetic hormone G (AKH-G) (RO II).
OS   Gryllus bimaculatus (Two-spotted cricket), and
OS   Romalea microptera (Lubber grasshopper).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
```

```
OC   Neoptera; Orthopteroidea; Orthoptera; Ensifera; Gryllidae; Gryllinae;
OC   Gryllus.
OX   NCBI_TaxID=6999, 7007;
RN   [1]
RP   SEQUENCE.
RC   SPECIES=G.bimaculatus; TISSUE=Corpora cardiaca;
RX   MEDLINE=88106553; PubMed=3426616;
RA   Gaede G., Rinehart K.L. Jr.;
RT   "Primary sequence analysis by fast atom bombardment mass spectrometry
RT   of a peptide with adipokinetic activity from the corpora cardiaca of
RT   the cricket Gryllus bimaculatus.";
RL   Biochem. Biophys. Res. Commun. 149:908-914(1987).
RN   [2]
RP   SEQUENCE.
RC   SPECIES=R.microptera; TISSUE=Corpora cardiaca;
RX   MEDLINE=89145002; PubMed=3226948;
RA   Gaede G., Hilbich C., Beyreuther K., Rinehart K.L. Jr.;
RT   "Sequence analyses of two neuropeptides of the AKH/RPCH-family from
RT   the lubber grasshopper, Romalea microptera.";
RL   Peptides 9:681-688(1988).
CC   -!- FUNCTION: THIS HORMONE, RELEASED FROM CELLS IN THE CORPORA
CC       CARDIACA AFTER THE BEGINNING OF FLIGHT, CAUSES RELEASE OF
CC       DIGLYCERIDES FROM THE FAT BODY AND THEN STIMULATES THE FLIGHT
CC       MUSCLES TO USE THESE DIGLYCERIDES AS AN ENERGY SOURCE.
CC   -!- SIMILARITY: BELONGS TO THE AKH / HRTH / RPCH FAMILY.
DR   PIR; A28004; A28004.
DR   InterPro; IPR002047; AKH.
DR   PROSITE; PS00256; AKH; 1.
KW   Neuropeptide; Amidation; Flight; Pyrrolidone carboxylic acid.
FT   MOD_RES       1      1       PYRROLIDONE CARBOXYLIC ACID.
FT   MOD_RES       8      8       AMIDATION.
SQ   SEQUENCE   8 AA;  938 MW;  867861B5B9C452D6 CRC64;

  Query Match             87.2%;  Score 41;  DB 1;  Length 8;
  Best Local Similarity   75.0%;  Pred. No. 1.3e+05;
  Matches    6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ELNFSTGW 8
              ::|||||
Db          1 QVNFSTGW 8



Search completed: October  2, 2003, 08:51:11
Job time : 28 secs

                              GenCore version 5.1.6
                    Copyright (c) 1993 - 2003  Compugen Ltd.


OM protein - protein search, using sw model

Run on:          October  2, 2003, 08:47:39 ; Search time 95 Seconds
                                            (without alignments)
                                            21.731 Million cell updates/sec

Title:           US-10-072-419-4
```

Perfect score: 47
Sequence: 1 ELNFSTGW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : SPTREMBL_23:*
1: sp_archea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	38	80.9	332	5	Q18441	Q18441 caenorhabdi
2	38	80.9	371	5	Q22420	Q22420 caenorhabdi
3	36	76.6	315	5	O18121	O18121 caenorhabdi
4	36	76.6	331	5	P91217	P91217 caenorhabdi
5	36	76.6	341	5	O62184	O62184 caenorhabdi
6	36	76.6	346	5	O18042	O18042 caenorhabdi
7	36	76.6	346	5	O18041	O18041 caenorhabdi
8	36	76.6	525	10	Q9ZNW2	Q9znw2 physcomitre
9	36	76.6	569	3	Q9C0V5	Q9c0v5 schizosacch
10	36	76.6	663	12	Q8JM11	Q8jm11 mamestra co
11	36	76.6	666	12	Q8QL90	Q8ql90 mamestra co
12	35	74.5	124	16	Q8XX03	Q8xx03 ralstonia s

13	35	74.5	183	4	O43923	O43923 homo sapien
14	35	74.5	324	2	O07078	O07078 bacillus su
15	35	74.5	344	5	Q18571	Q18571 caenorhabdi
16	35	74.5	349	16	P72649	P72649 synechocyst
17	35	74.5	370	16	Q99T29	Q99t29 staphylococ
18	35	74.5	370	16	Q8NVV2	Q8nvv2 staphylococ
19	35	74.5	444	2	Q9S093	Q9s093 borrelia bu
20	35	74.5	927	5	O02364	O02364 caenorhabdi
21	35	74.5	1702	12	Q8JXI5	Q8jxi5 norwalk-lik
22	35	74.5	1702	12	Q8JXI4	Q8jxi4 norwalk-lik
23	34	72.3	69	2	Q8KNR4	Q8knr4 bacillus th
24	34	72.3	324	3	Q8TGR8	Q8tgr8 saccharomyc
25	34	72.3	339	16	Q9I586	Q9i586 pseudomonas
26	34	72.3	348	16	Q98JG7	Q98jg7 rhizobium l
27	34	72.3	357	2	Q52098	Q52098 photobacter
28	34	72.3	412	3	O43029	O43029 schizosacch
29	34	72.3	465	5	Q21433	Q21433 caenorhabdi
30	34	72.3	702	16	Q8EI46	Q8ei46 shewanella
31	34	72.3	750	16	Q8XJ85	Q8xj85 clostridium
32	34	72.3	1044	10	Q8VY00	Q8vy00 arabidopsis
33	34	72.3	1090	10	Q9LQK8	Q9lqk8 arabidopsis
34	34	72.3	1524	16	Q8FSZ4	Q8fsz4 corynebacte
35	34	72.3	1884	4	Q9ULD7	Q9uld7 homo sapien
36	34	72.3	1885	4	Q8IZJ3	Q8izj3 homo sapien
37	33	70.2	168	12	Q84609	Q84609 paramecium
38	33	70.2	181	16	Q8Y0R3	Q8y0r3 ralstonia s
39	33	70.2	227	17	Q96YS6	Q96ys6 sulfolobus
40	33	70.2	245	8	Q8WF52	Q8wf52 venerupis p
41	33	70.2	269	11	Q8C7R5	Q8c7r5 mus musculu
42	33	70.2	276	2	Q9JPB2	Q9jpb2 rhodocyclus
43	33	70.2	310	16	Q8CWB3	Q8cwb3 escherichia
44	33	70.2	374	13	Q8AXQ0	Q8axq0 gallus gall
45	33	70.2	377	16	Q8CRX7	Q8crx7 staphylococ
46	33	70.2	396	16	Q8YH14	Q8yh14 brucella me
47	33	70.2	396	16	Q8G0U4	Q8g0u4 brucella su
48	33	70.2	413	10	Q8GWM0	Q8gwm0 arabidopsis
49	33	70.2	420	10	Q9SZC6	Q9szc6 arabidopsis
50	33	70.2	425	10	Q8LCW1	Q8lcw1 arabidopsis
51	33	70.2	432	17	Q973P1	Q973p1 sulfolobus
52	33	70.2	438	10	Q9SZ17	Q9sz17 arabidopsis
53	33	70.2	483	10	Q9S768	Q9s768 oryza sativ
54	33	70.2	484	10	Q94HC5	Q94hc5 oryza sativ
55	33	70.2	538	2	Q59143	Q59143 aeromonas s
56	33	70.2	550	3	Q8J266	Q8j266 hebeloma cy
57	33	70.2	559	17	Q9YF45	Q9yf45 aeropyrum p
58	33	70.2	652	5	Q9NDQ1	Q9ndq1 ciona intes
59	33	70.2	682	16	Q9PN45	Q9pn45 campylobact
60	33	70.2	706	16	Q8NMH7	Q8nmh7 corynebacte
61	33	70.2	749	8	Q9TL66	Q9tl66 helwingia j
62	33	70.2	800	16	Q8CX57	Q8cx57 oceanobacil
63	33	70.2	817	10	Q9LLF1	Q9llf1 oryza sativ
64	33	70.2	942	10	Q8S2C0	Q8s2c0 oryza sativ
65	33	70.2	3121	13	O42269	O42269 brachydanio
66	33	70.2	3202	12	Q8QY01	Q8qy01 bean common
67	33	70.2	3222	12	Q8QY00	Q8qy00 bean common
68	33	70.2	3419	11	O55147	O55147 rattus norv
69	33	70.2	3429	11	O08614	O08614 mus musculu

70	32.5	69.1	439	12	Q9DHQ9	Q9dhq9 yaba-like d
71	32	68.1	82	16	Q9PF19	Q9pf19 xylella fas
72	32	68.1	97	17	Q9HLC5	Q9hlc5 thermoplasm
73	32	68.1	99	15	O09983	O09983 human immun
74	32	68.1	100	17	Q978U6	Q978u6 thermoplasm
75	32	68.1	110	9	Q94MB9	Q94mb9 bacteriopha
76	32	68.1	110	9	Q94LZ7	Q94lz7 bacteriopha
77	32	68.1	110	9	Q94MG5	Q94mg5 bacteriopha
78	32	68.1	110	9	Q94LY9	Q94ly9 bacteriopha
79	32	68.1	110	9	Q94LZ6	Q94lz6 bacteriopha
80	32	68.1	110	9	Q94MG4	Q94mg4 bacteriopha
81	32	68.1	110	9	Q94MC2	Q94mc2 bacteriopha
82	32	68.1	110	9	Q94MC1	Q94mc1 bacteriopha
83	32	68.1	115	16	Q9S216	Q9s216 streptomyce
84	32	68.1	158	13	Q8UWB1	Q8uwb1 xenopus lae
85	32	68.1	183	15	Q9EFC5	Q9efc5 human immun
86	32	68.1	196	6	Q8MJ36	Q8mj36 canis famil
87	32	68.1	217	16	Q8ESH7	Q8esh7 oceanobacil
88	32	68.1	236	11	O70158	O70158 cricetulus
89	32	68.1	239	10	Q8H312	Q8h312 oryza sativ
90	32	68.1	241	16	Q8CUI8	Q8cui8 oceanobacil
91	32	68.1	242	9	Q94ML3	Q94ml3 bacteriopha
92	32	68.1	277	4	Q9Y3P2	Q9y3p2 homo sapien
93	32	68.1	300	16	Q8F4P2	Q8f4p2 leptospira
94	32	68.1	301	16	Q98I00	Q98i00 rhizobium l
95	32	68.1	318	2	Q8KLP3	Q8klp3 streptococc
96	32	68.1	328	2	Q9F7N0	Q9f7n0 uncultured
97	32	68.1	328	15	Q9EF69	Q9ef69 human immun
98	32	68.1	332	16	Q8Y1J8	Q8y1j8 ralstonia s
99	32	68.1	339	16	Q9WX36	Q9wx36 anabaena sp
100	32	68.1	352	11	Q8C785	Q8c785 mus musculu

ALIGNMENTS

```
RESULT 1
Q18441
ID   Q18441      PRELIMINARY;      PRT;   332 AA.
AC   Q18441;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-OCT-2001 (TrEMBLrel. 18, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Hypothetical 38.2 kDa protein.
GN   C34D4.8.
OS   Caenorhabditis elegans.
OC   Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC   Rhabditidae; Peloderinae; Caenorhabditis.
OX   NCBI_TaxID=6239;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=Bristol N2;
RX   MEDLINE=99069613; PubMed=9851916;
RA   None;
RT   "Genome sequence of the nematode C. elegans: a platform for
RT   investigating biology. The C. elegans Sequencing Consortium.";
RL   Science 282:2012-2018(1998).
```

```
RN   [2]
RP   SEQUENCE FROM N.A.
RC   STRAIN=Bristol N2;
RA   Du Z., Le T.T.;
RT   "The sequence of C. elegans cosmid C34D4.";
RL   Submitted (MAY-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   SEQUENCE FROM N.A.
RC   STRAIN=Bristol N2;
RA   Waterston R.;
RT   "Direct Submission.";
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; U58755; AAB00693.2; -.
DR   WormPep; C34D4.8; CE24826.
DR   InterPro; IPR003002; 7TM_chemo1.
DR   InterPro; IPR000168; 7TM_nematode.
DR   Pfam; PF01461; 7tm_4; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   332 AA;  38186 MW;  998E39D4DD997D04 CRC64;

  Query Match             80.9%;  Score 38;  DB 5;  Length 332;
  Best Local Similarity   62.5%;  Pred. No. 28;
  Matches    5;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 ELNFSTGW 8
              |:|: |||
Db        274 EMNYQTGW 281


Search completed: October  2, 2003, 08:52:55
Job time : 103 secs
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 2, 2003, 08:50:47 ; Search time 26 Seconds
(without alignments)
48.681 Million cell updates/sec

Title: US-10-072-419-4
Perfect score: 47
Sequence: 1 ELNFSTGW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 587654 seqs, 158212981 residues

Total number of hits satisfying chosen parameters: 587654

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description

1	47	100.0	8	12	US-10-072-419-4	Sequence 4, Appli
2	47	100.0	8	12	US-10-072-419-15	Sequence 15, Appl
3	47	100.0	8	12	US-10-072-419-25	Sequence 25, Appl
4	47	100.0	10	12	US-10-072-419-36	Sequence 36, Appl
5	44	93.6	8	12	US-10-072-419-24	Sequence 24, Appl
6	42	89.4	8	12	US-10-072-419-11	Sequence 11, Appl
7	42	89.4	8	12	US-10-072-419-30	Sequence 30, Appl
8	38	80.9	10	12	US-10-072-419-2	Sequence 2, Appli
9	38	80.9	463	15	US-10-156-761-12632	Sequence 12632, A
10	37	78.7	10	12	US-10-072-419-34	Sequence 34, Appl
11	35	74.5	8	12	US-10-072-419-5	Sequence 5, Appli
12	35	74.5	8	12	US-10-072-419-20	Sequence 20, Appl
13	35	74.5	8	12	US-10-072-419-21	Sequence 21, Appl
14	35	74.5	8	12	US-10-072-419-26	Sequence 26, Appl
15	35	74.5	183	9	US-09-801-196-33	Sequence 33, Appl
16	34	72.3	41	9	US-09-864-761-37864	Sequence 37864, A
17	33	70.2	706	10	US-09-738-626-6357	Sequence 6357, Ap
18	32	68.1	8	12	US-10-072-419-9	Sequence 9, Appli
19	32	68.1	8	12	US-10-072-419-12	Sequence 12, Appl
20	32	68.1	8	12	US-10-072-419-14	Sequence 14, Appl
21	32	68.1	8	12	US-10-072-419-17	Sequence 17, Appl
22	32	68.1	8	12	US-10-072-419-18	Sequence 18, Appl
23	32	68.1	10	12	US-10-072-419-1	Sequence 1, Appli
24	32	68.1	10	12	US-10-072-419-32	Sequence 32, Appl
25	32	68.1	10	12	US-10-072-419-35	Sequence 35, Appl
26	32	68.1	10	12	US-10-072-419-40	Sequence 40, Appl
27	32	68.1	72	11	US-09-899-495-78	Sequence 78, Appl
28	32	68.1	91	10	US-09-843-676-220	Sequence 220, App
29	32	68.1	91	11	US-09-438-486-220	Sequence 220, App
30	32	68.1	91	15	US-10-053-758-220	Sequence 220, App
31	32	68.1	91	15	US-10-054-295-220	Sequence 220, App
32	32	68.1	91	15	US-10-054-611-220	Sequence 220, App
33	32	68.1	115	15	US-10-156-761-14021	Sequence 14021, A
34	32	68.1	128	10	US-09-840-459-86	Sequence 86, Appl
35	32	68.1	208	10	US-09-764-868-652	Sequence 652, App
36	32	68.1	208	10	US-09-764-868-1078	Sequence 1078, Ap
37	32	68.1	610	9	US-09-748-107-2	Sequence 2, Appli
38	32	68.1	610	12	US-10-281-346-2	Sequence 2, Appli
39	32	68.1	660	12	US-10-238-075-732	Sequence 732, App
40	32	68.1	757	14	US-10-117-846-10	Sequence 10, Appl
41	32	68.1	758	14	US-10-117-846-16	Sequence 16, Appl
42	32	68.1	815	9	US-09-815-242-5106	Sequence 5106, Ap
43	32	68.1	1532	10	US-09-738-626-4321	Sequence 4321, Ap
44	31	66.0	8	12	US-10-072-419-13	Sequence 13, Appl
45	31	66.0	56	12	US-10-195-730-198	Sequence 198, App
46	31	66.0	68	10	US-09-764-855-93	Sequence 93, Appl
47	31	66.0	68	15	US-10-072-349-93	Sequence 93, Appl
48	31	66.0	72	15	US-10-156-761-8551	Sequence 8551, Ap
49	31	66.0	265	9	US-09-742-693-30	Sequence 30, Appl
50	31	66.0	274	12	US-10-023-617-5	Sequence 5, Appli
51	31	66.0	274	16	US-10-176-306-67	Sequence 67, Appl
52	31	66.0	433	16	US-10-080-170-547	Sequence 547, App
53	31	66.0	454	15	US-10-156-761-11138	Sequence 11138, A
54	31	66.0	486	9	US-09-925-301-1326	Sequence 1326, Ap
55	31	66.0	494	9	US-09-815-242-11055	Sequence 11055, A
56	31	66.0	866	16	US-10-222-038-2	Sequence 2, Appli

57	31	66.0	1352	11	US-09-784-554B-2	Sequence 2, Appli
58	31	66.0	2710	15	US-10-011-366-6	Sequence 6, Appli
59	31	66.0	2862	9	US-09-742-659-5	Sequence 5, Appli
60	31	66.0	2864	8	US-08-424-550B-394	Sequence 394, App
61	31	66.0	2864	9	US-09-742-659-2	Sequence 2, Appli
62	31	66.0	2865	9	US-09-742-659-6	Sequence 6, Appli
63	30	63.8	8	12	US-10-072-419-10	Sequence 10, Appl
64	30	63.8	56	9	US-09-864-761-44972	Sequence 44972, A
65	30	63.8	67	10	US-09-764-877-1293	Sequence 1293, Ap
66	30	63.8	76	15	US-10-074-475-277	Sequence 277, App
67	30	63.8	78	9	US-09-864-761-46012	Sequence 46012, A
68	30	63.8	133	12	US-10-084-843-288	Sequence 288, App
69	30	63.8	133	12	US-10-193-002-283	Sequence 283, App
70	30	63.8	157	15	US-10-227-629-20	Sequence 20, Appl
71	30	63.8	193	12	US-10-230-331-23	Sequence 23, Appl
72	30	63.8	214	12	US-10-032-585-7509	Sequence 7509, Ap
73	30	63.8	216	10	US-09-738-626-5748	Sequence 5748, Ap
74	30	63.8	249	10	US-09-712-363-172	Sequence 172, App
75	30	63.8	252	16	US-10-278-536-190	Sequence 190, App
76	30	63.8	337	12	US-10-238-075-1135	Sequence 1135, Ap
77	30	63.8	381	15	US-10-156-761-8102	Sequence 8102, Ap
78	30	63.8	440	16	US-10-080-170-164	Sequence 164, App
79	30	63.8	603	10	US-09-973-457-2	Sequence 2, Appli
80	30	63.8	630	9	US-09-843-598-10	Sequence 10, Appl
81	30	63.8	684	12	US-10-032-585-7759	Sequence 7759, Ap
82	30	63.8	714	12	US-10-032-585-7532	Sequence 7532, Ap
83	30	63.8	807	12	US-10-096-578-3	Sequence 3, Appli
84	30	63.8	1350	11	US-09-784-554B-4	Sequence 4, Appli
85	30	63.8	1456	10	US-09-870-759-95	Sequence 95, Appl
86	30	63.8	1456	12	US-09-751-708A-95	Sequence 95, Appl
87	30	63.8	1881	11	US-09-998-425-3	Sequence 3, Appli
88	30	63.8	1881	11	US-09-997-977-3	Sequence 3, Appli
89	30	63.8	4590	15	US-10-160-758-13	Sequence 13, Appl
90	30	63.8	4590	15	US-10-160-758-14	Sequence 14, Appl
91	30	63.8	4590	15	US-10-060-036-157	Sequence 157, App
92	29	61.7	8	12	US-10-072-419-16	Sequence 16, Appl
93	29	61.7	8	12	US-10-072-419-23	Sequence 23, Appl
94	29	61.7	18	9	US-09-864-761-47870	Sequence 47870, A
95	29	61.7	72	9	US-09-864-761-45981	Sequence 45981, A
96	29	61.7	82	11	US-09-764-891-3090	Sequence 3090, Ap
97	29	61.7	82	15	US-10-205-428-275	Sequence 275, App
98	29	61.7	92	11	US-09-764-891-3603	Sequence 3603, Ap
99	29	61.7	94	15	US-10-214-932-44	Sequence 44, Appl
100	29	61.7	118	11	US-09-530-139-22	Sequence 22, Appl

ALIGNMENTS

RESULT 1
US-10-072-419-4
; Sequence 4, Application US/10072419
; Publication No. US20030162717A1
; GENERAL INFORMATION:
; APPLICANT: Schacter, Bernice
; APPLICANT: Schacter, Lee

```
;  TITLE OF INVENTION: Compositions and Methods for Promoting Lipid Mobilization
in Humans
;  FILE REFERENCE: 10739-1
;  CURRENT APPLICATION NUMBER: US/10/072,419
;  CURRENT FILING DATE:  2002-02-07
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Schistocerca gregaria
US-10-072-419-4

  Query Match             100.0%;  Score 47;  DB 12;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+05;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ELNFSTGW 8
              ||||||||
Db          1 ELNFSTGW 8


RESULT 15
US-09-801-196-33
; Sequence 33, Application US/09801196
; Patent No. US20020037827A1
; GENERAL INFORMATION:
;  APPLICANT:  Wang, Kai
;  APPLICANT:  Smith, Ryan
;  APPLICANT:  Fajardo, Mark
;  APPLICANT:  Moss, Patrick
;  TITLE OF INVENTION:  A NOVEL MATRIX METALLOPROTEINASE (MMP-25)
;  TITLE OF INVENTION:  EXPRESSED IN SKIN CELLS
;  FILE REFERENCE:  240083.509
;  CURRENT APPLICATION NUMBER: US/09/801,196
;  CURRENT FILING DATE:  2001-03-06
;  NUMBER OF SEQ ID NOS:  37
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 33
;   LENGTH: 183
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-801-196-33

  Query Match             74.5%;  Score 35;  DB 9;  Length 183;
  Best Local Similarity   75.0%;  Pred. No. 70;
  Matches    6;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 ELNFSTGW 8
              || || ||
Db        162 ELGFSRGW 169


RESULT 27
US-09-899-495-78
```

; Sequence 78, Application US/09899495
; Publication No. US20030088060A1
; GENERAL INFORMATION:
; APPLICANT: Benjamin, Christopher W.
; APPLICANT: Roberts, Steven L.
; APPLICANT: Karnovsky, Alla M.
; APPLICANT: Ruble, Cara L.
; TITLE OF INVENTION: Human Ion Channels
; FILE REFERENCE: 00188US1
; CURRENT APPLICATION NUMBER: US/09/899,495
; CURRENT FILING DATE: 2001-07-05
; PRIOR APPLICATION NUMBER: 60/215,815
; PRIOR FILING DATE: 2000-07-05
; PRIOR APPLICATION NUMBER: 60/216,481
; PRIOR FILING DATE: 2000-07-06
; PRIOR APPLICATION NUMBER: 60/216,479
; PRIOR FILING DATE: 2000-07-06
; PRIOR APPLICATION NUMBER: 60/216,482
; PRIOR FILING DATE: 2000-07-06
; PRIOR APPLICATION NUMBER: 60/217,096
; PRIOR FILING DATE: 2000-07-10
; NUMBER OF SEQ ID NOS: 125
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 78
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-899-495-78

  Query Match   68.1%; Score 32; DB 11; Length 72;
  Best Local Similarity   100.0%; Pred. No. 1e+02;
  Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   4 FSTGW 8
              |||||
Db   18 FSTGW 22

Search completed: October 2, 2003, 08:54:45
Job time : 27 secs

GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: April 11, 2003, 18:59:09 ; Search time 29 Seconds
(without alignments)
56.841 Million cell updates/sec

Title: PCT-US03-03800-20
Perfect score: 49
Sequence: 1 ELNFSPNW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 9297

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL_21:*
1: sp_archea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description

1	26	53.1	15	6	Q9TRA6	Q9tra6 bos taurus
2	24	49.0	19	6	Q9N1W2	Q9n1w2 equus cabal
3	24	49.0	24	2	Q56150	Q56150 streptomyce
4	24	49.0	24	6	Q9N1W1	Q9n1w1 equus cabal
5	24	49.0	25	3	Q96VQ6	Q96vq6 neurospora
6	23	46.9	16	12	Q9YQ11	Q9yq11 transmissib
7	23	46.9	18	8	Q9ZYW4	Q9zyw4 habrobracon
8	23	46.9	23	2	Q44682	Q44682 bacillus am
9	23	46.9	25	2	O87961	O87961 helicobacte
10	22	44.9	19	8	Q9ZYW3	Q9zyw3 gnamptodon
11	22	44.9	20	4	Q92855	Q92855 homo sapien
12	22	44.9	22	13	Q9PRQ6	Q9prq6 morone saxa
13	22	44.9	23	4	Q16233	Q16233 homo sapien
14	22	44.9	23	11	Q9CV68	Q9cv68 mus musculu
15	21	42.9	13	8	Q9MQK0	Q9mqk0 cervus elap
16	21	42.9	16	4	Q9UCG5	Q9ucg5 homo sapien
17	21	42.9	16	4	Q9UCA6	Q9uca6 homo sapien
18	21	42.9	18	2	Q9R4V9	Q9r4v9 campylobact
19	21	42.9	19	8	Q9ZYW8	Q9zyw8 ichneutes b
20	21	42.9	20	6	P82666	P82666 bos taurus
21	21	42.9	22	4	Q9UNS8	Q9uns8 homo sapien
22	21	42.9	22	4	Q96Q24	Q96q24 homo sapien
23	21	42.9	22	15	Q75446	Q75446 human immun
24	21	42.9	23	11	Q91ZE2	Q91ze2 rattus norv
25	21	42.9	23	11	Q91V21	Q91v21 rattus norv
26	21	42.9	23	16	O26030	O26030 helicobacte
27	21	42.9	24	3	Q9UR88	Q9ur88 aspergillus
28	20	40.8	10	8	Q8SHB1	Q8shb1 rhampholeon
29	20	40.8	10	8	Q8SH99	Q8sh99 brookesia n
30	20	40.8	11	8	Q9G649	Q9g649 otocryptis
31	20	40.8	14	2	Q45876	Q45876 clostridium
32	20	40.8	14	2	Q45872	Q45872 clostridium
33	20	40.8	16	2	Q9R4F2	Q9r4f2 streptomyce
34	20	40.8	17	3	Q9URC6	Q9urc6 saccharomyc
35	20	40.8	18	11	Q9QW51	Q9qw51 mus sp. act
36	20	40.8	19	2	Q9R5N8	Q9r5n8 clostridium
37	20	40.8	19	10	P83206	P83206 gynostemma
38	20	40.8	20	2	Q9R4D9	Q9r4d9 escherichia
39	20	40.8	20	6	Q9TTG3	Q9ttg3 ateles belz
40	20	40.8	22	2	Q52009	Q52009 pseudomonas
41	20	40.8	23	11	P70635	P70635 rattus norv
42	20	40.8	25	2	Q9R685	Q9r685 bacillus sp
43	20	40.8	25	5	Q9NDS5	Q9nds5 drosophila
44	20	40.8	25	12	Q9WMG7	Q9wmg7 sigma virus
45	19.5	39.8	18	2	O30588	O30588 streptomyce

ALIGNMENTS

RESULT 1
Q9TRA6
ID Q9TRA6 PRELIMINARY; PRT; 15 AA.
AC Q9TRA6;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)

```
DE   PA700 subunit P31=ATP-dependent 20 S proteasome activator
DE   (Fragment).
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
OC   Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=94342244; PubMed=8063704;
RA   DeMartino G.N., Moomaw C.R., Zagnitko O.P., Proske R.J., Chu-Ping M.,
RA   Afendis S.J., Swaffield J.C., Slaughter C.A.;
RT   "PA700, an ATP-dependent activator of the 20 S proteasome, is an
RT   ATPase containing multiple members of a nucleotide-binding protein
RT   family.";
RL   J. Biol. Chem. 269:20878-20884(1994).
FT   NON_TER       1      1
FT   NON_TER      15     15
SQ   SEQUENCE   15 AA;  1659 MW;  D189812E9389B755 CRC64;

  Query Match             53.1%;  Score 26;  DB 6;  Length 15;
  Best Local Similarity   83.3%;  Pred. No. 1.9e+02;
  Matches    5;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 ELNFSP 6
           |||| |
Db       5 ELNFLP 10


Search completed: April 11, 2003, 19:01:03
Job time : 32 secs
```

GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: April 11, 2003, 18:58:50 ; Search time 11 Seconds
(without alignments)
30.165 Million cell updates/sec

Title: PCT-US03-03800-20
Perfect score: 49
Sequence: 1 ELNFSPNW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 1520

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	46	93.9	8	1	HTF_TENMO	P25419 tenebrio mo
2	43	87.8	8	1	HTF1_PERAM	P04548 periplaneta
3	40	81.6	8	1	RPCH_PANBO	P08939 pandalus bo
4	40	81.6	10	1	HTF1_ROMMI	P18110 romalea mic
5	38	77.6	8	1	AKH_MELML	P25423 melolontha
6	37	75.5	8	1	HTF2_PERAM	P04549 periplaneta
7	37	75.5	10	1	HTF2_CARMO	P11385 carausius m
8	37	75.5	10	1	HTF_NAUCI	P10939 nauphoeta c
9	35	71.4	8	1	AKH_LIBAU	P25418 libellula a
10	31	63.3	8	1	AKH_TABAT	P14595 tabanus atr
11	31	63.3	10	1	HTF_TABAT	P14596 tabanus atr
12	29	59.2	8	1	AKHG_GRYBI	P14086 gryllus bim
13	26	53.1	10	1	HTF_HELZE	P16353 heliothis z
14	25	51.0	18	1	A2M_OCTVU	P30800 octopus vul
15	23	46.9	10	1	AKHX_LOCMI	P81626 locusta mig
16	21	42.9	21	1	CFPA_TREPH	P56738 treponema p
17	20	40.8	13	1	YPNP_PHOLU	P41122 photorhabdu

18	19	38.8	6	1	EI01_LITRU	P82096 litoria rub
19	19	38.8	11	1	RANC_RANPI	P08951 rana pipien
20	19	38.8	18	1	NPA_BOVIN	P15506 bos taurus
21	19	38.8	23	1	FMK7_PSEAE	Q53391 pseudomonas
22	19	38.8	25	1	ATP0_SPIOL	P80082 spinacia ol
23	18	36.7	10	1	BRK_ONCMY	Q9prz1 oncorhynchu
24	18	36.7	13	1	BOML_PSEGU	P42991 pseudophryn
25	18	36.7	19	1	LPRM_STAAU	P03063 staphylococ
26	18	36.7	20	1	CRTC_SPIOL	P30806 spinacia ol
27	17	34.7	10	1	BPP2_BOTIN	P30422 bothrops in
28	17	34.7	10	1	BPP2_BOTJA	P01022 bothrops ja
29	17	34.7	10	1	TPIS_NICPL	P19118 nicotiana p
30	17	34.7	12	1	LMT1_LOCMI	P22395 locusta mig
31	17	34.7	13	1	BRK_PARID	P42717 parapolybia
32	17	34.7	13	1	LMT4_LOCMI	P41490 locusta mig
33	17	34.7	14	1	MAST_PARID	P42716 parapolybia
34	17	34.7	14	1	MAST_VESXA	P01515 vespa xanth
35	17	34.7	15	1	GLN2_PINPS	P81107 pinus pinas
36	17	34.7	16	1	VPR_HV1S3	P19555 human immun
37	17	34.7	17	1	TPIS_PINPS	P81666 pinus pinas
38	17	34.7	17	1	VESP_VESMC	P57672 vespula mac
39	17	34.7	19	1	BRKM_BOMMX	P83055 bombina max
40	17	34.7	19	1	COX4_ONCMY	P80327 oncorhynchu
41	17	34.7	19	1	CXR_CONTU	P58811 conus tulip
42	17	34.7	19	1	RS19_SPICI	O31159 spiroplasma
43	17	34.7	20	1	HGL1_FASHE	P80527 fasciola he
44	17	34.7	22	1	HGL2_FASHE	P80530 fasciola he
45	17	34.7	23	1	IAPP_LEPEU	Q07333 lepus europ

ALIGNMENTS

```
RESULT 1
HTF_TENMO
ID   HTF_TENMO      STANDARD;      PRT;     8 AA.
AC   P25419;
DT   01-MAY-1992 (Rel. 22, Created)
DT   01-FEB-1994 (Rel. 28, Last sequence update)
DT   01-FEB-1994 (Rel. 28, Last annotation update)
DE   Hypertrehalosaemic factor (HOTH) (Hypertrehalosemic neuropeptide).
OS   Tenebrio molitor (Yellow mealworm), and
OS   Zophobas rugipes.
OC   Eukaryota; Metazoa; Arthropoda; Mandibulata; Pancrustacea; Hexapoda;
OC   Insecta; Pterygota; Neoptera; Endopterygota; Coleoptera; Polyphaga;
OC   Cucujiformia; Tenebrionidae; Tenebrio.
OX   NCBI_TaxID=7067, 7075;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Corpora cardiaca;
RX   MEDLINE=90341081; PubMed=2381871;
RA   Gaede G., Rosinski G.;
RT   "The primary structure of the hypertrehalosemic neuropeptide from
RT   tenebrionid beetles: a novel member of the AKH/RPCH family.";
RL   Peptides 11:455-459(1990).
CC   -!- FUNCTION: HYPERTREHALOSAEMIC FACTORS ARE NEUROPEPTIDES THAT
CC       ELEVATE THE LEVEL OF TREHALOSE IN THE HEMOLYMPH (TREHALOSE IS
```

```
CC       THE MAJOR CARBOHYDRATE IN THE HEMOLYMPH OF INSECTS).
CC   -!- SIMILARITY: BELONGS TO THE AKH / HRTH / RPCH FAMILY.
DR   PIR; A43976; A43976.
DR   PIR; B43976; B43976.
DR   InterPro; IPR002047; AKH.
DR   PROSITE; PS00256; AKH; 1.
KW   Neuropeptide; Amidation.
FT   MOD_RES       1      1       PYRROLIDONE CARBOXYLIC ACID.
FT   MOD_RES       8      8       AMIDATION.
SQ   SEQUENCE   8 AA;  1005 MW;  86745775B9C44736 CRC64;

  Query Match             93.9%;  Score 46;  DB 1;  Length 8;
  Best Local Similarity   87.5%;  Pred. No. 1.1e+05;
  Matches    7;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ELNFSPNW 8
           :|||||||
Db       1 QLNFSPNW 8


Search completed: April 11, 2003, 19:00:26
Job time : 12 secs
```

GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: April 11, 2003, 18:59:35 ; Search time 15 Seconds
(without alignments)
51.272 Million cell updates/sec

Title: PCT-US03-03800-20
Perfect score: 49
Sequence: 1 ELNFSPNW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 4984

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_73:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	46	93.9	8	2	A43976	hypertrehalosemic
2	46	93.9	8	2	B43976	hypertrehalosemic
3	46	93.9	8	2	A05169	neuropeptide M-I -
4	43	87.8	8	2	S08995	hypertrehalosemic
5	43	87.8	8	2	A49823	adipokinetic hormo
6	43	87.8	8	2	A44960	neuropeptide Led-C
7	41	83.7	8	2	S21663	neuropeptide - flo
8	40	81.6	8	2	A61348	red pigment-concen
9	38	77.6	8	2	S15422	adipokinetic hormo
10	38	77.6	8	2	A58641	adipokinetic hormo
11	38	77.6	10	2	S53789	neuropeptide Pec-H
12	37	75.5	8	2	S08996	hypertrehalosemic
13	37	75.5	8	2	B49823	adipokinetic hormo

14	37	75.5	8	2	B44960	neuropeptide Led-C
15	37	75.5	10	2	A60421	hypertrehalosemic
16	37	75.5	10	2	S08997	hypertrehalosemic
17	37	75.5	10	2	S08998	hypertrehalosemic
18	37	75.5	10	2	A26381	hypertrehalosemic
19	37	75.5	10	2	JC1416	hypertrehalosemic
20	37	75.5	10	2	S09138	hypertrehalosemic
21	35	71.4	8	2	S10596	adipokinetic hormo
22	35	71.4	8	2	S11545	adipokinetic hormo
23	34	69.4	8	2	S55310	adipokinetic hormo
24	34	69.4	8	2	A58620	adipokinetic hormo
25	31	63.3	8	2	A33995	adipokinetic hormo
26	31	63.3	10	2	B33995	hypotrehalosemic h
27	29	59.2	8	2	A28004	adipokinetic hormo
28	26	53.1	10	2	A31571	hypertrehalosemic/
29	25	51.0	17	2	B31435	adherence lectin l
30	25	51.0	18	2	S23971	alpha-macroglobuli
31	25	51.0	24	2	A39509	mannose-specific l
32	24	49.0	9	2	A24244	adipokinetic hormo
33	24	49.0	18	2	PT0286	Ig heavy chain CDR
34	23	46.9	22	2	PQ0070	T-cell receptor be
35	23	46.9	23	2	T50545	reductase [importe
36	22	44.9	22	2	D32537	T-cell receptor al
37	22	44.9	24	2	T46622	hypothetical prote
38	21	42.9	8	2	A14683	aspartate transami
39	21	42.9	23	2	D64707	hypothetical prote
40	20	40.8	7	4	A58725	virotoxin - destro
41	20	40.8	14	2	S58862	botulinum neurotox
42	20	40.8	14	2	S58866	botulinum neurotox
43	20	40.8	16	2	A24099	crystal protein, 2
44	20	40.8	16	2	S51610	hypothetical prote
45	20	40.8	20	2	S67990	neurotoxin-associa

ALIGNMENTS

RESULT 1
A43976
hypertrehalosemic hormone - yellow mealworm
C;Species: Tenebrio molitor (yellow mealworm)
C;Date: 03-Feb-1993 #sequence_revision 03-Feb-1993 #text_change 07-May-1999
C;Accession: A43976
R;Gaede, G.; Rosinski, G.
Peptides 11, 455-459, 1990
A;Title: The primary structure of the hypertrehalosemic neuropeptide from tenebrionid beetles: a novel member of the AKH/RPCH family.
A;Reference number: A43976; MUID:90341081; PMID:2381871
A;Accession: A43976
A;Molecule type: protein
A;Residues: 1-8 <GAE>
C;Superfamily: adipokinetic hormone
C;Keywords: amidated carboxyl end; corpora cardiaca; hormone; neuropeptide; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;8/Modified site: amidated carboxyl end (Trp) #status experimental

Query Match 93.9%; Score 46; DB 2; Length 8;
Best Local Similarity 87.5%; Pred. No. 2.8e+05;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 ELNFSPNW 8
            :|||||||
Db       1 QLNFSPNW 8
```

Search completed: April 11, 2003, 19:01:23
Job time : 16 secs

GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: April 11, 2003, 19:00:30 ; Search time 14 Seconds
(without alignments)
34.935 Million cell updates/sec

Title: PCT-US03-03800-20
Perfect score: 49
Sequence: 1 ELNFSPNW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 248812 seqs, 61136040 residues

Total number of hits satisfying chosen parameters: 54760

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
7: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	31	63.3	10	10	US-09-767-460-40	Sequence 40, Appl
2	28	57.1	12	10	US-09-832-723-78	Sequence 78, Appl
3	27	55.1	25	10	US-09-864-761-40831	Sequence 40831, A

4	26	53.1	17	9	US-09-996-634-88	Sequence 88, Appl
5	26	53.1	17	9	US-09-996-634-89	Sequence 89, Appl
6	26	53.1	17	9	US-09-997-181-88	Sequence 88, Appl
7	26	53.1	17	9	US-09-997-181-89	Sequence 89, Appl
8	26	53.1	17	9	US-09-997-182-88	Sequence 88, Appl
9	26	53.1	17	9	US-09-997-182-89	Sequence 89, Appl
10	26	53.1	25	9	US-10-001-876-126	Sequence 126, App
11	25	51.0	7	10	US-09-205-658-230	Sequence 230, App
12	25	51.0	8	9	US-09-849-092-2	Sequence 2, Appli
13	25	51.0	10	10	US-09-767-460-88	Sequence 88, Appl
14	25	51.0	15	10	US-09-791-171-171	Sequence 171, App
15	25	51.0	20	9	US-10-196-703-11	Sequence 11, Appl
16	24	49.0	9	9	US-09-809-638-136	Sequence 136, App
17	24	49.0	9	9	US-09-809-638-264	Sequence 264, App
18	24	49.0	9	9	US-09-809-638-530	Sequence 530, App
19	24	49.0	9	9	US-09-809-638-644	Sequence 644, App
20	24	49.0	10	9	US-09-809-638-182	Sequence 182, App
21	24	49.0	10	9	US-09-809-638-274	Sequence 274, App
22	24	49.0	10	9	US-09-809-638-492	Sequence 492, App
23	24	49.0	10	9	US-09-809-638-580	Sequence 580, App
24	24	49.0	10	9	US-09-809-638-586	Sequence 586, App
25	24	49.0	10	9	US-09-809-638-696	Sequence 696, App
26	24	49.0	10	10	US-09-767-460-36	Sequence 36, Appl
27	24	49.0	13	9	US-09-880-748-2212	Sequence 2212, Ap
28	24	49.0	14	9	US-09-798-889-79	Sequence 79, Appl
29	24	49.0	15	9	US-10-012-896-965	Sequence 965, App
30	24	49.0	15	9	US-09-895-814-965	Sequence 965, App
31	24	49.0	15	10	US-09-953-510-86	Sequence 86, Appl
32	24	49.0	15	10	US-09-953-510-87	Sequence 87, Appl
33	24	49.0	17	10	US-09-864-761-35737	Sequence 35737, A
34	24	49.0	18	9	US-09-910-009A-389	Sequence 389, App
35	24	49.0	19	9	US-09-909-460-17	Sequence 17, Appl
36	24	49.0	19	10	US-09-864-761-39331	Sequence 39331, A
37	24	49.0	20	8	US-08-424-550B-341	Sequence 341, App
38	24	49.0	23	9	US-09-809-638-719	Sequence 719, App
39	24	49.0	25	10	US-09-864-761-44695	Sequence 44695, A
40	24	49.0	25	10	US-09-864-761-45769	Sequence 45769, A
41	23	46.9	5	10	US-09-870-379-5	Sequence 5, Appli
42	23	46.9	7	9	US-09-229-751A-21	Sequence 21, Appl
43	23	46.9	9	9	US-10-046-922-38	Sequence 38, Appl
44	23	46.9	13	9	US-10-097-175-67	Sequence 67, Appl
45	23	46.9	16	9	US-09-750-754-20	Sequence 20, Appl

ALIGNMENTS

RESULT 1
US-09-767-460-40
; Sequence 40, Application US/09767460
; Patent No. US20020009756A1
; GENERAL INFORMATION:
; APPLICANT: Mandell, Arnold
; APPLICANT: Selz, Karen
; APPLICANT: Shlesinger, Michael
; TITLE OF INVENTION: Algorithmic Design of Peptides for Binding and/or Modulation of the

```
;  TITLE OF INVENTION:  Functions of Receptors and/or Other Proteins
;  FILE REFERENCE: 01561-0002-CPUS01
;  CURRENT APPLICATION NUMBER: US/09/767,460
;  CURRENT FILING DATE:  2001-01-23
;  NUMBER OF SEQ ID NOS: 96
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 40
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-09-767-460-40

  Query Match             63.3%;  Score 31;  DB 10;  Length 10;
  Best Local Similarity   66.7%;  Pred. No. 10;
  Matches    4;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 NFSPNW 8
           ||:| |
Db       3 NFTPEW 8


RESULT 2
US-09-832-723-78
; Sequence 78, Application US/09832723
; Patent No. US20020098524A1
; GENERAL INFORMATION:
;  APPLICANT: Estell, David A.
;  APPLICANT:  Chen, Yiyou
;  APPLICANT:  Murray, Christopher J.
;  APPLICANT:  Tijerina, Pilar
;  TITLE OF INVENTION: METHODS FOR SELECTIVE TARGETING
;  FILE REFERENCE: GC617-2
;  CURRENT APPLICATION NUMBER: US/09/832,723
;  CURRENT FILING DATE:  2001-04-11
;  PRIOR APPLICATION NUMBER: US 60/197,259
;  PRIOR FILING DATE: 2000-04-14
;  NUMBER OF SEQ ID NOS: 117
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 78
;   LENGTH: 12
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: peptides screened from a phage display random
;   OTHER INFORMATION: peptide library
US-09-832-723-78

  Query Match             57.1%;  Score 28;  DB 10;  Length 12;
  Best Local Similarity   66.7%;  Pred. No. 42;
  Matches    4;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3 NFSPNW 8
           || | |
Db       1 NFFPTW 6
```

Search completed: April 11, 2003, 19:02:06
Job time : 15 secs

GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: April 11, 2003, 19:00:15 ; Search time 14 Seconds
(without alignments)
16.813 Million cell updates/sec

Title: PCT-US03-03800-20
Perfect score: 49
Sequence: 1 ELNFSPNW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 147762

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	35	71.4	10	2	US-08-747-137-122	Sequence 122, App
2	33	67.3	21	1	US-08-190-788A-14	Sequence 14, Appl
3	33	67.3	21	1	US-08-190-788A-253	Sequence 253, App
4	33	67.3	21	1	US-08-383-474B-20	Sequence 20, Appl
5	33	67.3	21	1	US-08-465-391A-14	Sequence 14, Appl
6	33	67.3	21	1	US-08-465-391A-253	Sequence 253, App
7	33	67.3	21	2	US-08-464-538B-14	Sequence 14, Appl
8	33	67.3	21	2	US-08-464-538B-253	Sequence 253, App
9	33	67.3	21	2	US-08-463-076E-23	Sequence 23, Appl
10	33	67.3	21	2	US-08-463-076E-310	Sequence 310, App
11	31	63.3	15	2	US-08-553-257A-50	Sequence 50, Appl

12	31	63.3	25	1	US-08-468-709B-16	Sequence 16, Appl
13	31	63.3	25	2	US-08-241-664B-16	Sequence 16, Appl
14	28	57.1	9	4	US-09-644-600-21	Sequence 21, Appl
15	28	57.1	12	2	US-08-934-222-51	Sequence 51, Appl
16	28	57.1	12	2	US-08-933-402-51	Sequence 51, Appl
17	28	57.1	12	2	US-09-207-621-51	Sequence 51, Appl
18	28	57.1	12	2	US-08-532-818-51	Sequence 51, Appl
19	28	57.1	12	3	US-09-231-797-51	Sequence 51, Appl
20	28	57.1	12	3	US-08-934-224-51	Sequence 51, Appl
21	28	57.1	12	3	US-08-933-843-51	Sequence 51, Appl
22	28	57.1	12	4	US-08-934-223-51	Sequence 51, Appl
23	28	57.1	12	4	US-09-413-492-51	Sequence 51, Appl
24	28	57.1	13	2	US-08-480-190-26	Sequence 26, Appl
25	28	57.1	13	2	US-08-488-379-26	Sequence 26, Appl
26	28	57.1	13	5	PCT-US93-07545-26	Sequence 26, Appl
27	26	53.1	10	3	US-08-159-339A-448	Sequence 448, App
28	26	53.1	15	2	US-08-553-257A-49	Sequence 49, Appl
29	26	53.1	17	4	US-08-990-823-88	Sequence 88, Appl
30	26	53.1	17	4	US-08-990-823-89	Sequence 89, Appl
31	26	53.1	17	4	US-09-025-769B-261	Sequence 261, App
32	26	53.1	20	1	US-08-200-900A-31	Sequence 31, Appl
33	26	53.1	20	5	PCT-US94-00616-31	Sequence 31, Appl
34	26	53.1	25	1	US-08-468-709B-14	Sequence 14, Appl
35	26	53.1	25	2	US-08-241-664B-14	Sequence 14, Appl
36	25	51.0	7	4	US-09-258-754-402	Sequence 402, App
37	25	51.0	7	4	US-09-042-107-402	Sequence 402, App
38	25	51.0	8	1	US-08-375-962B-2	Sequence 2, Appli
39	25	51.0	8	2	US-08-562-114B-2	Sequence 2, Appli
40	25	51.0	8	4	US-08-729-594A-2	Sequence 2, Appli
41	25	51.0	8	4	US-08-937-993-2	Sequence 2, Appli
42	25	51.0	10	2	US-08-934-222-74	Sequence 74, Appl
43	25	51.0	10	2	US-08-933-402-74	Sequence 74, Appl
44	25	51.0	10	2	US-09-207-621-74	Sequence 74, Appl
45	25	51.0	10	2	US-08-532-818-74	Sequence 74, Appl

ALIGNMENTS

```
RESULT 1
US-08-747-137-122
; Sequence 122, Application US/08747137
; Patent No. 5945033
;  GENERAL INFORMATION:
;    APPLICANT:  YEN, Richard C.K.
;    TITLE OF INVENTION:  NON-CROSSLINKED PROTEIN PARTICLES FOR
;    TITLE OF INVENTION:  THERAPEUTIC AND DIAGNOSTIC USE
;    NUMBER OF SEQUENCES:  184
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/747,137
;       FILING DATE:  12-NOV-1996
;       CLASSIFICATION:  424
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/212,546
;       FILING DATE:  14-MAR-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/069,831
;       FILING DATE:  01-JUN-1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/959,560
;       FILING DATE:  13-OCT-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/641,720
;       FILING DATE:  15-JAN-1991
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Apple, Randolph T.
;       REGISTRATION NUMBER:  36,429
;       REFERENCE/DOCKET NUMBER:  016197-000840US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-576-0200
;   INFORMATION FOR SEQ ID NO:  122:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10 amino acids
;       TYPE:  amino acid
;       STRANDEDNESS:  not relevant
;       TOPOLOGY:  not relevant
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  1
;       OTHER INFORMATION:  /product= "p-Glu"
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  10
;       OTHER INFORMATION:  /product= "Thr-Amide"
US-08-747-137-122

  Query Match             71.4%;  Score 35;  DB 2;  Length 10;
  Best Local Similarity   71.4%;  Pred. No. 1.4;
  Matches    5;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2 LNFSPNW 8
           :|||| |
Db       2 VNFSPGW 8


RESULT 2
US-08-190-788A-14
; Sequence 14, Application US/08190788A
; Patent No. 5608035
;  GENERAL INFORMATION:
;     APPLICANT:  Yanofsky, Stephen D.
;     APPLICANT:  Barrett, Ronald W.
```

```
;    APPLICANT:  Baldwin, David N.
;    APPLICANT:  Jacobs, Jeff W.
;    TITLE OF INVENTION:  Peptides and Compounds That Bind to the
;    TITLE OF INVENTION:  IL-1 Receptor
;    NUMBER OF SEQUENCES:  312
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Affymax Technologies N.V.
;      STREET:  4001 Miranda Avenue
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/190,788A
;      FILING DATE:  02-FEB-1994
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/847,567
;      FILING DATE:  05-MAR-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stevens, Lauren L.
;      REGISTRATION NUMBER:  36,691
;      REFERENCE/DOCKET NUMBER:  1019.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-496-2300
;      TELEFAX:  415-424-0832
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-190-788A-14

  Query Match             67.3%;  Score 33;  DB 1;  Length 21;
  Best Local Similarity   62.5%;  Pred. No. 6.9;
  Matches    5;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 ELNFSPNW 8
           |  :||||
Db       1 ENTYSPNW 8


Search completed: April 11, 2003, 19:01:44
Job time : 14 secs
```

GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: April 11, 2003, 18:58:34 ; Search time 34 Seconds
(without alignments)
31.353 Million cell updates/sec

Title: PCT-US03-03800-20
Perfect score: 49
Sequence: 1 ELNFSPNW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 320064

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	41	83.7	11	22	AAB92383	Miscellaneous pept
2	40	81.6	10	20	AAY31073	Non-crosslinked pr
3	33	67.3	21	16	AAR90518	Interleukin-1 type
4	33	67.3	21	18	AAW16220	Peptide containing
5	33	67.3	21	18	AAW15976	Interleukin-1 type
6	33	67.3	21	19	AAW68853	Peptide binding in
7	33	67.3	21	19	AAW68614	Peptide binding in
8	33	67.3	21	19	AAW58086	Interleukin-1 type
9	33	67.3	21	20	AAY09989	Interleukin-1 type
10	33	67.3	21	20	AAY09706	Interleukin-1 type
11	33	67.3	21	21	AAB17160	IL-1 antagonist pe
12	33	67.3	21	21	AAB17769	IL-1 antagonist pe
13	33	67.3	21	21	AAB17817	IL-1 antagonist pe
14	33	67.3	21	23	ABB72407	Interleukin 1 anta
15	33	67.3	21	23	ABB72665	Interleukin 1 anta
16	33	67.3	21	23	ABB72708	Interleukin 1 anta
17	31	63.3	10	23	AAU82819	Human Calcitonin t
18	31	63.3	15	16	AAR63881	Human tumoural pro
19	29	59.2	9	19	AAW83225	NPF motif EH domai
20	28	57.1	5	13	AAR26473	Serotinin release
21	28	57.1	9	22	AAB98511	Human TADG-15 pept
22	28	57.1	12	15	AAR67058	Immunomodulator pe
23	28	57.1	12	23	ABB05292	Collar soils bindi
24	28	57.1	13	15	AAR49316	Beta2m position 52
25	28	57.1	23	22	AAU04076	Human partial Beta
26	28	57.1	23	22	AAU04077	Human partial Beta
27	28	57.1	25	22	AAB69564	Human Repro-EN-1.0
28	27	55.1	7	19	AAW65273	Cysteine analogue
29	27	55.1	7	19	AAW52003	Peptide having imm
30	27	55.1	7	19	AAW51932	Peptide #34 having
31	27	55.1	7	19	AAW51053	Penicillamine cont
32	27	55.1	12	22	AAB60035	Internalising pept
33	27	55.1	23	22	AAU04078	Human partial Beta
34	27	55.1	25	22	ABB41808	Peptide #9314 enco
35	27	55.1	25	22	ABB25533	Protein #7532 enco
36	27	55.1	25	22	AAM62680	Human brain expres
37	27	55.1	25	22	AAM75498	Human bone marrow
38	27	55.1	25	22	AAM20613	Peptide #7047 enco
39	27	55.1	25	22	AAM35604	Peptide #9641 enco
40	27	55.1	25	23	ABG45057	Human peptide enco
41	26	53.1	7	18	AAW45058	Immunomodulatory p
42	26	53.1	7	19	AAW51985	Peptide having imm
43	26	53.1	7	19	AAW51136	Methionine contain
44	26	53.1	7	20	AAY09470	Immunoactive pepti
45	26	53.1	10	15	AAY38149	Hepatitis B virus-

ALIGNMENTS

RESULT 1

AAB92383
ID AAB92383 standard; Peptide; 11 AA.
XX
AC AAB92383;
XX
DT 22-JUN-2001 (first entry)
XX
DE Miscellaneous peptide SEQ ID NO:1559.
XX
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;
KW blood component; modification; succinimidyl; maleimido group; amino;
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200069900-A2.
XX
PD 23-NOV-2000.
XX
PF 17-MAY-2000; 2000WO-US13576.
XX
PR 17-MAY-1999; 99US-0134406.
PR 10-SEP-1999; 99US-0153406.
PR 15-OCT-1999; 99US-0159783.
XX
PA (CONJ-) CONJUCHEM INC.
XX
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;
XX
DR WPI; 2001-112059/12.
XX
PT Modifying and attaching therapeutic peptides to albumin prevents
PT peptidase degradation, useful for increasing length of in vivo activity
PT -
XX
PS Disclosure; Page 714; 733pp; English.
XX
CC The present invention describes a modified therapeutic peptide (I)
CC comprising a therapeutically active amino acid region (III) and a
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to
CC a less therapeutically active amino acid region (IV), which covalently
CC bonds with amino/hydroxyl/thiol groups on blood components to form a
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth
CC factors and neurotransmitters, to protect them from peptidase activity
CC in vivo for the treatment of various disorders. Endogenous therapeutic
CC peptides are not suitable as drug candidates as they require frequent
CC administration due to rapid degradation by peptidases in the body.
CC Modifying and attaching therapeutic peptides to albumin prevents or
CC reduces the action of peptidases to increase length of activity (half
CC life) and specificity as bonding to large molecules decreases
CC intracellular uptake and interference with physiological processes.
CC AAB90829 to AAB92441 represent peptides which can be used in the
CC exemplification of the present invention.
XX
SQ Sequence 11 AA;

Query Match 83.7%; Score 41; DB 22; Length 11;
Best Local Similarity 85.7%; Pred. No. 0.15;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2 LNFSPNW 8
           |||:|||
Db       2 LNFTPNW 8
```

RESULT 3
AAR90518
ID AAR90518 standard; peptide; 21 AA.
XX
AC AAR90518;
XX
DT 14-MAR-1996 (first entry)
XX
DE Interleukin-1 type I receptor binding peptide #4.
XX
KW Interleukin-1 type I receptor; IL-1; IL-1RtI; atherosclerosis;
KW rheumatoid arthritis; osteoporosis; HIV; AIDS; bacterial infection;
KW respiratory distress syndrome; acute myelogenous leukaemia;
KW coal miner pneumococcus; alcoholic cirrhosis; cuprophane haemodyalisis;
KW cardiopulmonary bypass; chronic hepatitis B; thermal injury;
KW reticulohistiocytosis; sarcoidosis; tuberculosis; obstructive jaundice;
KW Paget's disease; osteomalacia; IDDM; Kawasaki's disease;
KW inflammatory bowel disease; sepsis; toxic shock; luteal phase; therapy.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 13..20
FT /note= "core sequence #1"
XX
PN WO9520973-A1.
XX
PD 10-AUG-1995.
XX
PF 01-FEB-1995; 95WO-US01590.
XX
PR 02-FEB-1994; 94US-0190788.
XX
PA (AFFY-) AFFYMAX TECHNOLOGIES NV.
XX
PI Baldwin D, Barrett RW, Jacobs JW, Yanofsky SD;
XX
DR WPI; 1995-283605/37.
XX
PT Interleukin-1 type I receptor binding compounds - used e.g. in the
PT treatment of osteoporosis, HIV and hepatitis B
XX
PS Claim 22; Page 53; 56pp; English.
XX
CC The sequences represented by R909515-AAR90527 are interleukin-1 type I
CC receptor (IL-1RtI) binding peptides. These peptides contain the core
CC sequence represented by AAR83759. These sequences block the binding of

CC IL-1 to IL-1RtI. The sequences were synthesised by using solid phase
CC synthesis. These sequences are useful in vitro for studying the IL-1
CC receptor binding process, for developing and assaying other compounds
CC which bind to the receptor, and for measuring the expression of IL-1RtI
CC on cell surfaces. They can also be used to monitor the effectiveness of
CC treatments which influence IL-1 production. They could also be used for
CC treating disorders which are susceptible to treatment with an IL-1
CC inhibitor, e.g. atherosclerosis, rheumatoid arthritis, osteoporosis,
CC HIV, AIDS, bacterial infection, respiratory distress syndrome, acute
CC myelogenous leukaemia, coal miner pneumococcus, graft vs. host disease,
CC alcoholic cirrhosis, cuprophane haemodyalisis, cardiopulmonary bypass,
CC chronic hepatitis B, thermal injury, reticulohistiocytosis, sarcoidosis,
CC tuberculosis, obstructive jaundice, Paget's disease, osteomalacia, IDDM,
CC Kawasaki's disease, inflammatory bowel disease, sepsis, toxic shock and
CC luteal phase. These compounds may also be conjugated so that they act
CC as antagonists, or agonists, of IL-1RtI and may be used to direct a
CC cytotoxic or therapeutic agent to a cell expressing this receptor.
XX
SQ Sequence 21 AA;

Query Match 67.3%; Score 33; DB 16; Length 21;
Best Local Similarity 62.5%; Pred. No. 12;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy      1 ELNFSPNW 8
          |  :||||
Db      1 ENTYSPNW 8
```

RESULT 14
ABB72407
ID ABB72407 standard; Peptide; 21 AA.
XX
AC ABB72407;
XX
DT 05-APR-2002 (first entry)
XX
DE Interleukin 1 antagonist peptide SEQ ID NO:216.
XX
KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW sleep disorder; neurological degenerative disease; anaemia;
KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW Fanconi's syndrome.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200183525-A2.
XX
PD 08-NOV-2001.

XX
PF 02-MAY-2001; 2001WO-US14310.
XX
PR 03-MAY-2000; 2000US-0563286.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR WPI; 2002-130313/17.
XX
PT Novel vehicle-peptide molecule or its multimers useful for treating
PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS Claim 39; Page 32; 176pp; English.
XX
CC The present invention describes a vehicle-peptide molecule (I) or its
CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC neuroprotective activities. (I) can be used as a therapeutic or
CC prophylactic agent as well as for screening purposes. (I) is useful for
CC diagnosing diseases characterised by dysfunction of their associated
CC protein of interest, for identifying normal or abnormal proteins of
CC interest, as a part of diagnostic kit to detect the presence of their
CC proteins of interest in a biological sample. Additionally, (I) is useful
CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC infertility, and neurological degenerative diseases. (I), comprising
CC EPO-mimetic compounds are useful for treating disorders characterised by
CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC compounds are useful for treating conditions that involve an existing
CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC represent amino acid and nucleic acid sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 AA;

Query Match 67.3%; Score 33; DB 23; Length 21;
Best Local Similarity 62.5%; Pred. No. 12;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1 ELNFSPNW 8
            |  :||||
Db       1 ENTYSPNW 8
```

Search completed: April 11, 2003, 19:00:09
Job time : 35 secs

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: 10-7-2003
Art Unit: 1654 Phone Number 308-3975 Serial Number: 10/072,419
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL
CM1-11013/ CM1-9807

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Compositions And Methods For Promoting Lipid Mobilization In Humans

Inventors (please provide full names): B. Schacter, L. Schacter

Earliest Priority Filing Date: 2-7-2002

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the following partial sequence in STN:

[NT] [FY] [TS] [PSTA] [K].

If necessary, please require any hits to have 25 or fewer residues.

Thank you.

JR

RECEIVED
OCT - 7 2003
TECH CENTER 1600/2900

****

STAFF USE ONLY

Point of Contact
P. Sheppard
telephone number: (703) 308-4499

Searcher: _____ Type of Search NA Sequence (#)_____ Vendors and cost where applicable STN _____

Searcher Phone #: AA Sequence (#) Dialog _____

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:52:53 ON 07 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 7 Oct 2003  VOL 139 ISS 15
FILE LAST UPDATED: 5 Oct 2003  (20031005/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que
L1          8288 SEA FILE=REGISTRY ABB=ON  PLU=ON  [NT][FY][TS][PSTA]K/SQSP
L2            59 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 AND SQL<=25
L3            51 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2


=>
=>

=> d ibib abs hitrn l3 1-51

L3   ANSWER 1 OF 51  HCAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:717612  HCAPLUS
TITLE:                    Protein and cDNA sequences of a novel human G
                          protein-coupled receptor hgprbmy6, expressed highly in
                          small intestine
INVENTOR(S):              Feder, John N.; Mintier, Gabriel; Ramanathan, Chandra
                          S.; Hawken, Donald R.; Cacace, Angela M.; Barber,
                          Lauren E.; Kornacker, Michael G.; Nelson, Thomas C.;
                          Bol, David K.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 99 pp., Cont.-in-part of U.S.
                          Ser. No. 966,422.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     US 2003170671      A1   20030911       US 2002-262272    20020927
     US 2003044892      A1   20030306       US 2001-966422    20010926
PRIORITY APPLN. INFO.:                   US 2000-235602P   P  20000927
                                         US 2001-306604P   P  20010719
                                         US 2001-315412P   P  20010828
```

US 2001-966422 A2 20010926

AB The present invention provides protein and cDNA sequences of a newly discovered human G-protein coupled receptor hgprbmy6 that expresses highly in small intestine. Also described are expression vectors, host cells, agonists, antagonists, antisense mols., and antibodies assocd. with the polynucleotide and/or polypeptide of the present invention. In addn., methods for treating, diagnosing, preventing, and screening for disorders assocd. with aberrant cell growth and diseases or disorders related to the small intestine.

IT **408305-90-8**
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of a novel human G protein-coupled receptor hgprbmy6, expressed highly in small intestine)

L3 ANSWER 2 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:570453 HCAPLUS
DOCUMENT NUMBER: 139:132437
TITLE: Lung cancer antigens and cDNAs encoding them and their diagnostic, prophylactic and therapeutic uses
INVENTOR(S): Mericle, Barbara; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Henderson, Robert A.; Kalos, Michael D.; Spies, A. Gregory; Foy, Teresa M.; Fan, Liqun; Wang, Tongtong
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S. Ser. No. 7,700.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003138438	A1	20030724	US 2002-117982	20020405
US 6312695	B1	20011106	US 1998-123912	19980727
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130

PRIORITY APPLN. INFO.:

US 1998-40802	B2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404
US 2000-606421	A2	20000628
US 2000-630940	A2	20000802
US 2000-643597	A2	20000821
US 2000-662786	B2	20000915
US 2000-685696	A2	20001009
US 2000-735705	A2	20001212
US 2001-850716	A2	20010507
US 2001-897778	A2	20010628
US 2001-7700	A2	20011130

WO 1999-US5798 A1 19990317

AB Lung cancer-specific antigens are identified and characterized and cDNAs encoding a no. of them are cloned and characterized. The antigens, or epitopes derived from them may be useful in the diagnosis, prevention, or treatment of lung cancer. Characterization of a no. of antigens, including tissue distribution and the identification of T cell epitopes is demonstrated.

IT **387817-80-3**
RL: PRP (Properties)
(unclaimed sequence; lung cancer antigens and cDNAs encoding them and their diagnostic, prophylactic and therapeutic uses)

L3 ANSWER 3 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:491266 HCAPLUS
DOCUMENT NUMBER: 139:67789
TITLE: C-C chemokine antagonistic mutants for treating autoimmune and inflammatory diseases, cancers and infections
INVENTOR(S): Proudfoot, Amanda; Kosco-Vilbois, Marie; Shaw, Jeffrey
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051921	A1	20030626	WO 2002-EP14325	20021216

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2001-761 A 20011217

AB Mutants of specific CC-chemokines contg. a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants.

IT **549494-95-3**
RL: PRP (Properties)
(unclaimed sequence; c-C chemokine antagonistic mutants for treating autoimmune and inflammatory diseases, cancers and infections)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:356709 HCAPLUS
DOCUMENT NUMBER: 138:362621
TITLE: Liver response-associated protein isoforms as biomarkers of liver response to exogenous agents, including drugs, and to disease
INVENTOR(S): Amacher, David E.; Fasulo, Lisa M.; Herath, Herath Mudiyanselage Athua Chandrasiri; Holt, Gordon Duane; Stiger, Thomas R.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Oxford Glycosciences (UK) Ltd.
SOURCE: PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038444	A2	20030508	WO 2002-US34847	20021031

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-335964P P 20011031

AB The present invention provides methods and compns. for screening, diagnosing and prognosing liver response, for monitoring the effectiveness of liver response to treatment, and for drug development. The method involves testing a biol. sample (blood, serum, plasma, urine, liver tissue) for Liver Response-Assocd. Protein Isoforms (LRPIs). Antibodies or oligonucleotide probes can be used to detect LRPIs. A kit is also claimed comprising antibodies, other reagents, and instructions.

IT **521939-37-7**
RL: PRP (Properties)
(unclaimed sequence; liver response-assocd. protein isoforms as biomarkers of liver response to exogenous agents, including drugs, and to disease)

L3 ANSWER 5 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:261014 HCAPLUS
DOCUMENT NUMBER: 138:302631
TITLE: Lung carcinoma-derived polypeptides, polynucleotides, probes and primers, and antibodies for cancer therapy and diagnosis
INVENTOR(S): Wang, Tongtong; Wang, Aijun; Skeiky, Yasir A. W.; Li, Samuel X.; Kalos, Michael D.; Henderson, Robert A.; McNeill, Patricia D.; Fanger, Neil; Retter, Marc W.; Durham, Margarita; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Peckham, David W.; Cai, Feng; Foy, Teresa M.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 296 pp., Cont.-in-part of U.S. Ser. No. 897,778.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6312695	B1	20011106	US 1998-123912	19980727
US 2003119763	A1	20030626	US 1999-466396	19991217

US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003138438	A1	20030724	US 2002-117982	20020405

PRIORITY APPLN. INFO.:

US 1998-40802	A2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404
US 2000-606421	A2	20000628
US 2000-630940	A2	20000802
US 2000-643597	A2	20000821
US 2000-662786	A2	20000915
US 2000-685696	A2	20001009
US 2000-735705	A2	20001212
US 2001-850716	A2	20010507
US 2001-897778	A2	20010628
WO 1999-US5798	A1	19990317
US 2001-7700	A2	20011130

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The lung tumor antigens and encoding polynucleotides are isolated and characterized from human lung squamous cell carcinoma cDNA expression library by PCR-based subtraction, and human monoclonal antibodies and hybridomas are generated from transgenic mice.

IT **387817-80-3**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lung carcinoma-derived polypeptides, polynucleotides, probes and primers, and antibodies for cancer therapy and diagnosis)

L3 ANSWER 6 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:97435 HCAPLUS
DOCUMENT NUMBER: 138:149946
TITLE: Production of acylated polypeptides by recombinant expression of precursor proteins followed by acylation at the lysine .epsilon.-amino groups and proteolytic cleavage of the N-terminal extension
INVENTOR(S): Diers, Ivan; Balschmidt, Per; Markussen, Jan; Jonassen, Ib; Egel-Mitani, Michi; Kjeldsen, Thomas Borglum
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010186	A2	20030206	WO 2002-DK502	20020718

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003144471 A1 20030731 US 2002-205110 20020724
PRIORITY APPLN. INFO.: DK 2001-1141 A 20010724
US 2001-310793P P 20010808

OTHER SOURCE(S): MARPAT 138:149946

AB The present invention is related to a method of producing polypeptides in transformed host cells by expressing a precursor mol. of the desired polypeptide which is to be acylated at certain lysine .epsilon.-amino groups in a subsequent in vitro step. The N-terminal extensions allow for preferential acylation of the expressed precursor mol. and protects the expressed precursor mol. against proteolytic degrdn. within the host cell or in the culture medium. In addn., the precursor mol. is easier to purify and has a decreased tendency to form fibrils, thus allowing more flexibility when selecting down-stream sepn. and purifn. steps in large scale operations. The invention is also related to DNA sequences, vectors, and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. Thus EEAHK-Arg34(glucagon-like peptide I)(7-37)-Lys26 .gamma.-Glu-hexadecanoyl is produced in 52% yield with acylation of the N-terminal extended GLP-1(7-37) with Glu(ONSu)N-hexadecanoyl Me ester in the presence of 2 equiv of Zn2+ in CH3CN.

IT **494863-53-5**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(N-terminal extension; prodn. of acylated polypeptides by recombinant expression of precursor proteins followed by acylation at the lysine .epsilon.-amino groups and proteolytic cleavage of the N-terminal extension)

L3 ANSWER 7 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857455 HCAPLUS
DOCUMENT NUMBER: 137:380984
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XN11654	20020410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **474899-11-1**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 8 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857453 HCAPLUS
DOCUMENT NUMBER: 137:380982
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XL11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **474899-11-1**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 9 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857451 HCAPLUS
DOCUMENT NUMBER: 137:380980
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XJ11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **474842-20-1**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 10 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857450 HCAPLUS
DOCUMENT NUMBER: 137:380979
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XI11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **473790-80-6**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 11 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857449 HCAPLUS
DOCUMENT NUMBER: 137:380978
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XH11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **473328-98-2**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 12 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857448 HCAPLUS
DOCUMENT NUMBER: 137:380977
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XG11654	20020410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressedn in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **473790-80-6**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 13 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857447 HCAPLUS
DOCUMENT NUMBER: 137:380976
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XF11654	20020410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAsd corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **473328-98-2**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 14 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857443 HCAPLUS
DOCUMENT NUMBER: 137:321378
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XC11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **473790-80-6 473791-54-7**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 15 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:857436 HCAPLUS
DOCUMENT NUMBER: 137:321376
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XA11654	20020410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-US11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **473468-12-1 473468-22-3 473468-36-9**
473468-80-3 473469-06-6 473469-07-7
473469-21-5 473469-46-4 473469-67-9
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 16 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:814341 HCAPLUS
DOCUMENT NUMBER: 137:334071
TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-US11654	20020410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XA11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XB11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XC11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XD11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XE11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XF11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XG11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XH11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XI11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XJ11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XK11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XL11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XM11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XN11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XO11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003109470 A1 20030612 US 2002-121019 20020410
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **473328-98-2**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L3 ANSWER 17 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:778703 HCAPLUS
DOCUMENT NUMBER: 137:290681
TITLE: Lung cancer-associated cDNAs and proteins and their use in diagnosis and therapy
INVENTOR(S): Wang, Tongtong; Durham, Margarita; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Darrick; Watanabe,

Yoshihiro; Henderson, Robert A.; Peckham, David W.; Fanger, Neil
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 287 pp., Cont.-in-part of U.S. Ser. No. 850,716.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002147143	A1	20021010	US 2001-897778	20010628
US 6312695	B1	20011106	US 1998-123912	19980727
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002028940	A5	20020624	AU 2002-28940	20011130
US 2003064947	A1	20030403	US 2001-7700	20011130
US 2003138438	A1	20030724	US 2002-117982	20020405

PRIORITY APPLN. INFO.:

US 1998-40802	A2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404
US 2000-606421	A2	20000628
US 2000-630940	A2	20000802
US 2000-643597	A2	20000821
US 2000-662786	A2	20000915
US 2000-685696	A2	20001009
US 2000-735705	A2	20001212
US 2001-850716	A2	20010507
WO 1999-US5798	A1	19990317
US 2001-897778	A	20010628
US 2001-7700	A2	20011130
WO 2001-US47576	W	20011130

AB The cDNAs and corresponding proteins corresponding to mRNAs differentially expressed in lung squamous cell carcinoma and lung adenocarcinoma are disclosed. Antibodies to the lung cancer-assocd. proteins and probes for lung cancer-assocd. nucleic acids may be used in diagnosis of lung cancer. The proteins and cDNAs, antibodies to the proteins, T cells specific for these tumor proteins, and antigen-presenting cells expressing an epitope

of these proteins may be used in treatment of lung cancer, e.g., in vaccines. Thus, many novel lung cancer-assocd. cDNAs/proteins were identified and their expression in normal and tumor tissues examd. Some of these cDNAs were expressed in E. coli, HEK293, and CHL-1 cells. N- and C-terminal fragments of one of the proteins were expressed as fusions with Mycobaceterium tuberculosis 32-kilodalton serine proteinase-derived peptide. CTL lines specific for one of the tumor antigens were generated by in vitro whole-gene priming.

IT **387817-80-3**
RL: PRP (Properties)
(unclaimed sequence; lung cancer-assocd. cDNAs and proteins and their use in diagnosis and therapy)

L3 ANSWER 18 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:716429 HCAPLUS
DOCUMENT NUMBER: 137:246529
TITLE: Induction of tumor immunity by variants of folate binding protein
INVENTOR(S): Ioannides, Constantin G.; Peoples, George E.
PATENT ASSIGNEE(S): Board of Regents, University of Texas System, USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072766	A2	20020919	WO 2002-US7167	20020308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003185840	A1	20031002	US 2002-94097	20020308

PRIORITY APPLN. INFO.: US 2001-274676P P 20010309

AB The present invention is directed to variants of antigens comprising folate binding protein epitopes as a compn. assocd. with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.

IT **460039-30-9**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer vaccines comprising variants of folate binding protein epitopes)

L3 ANSWER 19 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:638210 HCAPLUS
DOCUMENT NUMBER: 137:196735
TITLE: Differentially expressed sequences and proteins for use in the therapy and diagnosis of human lung cancer
INVENTOR(S): Kalos, Michael D.; McNeill, Patricia D.; Retter, Marc W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 276 pp., Cont.-in-part of U.S.

Ser. No. 735,705.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002052329	A1	20020502	US 2000-735705	20001212
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028940	A5	20020624	AU 2002-28940	20011130
US 2003064947	A1	20030403	US 2001-7700	20011130
US 2003138438	A1	20030724	US 2002-117982	20020405

PRIORITY APPLN. INFO.:

US 2000-735705	A2	20001212
US 1998-40802	A2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404
US 2000-606421	A2	20000628
US 2000-630940	A2	20000802
US 2000-643597	A2	20000821
US 2000-662786	A2	20000915
US 2000-685696	A2	20001009
US 2001-850716	A	20010507
US 2001-897778	A	20010628
WO 2001-US21065	W	20010628
US 2001-7700	A2	20011130
WO 2001-US47576	W	20011130

AB Lung-specific expressed genes (cDNA) and their encoded proteins useful for

the therapy and diagnosis of cancer, particularly lung cancer, are identified. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IT **387817-80-3**
RL: ANT (Analyte); BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(L523S peptide; differentially expressed sequences and proteins for use in therapy and diagnosis of human lung cancer)

L3 ANSWER 20 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:539801 HCAPLUS
DOCUMENT NUMBER: 137:106028
TITLE: Cell or cell extract containing Skp2, p27, and Cks1 for identification of compounds useful for treatment of proliferative and differentiative disorders
INVENTOR(S): Pagano, Michele
PATENT ASSIGNEE(S): New York University, USA
SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055665	A2	20020718	WO 2002-US311	20020107
WO 2002055665	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002123082	A1	20020905	US 2002-42417	20020107

PRIORITY APPLN. INFO.: US 2001-260179P P 20010105

AB The present invention relates to the use of cells or cell exts. contg. the F box protein Skp2 (S-phase kinase-assocd. protein 2), p27 (a cell cycle-regulated cyclin-dependent kinase inhibitor) or p27 C-terminal fragment, and Cks1 (cyclin-dependent kinase subunit 1) for screening for potential therapeutic agents for the treatment of proliferative and differentiative disorders, such as cancer. The action of the potential drug comprises modulation of the activity of Skp2, which may be detected as a change in interaction of Skp2 with p27 or Cks1, by a change in ubiquitination of p27, or by degrdn. of p27 or Cks1.

IT **260388-05-4**
RL: PRP (Properties)
(unclaimed sequence; cell or cell ext. contg. Skp2, p27, and Cks1 for identification of compds. useful for treatment of proliferative and differentiative disorders)

L3 ANSWER 21 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:332673 HCAPLUS

DOCUMENT NUMBER: 136:354185
TITLE: Lung tumor-specific antigen, chimeric antigens, polynucleotides, and antibodies for therapy and diagnosis of lung cancer
INVENTOR(S): Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur, Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Henderson, Robert A.; McNeill, Patricia D.; Fanger, Neil
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 685,696.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002052329	A1	20020502	US 2000-735705	20001212
US 6312695	B1	20011106	US 1998-123912	19980727
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002115139	A1	20020822	US 2001-850716	20010507
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028940	A5	20020624	AU 2002-28940	20011130
US 2003064947	A1	20030403	US 2001-7700	20011130
US 2003138438	A1	20030724	US 2002-117982	20020405

PRIORITY APPLN. INFO.: US 1998-40802 A2 19980318
US 1998-123912 A2 19980727
US 1998-221107 A2 19981222
US 1999-285479 A2 19990402

US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404
US 2000-606421	A2	20000628
US 2000-630940	A2	20000802
US 2000-643597	A2	20000821
US 2000-662786	A2	20000915
US 2000-685696	A2	20001009
WO 1999-US5798	A1	19990317
US 2000-735705	A2	20001212
US 2001-850716	A	20010507
US 2001-897778	A	20010628
WO 2001-US21065	W	20010628
US 2001-7700	A2	20011130
WO 2001-US47576	W	20011130

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IT **387817-80-3**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lung tumor-specific antigen, chimeric antigens, polynucleotides, and antibodies for therapy and diagnosis of lung cancer)

L3 ANSWER 22 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:256474 HCAPLUS
DOCUMENT NUMBER: 136:290007
TITLE: cDNA and protein sequence of a novel human G protein-coupled receptor sequence homolog HGPRBMY6 and their uses in drug screening
INVENTOR(S): Feder, John N.; Mintier, Gabe; Ramanathan, Chandra Sekar; Hawken, Donald R.; Cacace, Angela; Barber, Lauren; Kornacker, Michael G.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026987	A2	20020404	WO 2001-US30614	20010926
WO 2002026987	A3	20030515		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002012990	A5	20020408	AU 2002-12990	20010926
EP 1325131	A2	20030709	EP 2001-981339	20010926

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-235602P P 20000927
US 2001-306604P P 20010719
US 2001-315412P P 20010828
WO 2001-US30614 W 20010926

AB The present invention describes a newly discovered human G-protein coupled receptor sequence homolog HGPRBMY6 and its encoding polynucleotide. The HGPRBMY6 is expressed highly in human small intestine and related to latrophilin, .alpha.-latrotoxin and CL3 receptors based on sequence similarity. The HGPRBMY6 can be used in drug screening, therapy and diagnosis of disorders related to over- and under-expression of HGPRBMY6.

IT **408305-90-8**
RL: PRP (Properties)
(unclaimed sequence; cDNA and protein sequence of a novel human G protein-coupled receptor sequence homolog HGPRBMY6 and their uses in drug screening)

L3 ANSWER 23 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:94109 HCAPLUS
DOCUMENT NUMBER: 136:117375
TITLE: Antigenic peptides from Neisseria meningitidis and Neisseria gonorrhoeae
INVENTOR(S): Galeotti, Cesira; Grandi, Guido; Masignani, Vega; Mora, Mariarosa; Pizza, Mariagrazia; Rappuoli, Rino; Ratti, Guilio; Scarlato, Vincenzo; Scarselli, Maria
PATENT ASSIGNEE(S): Chiron S.p.A., Italy
SOURCE: PCT Int. Appl., 974 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001031019 A2		20010503	WO 2000-IB1661	20001030

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-PV162616 19991029

AB This invention provides proteins and fragments thereof derived from the bacteria Neisseria meningitidis serotype A, N. meningitidis serotype B, and N. gonorrhoeae. Th protein sequences disclosed in International Application patents WO 1999/57280 and WO 2000/22430 were subjected to computer anal. to predict antigenic peptide fragments, using three algorithms: AMPHI, ANTIGENIC INDEX, and HYDROPHOBICITY. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto (e.g., antisense nucleic acids). Addnl., this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compns. of the protein fragments and/or nucleic acids for use as vaccines, diagnostic reagents, immunogenic compns., and the like. [This abstr. record is the sixth of 8 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

IT **375806-38-5**

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; Neisseria meningitidis and N. gonorrhoeae antigens and the genes encoding them for use as vaccine and diagnostic compns.)

L3 ANSWER 24 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:10236 HCAPLUS
DOCUMENT NUMBER: 136:101081
TITLE: Compositions and methods for the therapy and diagnosis of lung cancer
INVENTOR(S): Wang, Tongtong; Wang, Aijun; Skeiky, Yasir A. W.; Li, Samuel X.; Kalos, Michael D.; Henderson, Robert A.; Mcneill, Patricia D.; Fanger, Neil; Retter, Marc W.; Marnerakis, Margarita; Fanger, Gary Richard; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Peckham, David W.
PATENT ASSIGNEE(S): Corixa Corp., USA
SOURCE: PCT Int. Appl., 374 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6531315	B1	20030311	US 2000-606421	20000628
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
AU 2001073149	A5	20020108	AU 2001-73149	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:

US 2000-606421	A	20000628
US 2000-630940	A	20000802
US 2000-643597	A	20000821
US 2000-662786	A	20000915
US 2000-685696	A	20001009
US 2000-735705	A	20001212
US 2001-850716	A	20010507
US 1998-40802	B2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
WO 1999-US5798	A1	19990317
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404

WO 2001-US21065 W 20010628

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IT **387817-80-3**
RL: PRP (Properties)
(unclaimed sequence; compns. and methods for the therapy and diagnosis of lung cancer)

L3 ANSWER 25 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:871941 HCAPLUS
DOCUMENT NUMBER: 136:4714
TITLE: Antigenic peptides from Neisseria meningitidis and Neisseria gonorrhoeae
INVENTOR(S): Galeotti, Cesira; Grandi, Guido; Masignani, Vega; Mora, Mariarosa; Pizza, Mariagrazia; Rappuoli, Rino; Ratti, Guilio; Scarlato, Vincenzo; Scarselli, Maria
PATENT ASSIGNEE(S): Chiron S.p.A., Italy
SOURCE: PCT Int. Appl., 974 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001031019 A2		20010503	WO 2000-IB1661	20001030

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-PV162616 19991029

AB This invention provides proteins and fragments thereof derived from the bacteria Neisseria meningitidis serotype A, N. meningitidis serotype B, and N. gonorrhoeae. Th protein sequences disclosed in International Application patents WO 1999/57280 and WO 2000/22430 were subjected to computer anal. to predict antigenic peptide fragments, using three algorithms: AMPHI, ANTIGENIC INDEX, and HYDROPHOBICITY. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto (e.g., antisense nucleic acids). Addnl., this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compns. of the protein fragments and/or nucleic acids for use as vaccines, diagnostic reagents, immunogenic compns., and the like. [This abstr. is the fourth of 8 records for this codument necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

IT **375806-38-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; Neisseria meningitidis and N. gonorrhoeae antigens and the genes encoding them for use as vaccine and diagnostic

compns.)

L3 ANSWER 26 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:507834 HCAPLUS
DOCUMENT NUMBER: 135:106297
TITLE: Preparation of deallergenized patatins and permuteins and their use as insecticides
INVENTOR(S): Alibhai, Murtaza F.; Astwood, James D.; McWherter, Charles A.; Sampson, Hugh A.
PATENT ASSIGNEE(S): Monsanto Company, USA; Monsanto Technology LLC
SOURCE: PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049834	A2	20010712	WO 2001-US342	20010105
WO 2001049834	A3	20020906		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2001007474	A	20021008	BR 2001-7474	20010105
EP 1254167	A2	20021106	EP 2001-900904	20010105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-174669P P 20000106
WO 2001-US342 W 20010105

AB Modified potato patatins are disclosed that maintain enzymic (lipid acyl hydrolase) and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were obsd. to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was obsd. to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymic activity. Deallerginized patatins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.

IT **350229-19-5**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(prepn. of deallergenized patatins and permuteins and their use as insecticides)

IT **350258-05-8 350258-06-9 350472-94-5 350472-95-6 350472-96-7 350472-97-8 350472-98-9 350473-05-1 350473-07-3 350473-12-0 350473-13-1 350473-16-4 350473-71-1**
RL: PRP (Properties)
(unclaimed sequence; prepn. of deallergenized patatins and permuteins and their use as insecticides)

L3 ANSWER 27 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:507831 HCAPLUS
DOCUMENT NUMBER: 135:118780

TITLE: Improved lysosomal enzymes and lysosomal enzyme activators containing additional glycosylation sites introduced by site-specific mutagenesis

INVENTOR(S): Okkels, Jens Sigurd; Jensen, Anne Dam; Halkier, Torben; Jensen, Rikke Bolding; Schambye, Hans Thalsgaard

PATENT ASSIGNEE(S): Maxygen Aps, Den.

SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049830	A2	20010712	WO 2000-DK743	20001229
WO 2001049830	A3	20020207		
WO 2001049830	C2	20021107		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002127219	A1	20020912	US 2000-753126	20001229
EP 1246915	A2	20021009	EP 2000-987208	20001229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002002597	A2	20020110	WO 2001-DK459	20010629
WO 2002002597	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003036181	A1	20030220	US 2001-896896	20010629
EP 1299535	A2	20030409	EP 2001-944987	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:

DK 1999-1891	A	19991230
DK 2000-865	A	20000602
DK 2000-866	A	20000602
DK 2000-1027	A	20000630
US 2000-174652P	P	20000106
US 2000-210984P	P	20000612
US 2000-211124P	P	20000612
US 2000-217497P	P	20000711
DK 2000-1092	A	20000714
US 2000-225558P	P	20000816
WO 2000-DK743	W	20001229
WO 2001-DK90	W	20010209
WO 2001-DK459	W	20010629

AB A polypeptide selected from the group of lysosomal enzymes and lysosomal enzyme activators, comprising at least one introduced glycosylation site as compared to a corresponding parent enzyme or activator. By introducing addnl. glycosylation sites the resulting glycosylated lysosomal enzyme or

activator obtains improved in vivo activity and thereby provides for improved treatment of lysosomal storage diseases. Thus, in particular, glycosylation sites (Ser or Thr residues) are introduced into human glucocerebrosidase, and esp. in peptide addns. to the N-terminus of glucocerebrosidase. A fusion protein was also constructed comprising saposin C, a linker peptide, and human glucocerebrosidase. The N-glycan structures in glucocerebrosidase and its variants expressed in insect cells are characterized.

IT **350581-18-9**
RL: PRP (Properties)
(unclaimed sequence; improved lysosomal enzymes and lysosomal enzyme activators contg. addnl. glycosylation sites introduced by site-specific mutagenesis)

L3 ANSWER 28 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:489670 HCAPLUS
DOCUMENT NUMBER: 135:88016
TITLE: Nucleic acids containing single nucleotide polymorphisms in the human genome
INVENTOR(S): Shimkets, Richard A.; Leach, Martin
PATENT ASSIGNEE(S): Curagen Corp., USA
SOURCE: PCT Int. Appl., 484 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001048245	A2	20010705	WO 2000-US35346	20001227
WO 2001048245	A3	20021128		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1282726	A2	20030212	EP 2000-990358	20001227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 1999-472688 A2 19991227
WO 2000-US35346 W 20001227

AB The invention provides 651 nucleic acids contg. single-nucleotide polymorphisms (SNPs) identified for transcribed human sequences, as well as methods of using the nucleic acids. The polymorphisms are arranged in the order: 422 nucleotide sequences for SNPs that are silent; 58 nucleotide sequences for SNPs that lead to conservative amino acid changes; 139 nucleotide changes for SNPs that lead to nonconservative amino acid changes; and 32 nucleotide sequences for SNPs that involve a gap. In particular, the polymorphisms are related to angiopoietin, 4-hydroxybutyrate dehydrogenase, ATP-dependent RNA helicase, MHC Class I histocompatibility antigen, or phosphoglycerate kinase.

IT **345315-58-4**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(SNP involving nonconservative amino acid change; nucleic acids contg. single nucleotide polymorphisms in the human genome)

L3 ANSWER 29 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:435102 HCAPLUS
DOCUMENT NUMBER: 135:56043
TITLE: Complementary peptide ligands generated from higher eukaryote genome sequences
INVENTOR(S): Roberts, Gareth Wyn; Heal, Jonathan Richard
PATENT ASSIGNEE(S): Proteom Limited, UK
SOURCE: PCT Int. Appl., 488 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042276	A1	20010614	WO 2000-GB4773	20001213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1244691	A1	20021002	EP 2000-981486	20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: GB 1999-29471 A 19991213
WO 2000-GB4773 W 20001213

AB The invention relates to the identification of complementary peptides from the anal. of protein and nucleotide sequence databases from higher eukaryote genomes excluding human and plants. These specific complementary peptides interact with their relevant target proteins encoded in the eukaryote genome. Specific complementary peptides to the proteins encoded in the eukaryote genome can be used as reagents and drugs from drug discovery programs and as lead ligands to facilitate drug design and development.

IT **345600-50-2 345600-52-4**
RL: PRP (Properties)
(unclaimed sequence; complementary peptide ligands generated from higher eukaryote genome sequences)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:338721 HCAPLUS
DOCUMENT NUMBER: 134:364015
TITLE: Sequences of antigenic proteins of a group B Streptococcus and the genes encoding them and their uses in vaccination
INVENTOR(S): Le Page, Richard William Falla; Wells, Jeremy Mark; Hanniffy, Sean Bosco
PATENT ASSIGNEE(S): Microbial Technics Limited, UK
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001032882	A2	20010510	WO 2000-GB3437	20000907
WO 2001032882	A3	20011115		
W: CA, CN, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1214417	A2	20020619	EP 2000-958822	20000907
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003527100	T2	20030916	JP 2001-535564	20000907
US 2003170782	A1	20030911	US 2002-91007	20020306

PRIORITY APPLN. INFO.: GB 1999-21125 A 19990907
WO 2000-GB3437 W 20000907

AB The invention provides protein and DNA sequences of novel protein antigens from Streptococcus agalactiae, a group B Streptococcus. Their use in vaccines and screening methods is also described. Gene/partial gene sequences putatively encoding exported proteins in S. agalactiae have been identified using the nuclease screening system vis the LEEP (Lactococcus Expression of Exported Proteins) system. Genes contg. signal sequences were identified using a nuclease reporter gene. Tru9I restriction digest fragments were cloned upstream of the nuclease gene and transformants screened using a DNA-Toluidine blue agar overlay which allowed colonies secreting the nuclease to be detected by formation of a pink halo. Mice vaccinated with a no. of the genes showed statistically significant longer survival time than did unvaccinated controls when challenged with. S. agalactiae.

IT **339523-85-2**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; sequences of antigenic proteins of group B Streptococcus and genes encoding them and their uses in vaccination)

L3 ANSWER 31 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:319937 HCAPLUS
DOCUMENT NUMBER: 134:336710
TITLE: Protein and cDNA sequences of a novel human zinc finger-containing protein 56 (ZFP56) and diagnostic and therapeutic uses thereof
INVENTOR(S): Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S): Shanghai Bio Road Gene Development Ltd., Peop. Rep. China
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030827	A1	20010503	WO 2000-CN393	20001027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CN 1303936	A	20010718	CN 1999-119861	19991027

PRIORITY APPLN. INFO.: CN 1999-119861 A 19991027

AB The invention provides protein and cDNA sequences for a novel human zinc

L3 ANSWER 43 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:69165 HCAPLUS
DOCUMENT NUMBER: 122:183539
TITLE: Probing the steric tolerance of the insect hypertrehalosemic hormone receptor to develop an effective photoaffinity probe
AUTHOR(S): Hayes, T. K.; Nails, F. L.; Ford, M. M.
CORPORATE SOURCE: Institute of Biosciences and Technology, Texas A&M University, College Station, TX, 77843, USA
SOURCE: Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 13th (1994), Meeting Date 1993, 666-8. Editor(s): Hodges, Robert S.; Smith, John A. ESCOM: Leiden, Neth.
CODEN: 60LXAW
DOCUMENT TYPE: Conference
LANGUAGE: English
AB Hypertrehalosemic hormone (HTH) stimulates the insect fat body to synthesize and release trehalose into the hemolymph. This study involved structure-activity studies in the cockroach Blaberus discoidalis to develop a photoaffinity label to study the properties of HTH receptors. Single amino acid replacement analogs helped det. that the most crit. side chains were pGlu1, Phe4, and Trp8. The ring nature of the pGlu seems important and the aromaticity of the Phe and Trp is required. A series of analogs where a single amino acid was replaced with its D-enantiomer were compared with the bioassay system to gain initial indications where important conformational elements might be located or induced for receptor interaction. The loss of activity or potency around the arom. amino acids confirms the importance of these residues towards the biol. activity of HTH. The relatively high potency of HTH analogs that have D-amino acids in positions 6 or 7 is a first indicator that a turn centered around the Pro-Gly sequence may be important for the biol. activity of the hormone. The design of a photoaffinity label to better study the properties of HTH receptors must include a site for radioiodination. However, attempts to either incorporate a site for iodination or to iodinate acceptable sites resulted in analogs that were inactive or had unacceptably low potencies. The aim of addnl. analogs is to attach radioiodination and photocrosslinking sites outside the region of HTH that is crit. for receptor interaction. The construction of a branched chain analog at position 7 in the D-configuration is the best candidate to continue this approach.
IT **161389-51-1 161389-55-5 161510-72-1**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(receptor-binding activity; probing the steric tolerance of the insect hypertrehalosemic hormone receptor to develop an effective photoaffinity probe)

L3 ANSWER 44 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:603095 HCAPLUS
DOCUMENT NUMBER: 121:203095
TITLE: Hemagglutinating and chemotactic properties of synthetic peptide segments of fimbrial protein from Porphyromonas gingivalis
AUTHOR(S): Ogawa, T.; Hamada, S.
CORPORATE SOURCE: Fac. Dent., Osaka Univ., Suita, Japan
SOURCE: Infection and Immunity (1994), 62(8), 3305-10
CODEN: INFIBR; ISSN: 0019-9567
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Porphyromonas gingivalis 381 fimbriae, their synthetic peptide segments, and lipopolysaccharide (LPS) were examd. for hemagglutinating the migration-stimulating activities. P. gingivalis 381 fimbriae clearly

caused hemagglutination, and several oligopeptide segments such as FP381 (61-80), FP381 (171-185), and FP381 (302-321), agglutinated erythrocytes although less effectively than the native fimbriae. Furthermore, P. gingivalis 381 LPS but not Escherichia coli 055:B5 LPS definitely exhibited hemagglutination. P. gingivalis fimbriae as well as their synthetic peptides possessing hemagglutinating activity enhanced the chemotaxically induced migration of human peripheral blood monocytes. The results of the analyses using synthetic peptide FP381 (61-80), its related compds., and an analog suggested that the amino acid sequence XLTXXLTXXNXX within fimbrial protein mols. may play an important role structurally in the attachment of the protein to host cells such as erythrocytes and monocytes.

IT **138166-46-8**
RL: BIOL (Biological study)
(of fimbrial protein of Porphyromonas gingivalis, hemagglutination by)

L3 ANSWER 45 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:449901 HCAPLUS
DOCUMENT NUMBER: 119:49901
TITLE: Synthesis and conformational studies on peptides corresponding to a putative autophosphorylation site of abl TPK
AUTHOR(S): Ruzza, Paolo; Calderan, Andrea; Filippi, Bruno; Donella-Deana, Arianna; Pinna, Lorenzo A.; Borin, Gianfranco
CORPORATE SOURCE: Dep. Org. Chem., Univ. Padua, Padua, Italy
SOURCE: International Journal of Peptide & Protein Research (1993), 41(3), 291-9
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Octapeptide H-Gly-Asp-Thr-Tyr-Thr-Ala-His-Ala-OH, corresponding to the sequence of the main putative autophosphorylation site (Tyr515) of the transforming gene of Abelson murine leukemia virus (v-abl) which codes for a membrane-assocd. tyrosine-specific protein kinase (abl TPK), as well as some of its analogs modified in positions -2, -1, +1 and +3, were prepd. by classical soln. methods. Anal. of the v-abl gene has shown that both the fibroblast-transforming and tyrosine-protein kinase activities reside within a minimal region encoding . The synthetic peptides were tested as substrates for a protein of 43 kDa (p43v-abl), which represents the most active, isolated form of this enzyme. The kinetic data obtained indicate that the phosphorylation rates vary considerably, depending on the sequence of the peptide, as expected. As a rule, no significant incremental efficiency results from each substitution in the parent sequence. While the replacement of the two charged residues (Asp2 and His7) with neutral Ala is well tolerated, the substitution with amino acids bearing opposite charges is detrimental. The correlation between secondary structure of the synthetic octapeptides and their substrate recognition by p43v-abl was studied using CD and fluorescence spectroscopy. A comparison of the spectroscopic data with the kinetic parameters does not confirm a close relationship between the conformational properties of these peptides and their enzymic role.

IT **148693-03-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., conformation, and kinetics of phosphorylation of, as model for autophosphorylation site of leukemia virus tyrosine-specific protein kinase)

IT **148693-21-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., deblocking, and peptide coupling reactions of, in prepn. of autophosphorylation site model octapeptide)

L3 ANSWER 46 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1993:166893 HCAPLUS
DOCUMENT NUMBER: 118:166893
TITLE: Location of the epitope recognized by monoclonal antibody 63G on the primary structure of human respiratory syncytial virus G glycoprotein and the ability of synthetic peptides containing this epitope to induce neutralizing antibodies
AUTHOR(S): Garcia-Barreno, Blanca; Delgado, Teresa; Akerlind-Stopner, Britt; Norrby, Erling; Melero, Jose A.
CORPORATE SOURCE: Cent. Nac. Microbiol., Inst. Salud "Carlos III", Madrid, 28220, Spain
SOURCE: Journal of General Virology (1992), 73(10), 2625-30
CODEN: JGVIAY; ISSN: 0022-1317
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The location of the epitope recognized by monoclonal antibody (MAb) 63G on the primary structure of the human respiratory syncytial virus G glycoprotein was detd. by testing the reactivity of synthetic peptides with the MAb. The role of individual amino acids in this epitope was detd. by using a set of 13-mer peptides contg. single residue deletions. Residues 204-209 were essential for antibody binding. Several peptides, free or bound to keyhole limpet hemocyanin (KLH), were used to raise antisera in rabbits. The antipeptide antibodies reacted with the G protein in Western blots. However, only peptide G1-KLH (residues 187-200 bound to KLH) induced antibodies that reacted with the intact G protein and inhibited infectivity.
IT **146646-03-9**
RL: BIOL (Biological study)
(of G glycoproteins of human respiratory syncytial virus, monoclonal antibody recognition of and neutralizing antibodies induction by)

L3 ANSWER 47 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:585027 HCAPLUS
DOCUMENT NUMBER: 117:185027
TITLE: Synthetic analogs of the carboxyl-terminus of .beta.-thyrotropin: the importance of basic amino acids in receptor binding activity
AUTHOR(S): Leinung, Matthew C.; Bergert, Elizabeth R.; McCormick, Daniel J.; Morris, John C.
CORPORATE SOURCE: Dep. Biochem. Mol. Biol., Mayo Clin. Med. Sch., Rochester, MN, 55901, USA
SOURCE: Biochemistry (1992), 31(41), 10094-8
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Previously, using a synthetic peptide strategy, it was detd. that four distinct regions of human .beta.-TSH (.beta.TSH) were responsible for interaction of TSH and TSH receptor. The most potent of these four regions was the carboxyl-terminus of the subunit, represented by the peptide sequence .beta.101-112, which inhibited binding of radiolabeled .beta.TSH to receptor in radio receptor assay with an IC50 of approx. 100 .mu.M. In the current studies, the native amino acids in region .beta.101-112 were systemically substituted with alanine, and which residues within this span are important to the binding activity of TSH to its receptor were detd. Substitution of Lys101, Asn103, Tyr104, Cys105, Lys107 and Lys110 with alanine each caused a significant fall in activity as compared to the native sequence, whereas substitution at the remaining positions had little or no effect. Because three of these residues are pos. charged at physiol. pH, it was hypothesized that this charge may be important to the binding activity of the sequence. The charge characteristics of the region were modified by synthesizing two series of analogs in which the residues identified in the alanine substitution

studies were substituted with Arg, D-Lys, and D-Arg at each position. In addn., a series of analogs contg. basic residues, either added to or substituted for nonbasic residues in the sequence .beta.101-112, was synthesized. Substitution of Arg, D-Lys, and D-Arg for Lys101, Lys107, and Lys110 had little effect on activity; however, inclusion of addnl. basic residues in the .beta.101-112 sequence significantly enhanced the inhibitory activity of the region. Substitution of Ala, Ser, Lys or D-Lys for Cys105 resulted in marked redn. in activity. In order to det. if the activity of the region was sequence specific or, rather, due to the amino acid compn. of the region, the amino acid residues in an addnl. series of peptides were reversed and scrambled. The peptide with reversed sequence as well as four peptides with scrambled sequence possessed equal activity to the native peptide, suggesting that the amino acid compn. and the net charge of the region is more important than its specific sequence. Thus, a net pos. charge of region 101-112 of .beta.TSH is an important factor in the inhibitory activity of peptides representing this portion of the hormone. Enhancement of the charge, by addn. of basic residues, may increase the potency of interaction of TSH with its receptor. However, pos. charge is not all important, as removal of Cys105 results in marked loss in activity even though the resulting peptide may have overall significantly greater charge.

IT **143681-09-8**
RL: PROC (Process)
(as TSH .beta.-subunit C-terminal region analog, TSH receptor binding of, mol. structure in relation to)

L3 ANSWER 48 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:252016 HCAPLUS
DOCUMENT NUMBER: 116:252016
TITLE: Synthetic peptides analogous to the fimbrillin sequence inhibit adherence of Porphyromonas gingivalis
AUTHOR(S): Lee, Jin Yong; Sojar, Hakimuddin T.; Bedi, Gurrinder S.; Genco, Robert J.
CORPORATE SOURCE: Dep. Oral Biol., State Univ. New York, Buffalo, NY, 14214, USA
SOURCE: Infection and Immunity (1992), 60(4), 1662-70
CODEN: INFIBR; ISSN: 0019-9567
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Fimbriae are important in the adherence of many bacterial species to the surfaces they eventually colonize. Porphyromonas (Bacteroides) gingivalis fimbriae appear to mediate adherence to oral epithelial cells and the pellicle-coated tooth surface. The role and contribution of fimbriae in the binding of P. gingivalis to hydroxyapatite (HAP) coated with saliva as a model for the pellicle-coated tooth surface were investigated. 3H-labeled P. gingivalis or the radioiodinated purified fimbriae were incubated with 2 mg of HAP beads coated with whole human saliva (sHAP) and layered on 100% Percoll to sep. unbound from sHAP-bound components. The radioactivity of the washed beads was a measure of the bound components. The binding of P. gingivalis 2561 (381) cells and that of purified fimbriae were concn. dependent and saturable at approx. 108 cells and 40 .mu.g of fimbriae added, resp. The addn. of fimbriae inhibited binding of P. gingivalis to sHAP beads by 65%, while the 75-kDa protein, which is another major surface component of P. gingivalis 2561, did not show significant inhibition, suggesting that the fimbriae are important in adherence. Encapsulated and sparsely fimbriated P. gingivalis W50 did not bind to sHAP beads. On the basis of the predicted sequence of the fimbrillin, a structural subunit of fimbriae, a series of peptides was synthesized and used to localize the active fimbrillin domains involved in P. gingivalis adherence to sHAP beads. Peptides from the carboxyl-terminal one-third of the fimbrillin strongly inhibited P. gingivalis binding to sHAP beads. Active residues within the sequence of inhibitory peptide 226-245 (peptide contg. residues 226 to 245) and

peptide 293-306 were identified by using smaller fragments prepd. either by trypsin cleavage of the peptide 226-245 or by synthesis of smaller segments of peptide 293-306. Hemagglutinin activity, lectinlike binding, and ionic interaction did not seem to be involved in this binding since lysine, arginine, carbohydrates, and calcium ions failed to affect the binding of P. gingivalis. The observation that poly-L-lysine, bovine serum albumin, and defatted bovine serum albumin, even at high concns., only partially blocked the binding of P. gingivalis indicates that hydrophobic interactions are not the major forces involved in P. gingivalis binding to sHAP beads. Protease inhibitors such as EDTA, leupeptin, pepstatin, 1,10-phenanthroline, and phenylmethylsulfonyl fluoride did not interfere with the binding of P. gingivalis. However, the binding of P. gingivalis to trypsin- or chymotrypsin-pretreated sHAP beads was reduced. Overall, these results suggest that fimbrillin has domains primarily confined in the carboxyl-terminal region of the protein which are responsible for binding P. gingivalis to surface-bound salivary components through specific protein-protein interactions. Specific fimbrillin-mediated binding may be important in P. gingivalis attachment to oral surfaces coated with salivary components.

IT **141631-38-1 141631-39-2**
RL: BIOL (Biological study)
(synthetic fimbrillin analog, adherence of Porphyromonas gingivalis inhibition by)

L3 ANSWER 49 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:21468 HCAPLUS
DOCUMENT NUMBER: 116:21468
TITLE: Preparation of calcitonin analogs as hypocalcemic agents
INVENTOR(S): Basava, Channa; Hostetler, Karl Y.
PATENT ASSIGNEE(S): Vical, Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9107978	A1	19910613	WO 1990-US6352	19901031
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
US 5175146	A	19921229	US 1990-572674	19900824
CA 2069943	AA	19910606	CA 1990-2069943	19901031
AU 9067512	A1	19910626	AU 1990-67512	19901031
EP 504168	A1	19920923	EP 1990-917399	19901031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05504558	T2	19930715	JP 1991-500475	19901031

PRIORITY APPLN. INFO.: US 1989-446932 19891205
US 1990-572674 19900824
WO 1990-US6352 19901031

OTHER SOURCE(S): MARPAT 116:21468

AB Y-(R1-R2-A1-A2-A3-A4-Ser-Thr)mA7-xCT(8-32) [I; Y = a dicarboxylic acid residue; R1 = H, H(CH2)nO, H2N(CH2)nO, etc.; R2 = 1-amino-1-cyclopropylcarboxylic acid residue, etc.; A1, A7 = Cys, Thr, D-Thr, Tyr, etc.; A2 = Gly, Ala, Ser, bond; A3 = Asn, Ser, bond; A4 = Leu, bond; m = 1, 2; n = 1-22; xCT = amino acid sequence corresponding at least at residues 9-11, 13-15, 17, 18, 23-26, and 28-32 to murine, salmon, eel, avian, porcine, bovine, ovine, or human calcitonin; provisos apply] were prepd. by the solid phase method. E.g., [(Ser-Thr)2-Lys-7]-avian calcitonin (7-32) was prepd. by the solid phase method starting from methylbenzhydrylamine resin-bound BOC-Pro-NH2 using the appropriate

protected amino acids. This at 1 .mu.g/kg s.c. effected 2.09 mg Ca decrease per dL blood in rats.

IT **138038-10-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hypocalcemic)

L3 ANSWER 50 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:19422 HCAPLUS
DOCUMENT NUMBER: 116:19422
TITLE: Immunobiological activities of synthetic peptide segments of fimbrial protein from Porphyromonas gingivalis
AUTHOR(S): Ogawa, Tomohiko; Kusumoto, Yutaka; Uchida, Hiroshi; Nagashima, Shigeru; Ogo, Hideji; Hamada, Shigeyuki
CORPORATE SOURCE: Fac. Dent., Osaka Univ., Suita-Osaka, 565, Japan
SOURCE: Biochemical and Biophysical Research Communications (1991), 180(3), 1335-41
CODEN: BBRCA9; ISSN: 0006-291X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Several oligopeptide segments of fimbrial subunit protein (fimbrilin) of P. gingivalis strain 381 were synthesized and tested for immunobiol. activities. Peptides F3(31-50; amino acid residue nos. 31-50, based on the amino acid sequence of the fimbrilin proposed by Dickinson et al., (1988), F12(212-231) and F17(312-331) were found to be immunodominant epitopes of this fimbrial protein as revealed by ELISA. Furthermore, peptides F5(71-90) and F17(312-331) could agglutinate rabbit erythrocytes, and were mitogenic for BALB/c spleen cells but not thymocytes. These peptides enhanced the no. of fimbria-specific antibody-secreting cells in BALB/c spleen cell cultures, and induced cytokines such as tumor necrosis factor-.alpha. and interleukin-6 prodn. in human monocyte/macrophage cultures. Evidently these defined peptide segments are responsible for the immunostimulating portions within the fimbrial protein mol.

IT **138166-46-8**
RL: BIOL (Biological study)
(of fimbrial protein, of Porphyromonas gingivalis, immunobiol. of)

L3 ANSWER 51 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1979:611830 HCAPLUS
DOCUMENT NUMBER: 91:211830
TITLE: Somatostatin analogs
INVENTOR(S): Strachan, Robert G.; Paleveda, William J.; Veber, Daniel F.; Holly, Frederick W.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4162248	A	19790724	US 1978-894266	19780407
PRIORITY APPLN. INFO.:			US 1976-732692	19761014
			US 1977-781610	19770328

AB Somatostatin analogs cyclo(Xj-X1k-X2l-Phe-Phe-X3-Lys-Thr-Phe-Thr-X4m) [I; X = HN(CH2)nCO (n = 0-4); X1 = Lys, Lys(INOC) (INOC = isonicotinyloxycarbonyl); X2 = Asn, Ala, HNCHEtCO; X3 = Trp, D-Trp; X4 = Ser, Gly; j, k, l, and m = 0, 1 except that j-m .noteq. all 0 and all 1; the peptide backbone ring must contain 24-33 atoms] and their pharmaceutically acceptable salts, which inhibit the release of growth hormone, insulin, glucagon, and gastric secretions, were prepd. by

solid-phase methods. Thus, R-D-Trp-Lys(INOC)-Thr(CH2Ph)-Phe-Thr(CH2Ph)-Asn-Phe-Phe-O-resin [II, R = Me3CO2C (BOC)] was prepd. by stepwise solid-phase couplings, BOC-deblocked by CF3CO2H to give II (R = H), and then resin-cleaved by H2NNH2 to give H-D-Trp-Lys(INOC)-Thr(CH2Ph)-Phe-Thr(CH2Ph)-Asn-Phe-Phe-NHNH2 (III). III was converted to the azide, which was cyclized to give cyclo[Asn-Phe-Phe-D-Trp-Lys(INOC)-Thr(CH2Ph)-Phe-Thr(CH2Ph)], which was deblocked by HF to give cyclo[Asn-Phe-Phe-D-Trp-Lys(INOC)-Thr-Phe-Thr], which was reduced with Zn/HOAc to give cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr). I can be used to treat acromegaly, gastric ulcers, and diabetes (no data).

IT **71645-27-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

=>
=>

=> fil caold
FILE 'CAOLD' ENTERED AT 14:53:26 ON 07 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=>
=> s l2
L4 0 L2

=>
=>

=> fil reg
FILE 'REGISTRY' ENTERED AT 14:53:39 ON 07 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 OCT 2003 HIGHEST RN 599148-37-5
DICTIONARY FILE UPDATES: 5 OCT 2003 HIGHEST RN 599148-37-5

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

finger-contg. protein 56 (ZFP56), which is a novel member of Kruppel protein family. The ZFP56 shares sequence homol. with human zinc finger-contg. protein 131 (ZFP131). The invention also relates to constructs and methods to express the cloned gene for the prepn. of its protein and antibodies using E.coli cells or eukaryotic cells, and diagnostic and therapeutic uses for ZFP56 related diseases.

IT **337966-36-6**
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of a novel human zinc finger-contg. protein 56 (ZFP56) and diagnostic and therapeutic uses thereof)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:488806 HCAPLUS
DOCUMENT NUMBER: 133:347529
TITLE: Mathematical modeling of insect neuropeptide potencies. Are quantitatively predictive models possible?
AUTHOR(S): Lee, M. J.; de Jong, S.; Gade, G.; Poulos, C.; Goldsworthy, G. J.
CORPORATE SOURCE: Biotechnology, Unilever Research Vlaardingen, Vlaardingen, 3133 AT, Neth.
SOURCE: Insect Biochemistry and Molecular Biology (2000), 30(10), 899-907
CODEN: IBMBES; ISSN: 0965-1748
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The potencies of natural adipokinetic hormones and synthetic variants have been detd. in Locusta migratoria using the lipid mobilization assay in vivo, and/or the acetate uptake assay in vitro. These data are combinations of previously published and unpublished data (a total of sixty-nine analogs), and form data sets for the construction of math. models of the hormone potencies. The sequence variations of amino acids in both natural and artificial adipokinetic hormone analogs were described using continuous descriptor scales z1', z2', and z3', each previously published scale being derived from various properties of the amino acids. By means of these z'-scales and partial least squares regression we attempted to model the potencies in Locusta migratoria of adipokinetic hormones in the two assays. Correlations (r2 values) between predicted and actual potencies of the different peptides were up to 0.73. We discuss the potential of the partial least squares method for formulating quant. relationships between different hormone structures and their potencies, and describe how the procedure might be used in structure-activity prediction with the construction of an optimized peptide data set.

IT **304868-61-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(math. models for QSAR of adipokinetic hormone analogs in Locusta migratoria)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 33 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:161423 HCAPLUS
DOCUMENT NUMBER: 132:204851
TITLE: Human ubiquitin ligases substrate-targeting subunits and their cDNA sequences and uses as therapeutic targets
INVENTOR(S): Chiaur, Dah Shiarn; Pagano, Michele; Latres, Esther

PATENT ASSIGNEE(S): New York University, USA
SOURCE: PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012679	A1	20000309	WO 1999-US19560	19990827
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341064	AA	20000309	CA 1999-2341064	19990827
AU 9955869	A1	20000321	AU 1999-55869	19990827
EP 1108008	A1	20010620	EP 1999-942510	19990827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003512008	T2	20030402	JP 2000-567666	19990827

PRIORITY APPLN. INFO.:

US 1998-98355P	P	19980828
US 1999-118568P	P	19990203
US 1999-124449P	P	19990315
US 1998-118568P	P	19990203
US 1998-124449P	P	19990315
WO 1999-US19560	W	19990827

AB The present invention relates to the discovery, identification, and characterization of human cDNA sequences that encode 26 novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleic acids encoding the novel substrate-targeting subunits of ubiquitin ligases, transgenic mice, knock-out mice, host cell expression systems, and proteins encoded by the nucleic acids of the present invention. The ubiquitin ligase subunits (FBPs) each contain an F box motif through which they interact with the other components of the ubiquitin ligase complex. In addn., some of these FBPs contain WD-40 domains and LRRs (which appear to be involved in their interaction with substrates), while other FBPs contain potential potential protein-protein interaction modules not yet identified in FBPs, such as leucine zippers, ring fingers, helix-loop-helix motifs, proline-rich motifs, and SH2 domains. The invention is also based, in part, on the discovery and identification of FBP-specific substrates p27 and .beta.-catenin and on methods to identify novel FBP substrates. Some of the genes encoding the novel F box proteins were also mapped to chromosome sites frequently altered in various malignant disorders. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small mols., compds. or derivs. and analogs of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compns. designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.

IT **260388-05-4**
RL: PRP (Properties)
(unclaimed sequence; human ubiquitin ligases substrate-targeting subunits and their cDNA sequences and uses as therapeutic targets)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 34 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:734986 HCAPLUS
DOCUMENT NUMBER: 130:10630
TITLE: Factor VIIa inhibitors from Kunitz-domain proteins
INVENTOR(S): Dennis, Mark S.; Lazarus, Robert A.
PATENT ASSIGNEE(S): Genentech Inc., USA
SOURCE: U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 206,310.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5834244	A	19981110	US 1995-398010	19950303
US 5795954	A	19980818	US 1994-206310	19940304
CA 2184058	AA	19950908	CA 1995-2184058	19950303

PRIORITY APPLN. INFO.: US 1994-206310 19940304
OTHER SOURCE(S): MARPAT 130:10630
AB A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical compn. for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.
IT **171281-94-0**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(factor VIIa inhibitors from Kunitz-domain proteins)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:508908 HCAPLUS
DOCUMENT NUMBER: 129:156937
TITLE: Use of Kunitz type plasma kallikrein inhibitors
INVENTOR(S): Dennis, Mark S.; Lazarus, Robert A.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: U.S., 41 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5786328	A	19980728	US 1995-463432	19950605

PRIORITY APPLN. INFO.: US 1995-463432 19950605
OTHER SOURCE(S): MARPAT 129:156937
AB Potent and specific serine protease inhibitors are provided that are capable of inhibiting plasma kallikrein. The inhibitors are provided in pharmaceutical compns. for the treatment of diseases and disorders where inhibition of plasma kallikrein in indicated.
IT **185557-76-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of Kunitz type plasma kallikrein inhibitors)
REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 36 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:163759 HCAPLUS
DOCUMENT NUMBER: 128:228247
TITLE: Tumor-associated proteins for development of immunoassays for detecting cervical cancer
INVENTOR(S): Keesee, Susan K.; Obar, Robert; Wu, Ying-Jye
PATENT ASSIGNEE(S): Matritech, Inc., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9809170	A2	19980305	WO 1997-US14526	19970819
WO 9809170	A3	19980423		
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5858683	A	19990112	US 1996-705660	19960830
AU 9740732	A1	19980319	AU 1997-40732	19970819
EP 923740	A2	19990623	EP 1997-938400	19970819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001500609	T2	20010116	JP 1998-511706	19970819
US 6027905	A	20000222	US 1997-989045	19971211
US 2003157482	A1	20030821	US 1999-315355	19990517

PRIORITY APPLN. INFO.: US 1996-705660 A 19960830
WO 1997-US14526 W 19970819
US 1997-989045 A3 19971211

AB The invention provides a wide range of methods and compns. for detecting and treating cervical cancer in an individual. Specifically, the invention provides target cervical cancer-assocd. proteins, which permit a rapid detection, preferably before metastases occur, of cervical cancer. The target cervical cancer-assocd. protein, may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of cervical cancer in an individual. In addn., the invention provides methods utilizing the cervical cancer-assocd. proteins either as targets for treating cervical cancer or as indicators for monitoring of the efficacy of such a treatment.

IT **204440-33-5**
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; tumor-assocd. proteins for development of immunoassays for detecting cervical cancer)

L3 ANSWER 37 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:476303 HCAPLUS
DOCUMENT NUMBER: 127:104342
TITLE: Fusion proteins of a tissue factor and a Kunitz inhibitor for inhibition of factor VIIa and the extrinsic pathway
INVENTOR(S): Kelley, Robert F.; Lazarus, Robert A.; Lee, Geoffrey F.
PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9720939	A1	19970612	WO 1996-US18756	19961122
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5736364	A	19980407	US 1995-566800	19951204
AU 9710234	A1	19970627	AU 1997-10234	19961122
EP 866870	A1	19980930	EP 1996-940592	19961122
EP 866870	B1	20030312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000503528	T2	20000328	JP 1997-521312	19961122
AT 234359	E	20030315	AT 1996-940592	19961122
US 5874407	A	19990223	US 1997-932589	19970917

PRIORITY APPLN. INFO.: US 1995-566459 A 19951201
US 1995-566800 A 19951204
WO 1996-US18756 W 19961122

AB Fusion proteins of Kunitz proteinase inhibitors and tissue factor that are useful as inhibitors of factor VII activation and of factor VIIa-dependent processes in the extrinsic pathway of blood coagulation are described for therapeutic use. Inhibitor domains from a broad array of Kunitz inhibitors can be used. A series of fusion proteins of tissue factor and Kunitz domains were prepd. by expression of the cloned gene in Escherichia coli. The proteins retained the structural integrity of the tissue factor domain, as shown by monoclonal antibody binding, and trypsin inhibition activity. The fusion proteins tested also inhibited factor VIIa-dependent activation of factor IX and several significantly prolonged clotting in an activated partial thromboplastin time assay.

IT **171281-94-0D**, fusion with factor VII
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fusion proteins of tissue factor and Kunitz inhibitor for inhibition of factor VIIa and extrinsic pathway)

L3 ANSWER 38 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:223138 HCAPLUS
DOCUMENT NUMBER: 126:250187
TITLE: Antagonistic effect of synthetic peptides corresponding to the binding regions within fimbrial subunit protein from Porphyromonas gingivalis to human gingival fibroblasts
AUTHOR(S): Ogawa, Tomohiko; Ogo, Hideji; Kinoshita, Akihiro
CORPORATE SOURCE: Department of Oral Microbiology, Osaka University Faculty of Dentistry, Osaka, 565, Japan
SOURCE: Vaccine (1997), 15(2), 230-236
CODEN: VACCDE; ISSN: 0264-410X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Specific binding region within fimbrial subunit protein (fimbrilin) from Porphyromonas gingivalis strain 381 was studied in cultured human gingival fibroblasts. Fluorescent micrographs visualized FITC-labeled fimbriae of P. gingivalis specifically bound to normal human fibroblast cell line (Gin-1) along the cell surface. Flow cytometric anal. also revealed the binding of FITC-labeled fimbriae to Gin-1 cells. Synthetic peptides composed of residues 1-20 (AFGVGDDESKVAKLTVMVYN) of the fimbrilin from P. gingivalis, FP381 (1-20), FP381 (69-80; ALTTELTAENQE) and FP381 (171-181; DA-NYLTGSLTT) definitely inhibited P. gingivalis fimbria-binding to Gin-1 cells by ELISA. Furthermore, based on the Scatchard plot anal. of the binding of 125I-labeled P. gingivalis fimbriae to Gin-1 cells, the apparent dissocn. const. (Kd) was calcd. as 15.9 pM, and the no. of binding sites (Rt) was estd. as 150 sites/cell. Binding studies of 125I-labeled FP381 (171-181) also revealed the presence of a non-interacting, single class of affinity binding sites: the apparent Kd and Rt were 29.2 nM and 18440 sites/cell on Gin-1 cells, resp. These results demonstrate that specific binding regions on P. gingivalis fimbriae to human gingival fibroblasts are present, and certain corresponding peptides clearly inhibited the binding of P. gingivalis fimbriae to human gingival fibroblasts.

IT **138166-46-8P**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(antagonistic effect of synthetic peptides corresponding to the binding regions within fimbrial subunit protein from Porphyromonas gingivalis to human gingival fibroblasts)

L3 ANSWER 39 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:72395 HCAPLUS
DOCUMENT NUMBER: 126:84615
TITLE: Kunitz-type plasma kallikrein inhibitors comprising non-native protein domains, pharmaceutical uses, and expression vectors
INVENTOR(S): Dennis, Mark S.; Lazarus, Robert A.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639519	A1	19961212	WO 1996-US9059	19960604
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5780265	A	19980714	US 1995-463155	19950605
CA 2220130	AA	19961212	CA 1996-2220130	19960604
AU 9660482	A1	19961224	AU 1996-60482	19960604
ZA 9604608	A	19971204	ZA 1996-4608	19960604
EP 832232	A1	19980401	EP 1996-918158	19960604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11511963	T2	19991019	JP 1996-501470	19960604

PRIORITY APPLN. INFO.: US 1995-463155 A 19950605
WO 1996-US9059 W 19960604
OTHER SOURCE(S): MARPAT 126:84615

AB Potent and specific serine protease inhibitors are provided that are capable of inhibiting plasma kallikrein. The inhibitors comprise a non-native Kunitz type serine protease inhibitor domain. The inhibitors are provided in pharmaceutical compns. for the treatment of diseases and disorders where inhibition of plasma kallikrein is indicated. Expression vectors are also included.

IT **185557-76-0DP**, peptide derivs.
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Kunitz-type plasma kallikrein inhibitors comprising non-native protein domains, pharmaceutical uses, and expression vectors)

L3 ANSWER 40 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:467371 HCAPLUS
DOCUMENT NUMBER: 125:151136
TITLE: Fimbrial polypeptides useful in the prevention of periodontitis
INVENTOR(S): Evans, Richard T.; Bedi, Gurrinder S.; Genco, Robert J.; Sojar, Hakimuddin T.
PATENT ASSIGNEE(S): State University of New York, USA
SOURCE: U.S., 23 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5536497	A	19960716	US 1992-994277	19921221

PRIORITY APPLN. INFO.: US 1992-994277 19921221

AB Polypeptides related to fimbriae of Porphyromonas gingivalis are described and claimed which exhibit inhibition of bacterial adhesion to saliva-coated surfaces. The polypeptides are selected from the group consisting of fimbriae, fimbrillin, and fimbrial-related. peptides derived therefrom. The polypeptides are used as active ingredients in various oral formulations designed to prevent adhesion of P. gingivalis to host mucosal surfaces and thus interfering with the development of periodontitis. The polypeptides are also used in subunit vaccine formulations for use against pathogenic, fimbriated P. gingivalis in the prophylactic treatment of periodontitis. Use of the polypeptides for inducing protective immunity in serum and gingival crevicular fluid may prevent primary infection with P. gingivalis as well as the spread of the organism between intraoral reservoirs.

IT **141631-38-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fimbrial polypeptides useful in the prevention of periodontitis)

L3 ANSWER 41 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:975430 HCAPLUS
DOCUMENT NUMBER: 124:781
TITLE: Kunitz domain inhibitor proteins derived from Alzheimer's amyloid .beta.-protein precursor inhibitor
INVENTOR(S): Dennis, Mark S.; Lazarus, Robert A.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9523860	A2	19950908	WO 1995-US2637	19950303
WO 9523860	A3	19950928		
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5795954	A	19980818	US 1994-206310	19940304
CA 2184058	AA	19950908	CA 1995-2184058	19950303
EP 748380	A1	19961218	EP 1995-913532	19950303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509838	T2	19971007	JP 1995-523045	19950303

PRIORITY APPLN. INFO.: US 1994-206310 19940304
WO 1995-US2637 19950303

AB A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin derived from Alzheimer's Amyloid beta-Protein Precursor Inhibitor (APPI) is provided. The inhibitor is provided in a pharmaceutical compn. for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.

IT **171281-94-0**
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(*Kunitz domain inhibitor proteins derived from Alzheimer's amyloid .beta.-protein precursor inhibitor*)

L3 ANSWER 42 OF 51 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:260464 HCAPLUS
DOCUMENT NUMBER: 122:53472
TITLE: The potential protective immune responses to synthetic peptides containing conserved epitopes of Porphyromonas gingivalis fimbrial protein
AUTHOR(S): Ogawa, T.
CORPORATE SOURCE: Faculty of Dentistry, Osaka University, Suita-Osaka, 565, Japan
SOURCE: Journal of Medical Microbiology (1994), 41(5), 349-58
CODEN: JMMIAV; ISSN: 0022-2615
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The immunodominant and T-cell epitopes within the fimbrial subunit protein (fimbrillin) of P. gingivalis strain 381 were analyzed by multi-pin peptide synthesis technol. Six regions with immunodominant epitopes within a sequence of 337 amino acids that reacted with the serum of patients with adult periodontitis were detected. T cells from mice immunized with P. gingivalis fimbriae exhibited proliferative responses to P. gingivalis fimbriae or to six 10-mer synthetic peptides from the amino acid sequence of the fimbrillin. Three synthetic peptides that contained the regions responsible for the immunodominant epitopes as well as those which coincided with a T-cell epitope of P. gingivalis fimbrial mols.: FP381(142-161), FP381(202-221), and FP381(216-243), were selected and synthesized. When guinea pigs were immunized with fimbriae or one of the 3 synthetic peptide segments and an adjuvant in Freund's incomplete adjuvant, enhanced prodn. of the antigen-specific IgG antibodies was induced in the serum of the animals. Furthermore, of the 3 synthetic peptides tested, FP381(202-221) produced the greatest protective immune response in guinea pigs infected with P. gingivalis and this was more effective than the native fimbrial protein.

IT **159928-16-2**
RL: PRP (Properties)
(*in epitope mapping on Porphyromonas gingivalis fimbrial protein fimbrillin*)

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d .seq l2 tot

L2 ANSWER 1 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 549494-95-3 REGISTRY
CN L-Cysteine, L-cysteinyl-L-cysteinyl-L-phenylalanyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-lysyl-L-isoleucyl-L-seryl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-lysyl-L-seryl-L-tyrosyl-L-valyl-L-isoleucyl-L-threonyl-L-threonyl-L-seryl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 21: PN: WO03051921 FIGURE: 9 unclaimed sequence
SQL **25**
SQL **25**

SEQ 1 CCFTFSSKKI SLQRLKSYVI TTSRC
=====
HITS AT: 4-8

REFERENCE 1: 139:67789

L2 ANSWER 2 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 521939-37-7 REGISTRY
CN L-Lysine, L-leucyl-L-isoleucyl-L-cysteinyl-L-.alpha.-glutamyl-L-alanyl-L-threonyl-L-asparaginyl-L-phenylalanyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 123: PN: WO03038444 SEQID: 236 unclaimed sequence
SQL **11**
SQL **11**

SEQ 1 LICEATNFSP K
==== =
HITS AT: 7-11

REFERENCE 1: 138:362621

L2 ANSWER 3 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 494863-53-5 REGISTRY
CN L-Lysine, L-.alpha.-glutamyl-L-.alpha.-glutamylglycyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 20: PN: WO03010186 SEQID: 20 claimed protein
SQL **8**
SQL **8**

SEQ 1 EEGNYTPK
=====
HITS AT: 4-8

REFERENCE 1: 138:149946

L2 ANSWER 4 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 474899-11-1 REGISTRY
CN L-Serine, L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)
SQL **9**
SQL **9**

SEQ 1 VPYTFSSKS
=====
HITS AT: 4-8

REFERENCE 1: 137:380984

REFERENCE 2: 137:380982

L2 ANSWER 5 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 474842-20-1 REGISTRY
CN L-Asparagine, L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl- (9CI) (CA INDEX NAME)
SQL **9**
SQL **9**

SEQ 1 TFSSKSPGN
=====
HITS AT: 1-5

REFERENCE 1: 137:380980

L2 ANSWER 6 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473791-54-7 REGISTRY
CN L-Asparagine, L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl- (9CI) (CA INDEX NAME)
SQL **10**
SQL **10**

SEQ 1 YTFSSKSPGN
=====
HITS AT: 2-6

REFERENCE 1: 137:321378

L2 ANSWER 7 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473790-80-6 REGISTRY
CN L-Lysine, L-glutaminyl-L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)
SQL **10**
SQL **10**

SEQ 1 QQVPYTFSSK
=====
HITS AT: 6-10

REFERENCE 1: 137:380979

REFERENCE 2: 137:380977

REFERENCE 3: 137:321378

L2 ANSWER 8 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473469-67-9 REGISTRY
CN L-Serine, L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl-L-asparaginylglycyl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 QVPYTFSSKS PGNGS
=====
HITS AT: 5-9

REFERENCE 1: 137:321376

L2 ANSWER 9 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473469-46-4 REGISTRY
CN L-Alanine, L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl-L-asparaginylglycyl-L-seryl-L-leucyl-L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 TFSSKSPGNG SLREA
======
HITS AT: 1-5

REFERENCE 1: 137:321376

L2 ANSWER 10 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473469-21-5 REGISTRY
CN L-Proline, L-tyrosyl-L-leucyl-L-.alpha.-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 YLDQQVPYTF SSKSP
== ===
HITS AT: 9-13

REFERENCE 1: 137:321376

L2 ANSWER 11 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473469-07-7 REGISTRY
CN Glycine, L-glutaminyl-L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 QQVPYTFSSK SPGNG
=====
HITS AT: 6-10

REFERENCE 1: 137:321376

L2 ANSWER 12 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473469-06-6 REGISTRY
CN L-Serine, glycyl-L-tyrosyl-L-leucyl-L-.alpha.-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 GYLDQQVPYT FSSKS
= ====
HITS AT: 10-14

REFERENCE 1: 137:321376

L2 ANSWER 13 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473468-80-3 REGISTRY
CN L-Arginine, L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl-L-asparaginylglycyl-L-seryl-L-leucyl- (9CI)

(CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 PYTFSSKSPG NGSLR
=====
HITS AT: 3-7

REFERENCE 1: 137:321376

L2 ANSWER 14 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473468-36-9 REGISTRY
CN L-Glutamic acid, L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl-L-asparaginylglycyl-L-seryl-L-leucyl-L-arginyl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 YTFSSKSPGN GSLRE
=====
HITS AT: 2-6

REFERENCE 1: 137:321376

L2 ANSWER 15 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473468-22-3 REGISTRY
CN L-Asparagine, L-.alpha.-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolylglycyl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 DQQVPYTFSS KSPGN
==== =
HITS AT: 7-11

REFERENCE 1: 137:321376

L2 ANSWER 16 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473468-12-1 REGISTRY
CN L-Lysine, L-alanylglycyl-L-tyrosyl-L-leucyl-L-.alpha.-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)
SQL **15**
SQL **15**

SEQ 1 AGYLDQQVPY TFSSK
=====
HITS AT: 11-15

REFERENCE 1: 137:321376

L2 ANSWER 17 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 473328-98-2 REGISTRY
CN L-Lysine, L-glutaminyl-L-valyl-L-prolyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)
SQL **9**
SQL **9**

SEQ 1 QVPYTFSSK
=====
HITS AT: 5-9

REFERENCE 1: 137:380978

REFERENCE 2: 137:380976

REFERENCE 3: 137:334071

L2 ANSWER 18 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 460039-30-9 REGISTRY
CN L-Valine, L-.alpha.-glutamyl-L-isoleucyl-L-tryptophyl-L-threonyl-L-phenylalanyl-L-seryl-L-threonyl-L-lysyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: WO02072766 SEQID: 5 claimed sequence
SQL **9**
SQL **9**

SEQ 1 EIWTFSTKV
=====
HITS AT: 4-8

REFERENCE 1: 137:246529

L2 ANSWER 19 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 408305-90-8 REGISTRY
CN L-Glutamine, L-glutaminyl-L-seryl-L-lysyl-L-threonyl-L-phenylalanyl-L-threonyl-L-alanyl-L-lysyl-L-seryl-L-.alpha.-aspartyl-L-phenylalanyl-L-seryl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 27: PN: WO0226987 SEQID: 27 unclaimed sequence
SQL **13**
SQL **13**

SEQ 1 QSKTFTAKSD FSQ
=====
HITS AT: 4-8

REFERENCE 1: 136:290007

L2 ANSWER 20 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 387817-80-3 REGISTRY
CN L-Leucine, L-alanyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-threonyl-L-tyrosyl-L-seryl-L-seryl-L-lysyl-L-.alpha.-aspartyl-L-glutaminyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-leucyl-L-.alpha.-aspartyl-L-lysyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 399: PN: US20020115139 SEQID: 405 claimed protein
CN 403: PN: US20020052329 SEQID: 405 claimed sequence
CN 405: PN: US20030138438 SEQID: 405 unclaimed protein
CN 405: PN: WO0200174 SEQID: 405 unclaimed sequence
CN 406: PN: US20020147143 SEQID: 405 unclaimed sequence
CN 54: PN: US20030064947 SEQID: 405 claimed sequence
SQL **20**
SQL **20**

SEQ 1 AVVNVTYSSK DQARQALDKL
=====
HITS AT: 6-10

REFERENCE 1: 139:132437

REFERENCE 2: 138:302631

REFERENCE 3: 137:290681

REFERENCE 4: 137:196735

REFERENCE 5: 136:354185

REFERENCE 6: 136:101081

L2 ANSWER 21 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 375806-38-5 REGISTRY
CN L-Tryptophan, L-threonyl-L-tyrosyl-L-threonyl-L-prolyl-L-lysyl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2842: PN: WO0131019 PAGE: 660 claimed protein
CN 810: PN: WO0131019 PAGE: 365 claimed sequence
SQL 8
SQL 8

SEQ 1 TYTPKKSW
=====
HITS AT: 1-5

REFERENCE 1: 136:117375

REFERENCE 2: 136:4714

L2 ANSWER 22 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350581-18-9 REGISTRY
CN L-Threonine, L-alanyl-L-phenylalanyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-seryl-L-lysyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 77: PN: WO0149830 PAGE: 62 unclaimed sequence
SQL 10
SQL 10

SEQ 1 AFNYTSKNST
=====
HITS AT: 3-7

REFERENCE 1: 135:118780

L2 ANSWER 23 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350473-71-1 REGISTRY
CN L-Lysine, L-alanyl-L-phenylalanyl-L-phenylalanyl-L-.alpha.-aspartyl-L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 112: PN: WO0149834 SEQID: 283 unclaimed sequence
SQL 10
SQL 10

SEQ 1 AFFDKTYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 24 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350473-16-4 REGISTRY
CN L-Threonine, L-lysyl-L-threonyl-L-phenylalanyl-L-threonyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 40: PN: WO0149834 SEQID: 187 unclaimed sequence
SQL 10
SQL 10

```
SEQ      1 KTFTAKEAAT
             ======
HITS AT:   2-6

REFERENCE   1:  135:106297

L2   ANSWER 25 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   350473-13-1  REGISTRY
CN   L-Alanine, L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl-L-lysyl-L-
     .alpha.-glutamyl-L-alanyl-L-alanyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   37: PN: WO0149834 SEQID: 184 unclaimed sequence
SQL  10
SQL  10

SEQ      1 KTYTAKEAAA
             ======
HITS AT:   2-6

REFERENCE   1:  135:106297

L2   ANSWER 26 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   350473-12-0  REGISTRY
CN   L-Threonine, L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl-L-lysyl-L-
     alanyl-L-alanyl-L-alanyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   36: PN: WO0149834 SEQID: 183 unclaimed sequence
SQL  10
SQL  10

SEQ      1 KTYTAKAAAT
             ======
HITS AT:   2-6

REFERENCE   1:  135:106297

L2   ANSWER 27 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   350473-07-3  REGISTRY
CN   L-Threonine, L-alanyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl-L-lysyl-L-
     .alpha.-glutamyl-L-alanyl-L-alanyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   31: PN: WO0149834 SEQID: 178 unclaimed sequence
SQL  10
SQL  10

SEQ      1 ATYTAKEAAT
             =====
HITS AT:   2-6

REFERENCE   1:  135:106297

L2   ANSWER 28 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   350473-05-1  REGISTRY
CN   L-Lysine, L-seryl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-
     lysyl-L-threonyl-L-phenylalanyl-L-threonyl-L-alanyl- (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   28: PN: WO0149834 SEQID: 176 unclaimed sequence
SQL  10
SQL  10

SEQ      1 SEFDKTFTAK
                =====
```

HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 29 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350472-98-9 REGISTRY
CN L-Lysine, L-seryl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-alanyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 21: PN: WO0149834 SEQID: 169 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 SEFDATYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 30 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350472-97-8 REGISTRY
CN L-Lysine, L-seryl-L-.alpha.-glutamyl-L-phenylalanyl-L-alanyl-L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 20: PN: WO0149834 SEQID: 168 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 SEFAKTYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 31 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350472-96-7 REGISTRY
CN L-Lysine, L-seryl-L-.alpha.-glutamyl-L-alanyl-L-.alpha.-aspartyl-L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 19: PN: WO0149834 SEQID: 167 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 SEADKTYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 32 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350472-95-6 REGISTRY
CN L-Lysine, L-seryl-L-alanyl-L-phenylalanyl-L-.alpha.-aspartyl-L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 18: PN: WO0149834 SEQID: 166 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 SAFDKTYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 33 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350472-94-5 REGISTRY
CN L-Lysine, L-alanyl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 17: PN: WO0149834 SEQID: 165 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 AEFDKTYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 34 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350258-06-9 REGISTRY
CN L-Threonine, L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 126: PN: WO0149834 SEQID: 77 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 KTYTAKEAAT
=====
HITS AT: 2-6

REFERENCE 1: 135:106297

L2 ANSWER 35 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350258-05-8 REGISTRY
CN L-Lysine, L-seryl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 125: PN: WO0149834 SEQID: 65 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 SEFDKTYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 36 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350229-19-5 REGISTRY
CN L-Lysine, L-cysteinyl-L-isoleucyl-L-phenylalanyl-L-.alpha.-aspartyl-L-seryl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 37: PN: WO0149834 SEQID: 284 claimed sequence
SQL **10**
SQL **10**

SEQ 1 CIFDSTYTAK
=====
HITS AT: 6-10

REFERENCE 1: 135:106297

L2 ANSWER 37 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 345600-52-4 REGISTRY

CN L-Lysine, L-phenylalanyl-L-seryl-L-seryl-L-seryl-L-prolyl-L-threonyl-L-tyrosyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1470: PN: WO0142276 SEQID: 1487 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 FSSSPTYSPK
=====
HITS AT: 6-10

REFERENCE 1: 135:56043

L2 ANSWER 38 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 345600-50-2 REGISTRY
CN L-Asparagine, L-seryl-L-seryl-L-seryl-L-prolyl-L-threonyl-L-tyrosyl-L-seryl-L-prolyl-L-lysyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1468: PN: WO0142276 SEQID: 1485 unclaimed sequence
SQL **10**
SQL **10**

SEQ 1 SSSPTYSPKN
=====
HITS AT: 5-9

REFERENCE 1: 135:56043

L2 ANSWER 39 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 345315-58-4 REGISTRY
CN L-Serine, L-asparaginyl-L-phenylalanyl-L-threonyl-L-seryl-L-lysyl-L-tyrosyl-L-histidyl-L-methionyl-L-lysyl-L-valyl-L-leucyl-L-tyrosyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 221: PN: WO0148245 SEQID: 750 claimed protein
SQL **14**
SQL **14**

SEQ 1 NFTSKYHMKV LYLS
=====
HITS AT: 1-5

REFERENCE 1: 135:88016

L2 ANSWER 40 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 339523-85-2 REGISTRY
CN L-Valine, L-methionyl-L-prolyl-L-leucyl-L-threonyl-L-alanyl-L-leucyl-L-.alpha.-glutamyl-L-isoleucyl-L-lysyl-L-.alpha.-aspartyl-L-lysyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-phenylalanyl-L-arginylglycyl-L-tyrosyl-L-seryl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 138: PN: WO0132882 FIGURE: 1 claimed sequence
SQL **25**
SQL **25**

SEQ 1 MPLTALEIKD KTFSSKFRGY SEEEV
=====
HITS AT: 12-16

REFERENCE 1: 134:364015

L2 ANSWER 41 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN

RN 337966-36-6 REGISTRY
CN L-Leucine, L-methionyl-L-alanyl-L-phenylalanyl-L-arginyl-L-histidyl-L-leucyl-L-isoleucyl-L-.alpha.-glutamyl-L-phenylalanyl-L-threonyl-L-tyrosyl-L-threonyl-L-alanyl-L-lysyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 7: PN: WO0130827 SEQID: 7 unclaimed sequence
SQL **15**
SQL **15**

SEQ 1 MAFRHLIEFT YTAKL
= ====
HITS AT: 10-14

REFERENCE 1: 134:336710

L2 ANSWER 42 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 304868-61-9 REGISTRY
CN L-Threoninamide, 5-oxo-L-prolyl-L-leucyl-L-asparaginyl-L-phenylalanyl-L-threonyl-L-prolyl-L-lysyl-L-tryptophylglycyl- (9CI) (CA INDEX NAME)
NTE modified

type	------ location ------		description
terminal mod.	Thr-10	-	C-terminal amide
uncommon	Glp-1	-	-

SQL **10**
SQL **10**

SEQ 1 XLNFTPKWGT
=====
HITS AT: 3-7

REFERENCE 1: 133:347529

L2 ANSWER 43 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 260388-05-4 REGISTRY
CN L-Glutamine, L-cysteinyl-L-.alpha.-glutamyl-L-seryl-L-seryl-L-phenylalanyl-L-seryl-L-leucyl-L-asparaginyl-L-methionyl-L-asparaginyl-L-phenylalanyl-L-seryl-L-seryl-L-lysyl-L-arginyl-L-threonyl-L-lysyl-L-phenylalanyl-L-lysyl-L-isoleucyl-L-threonyl-L-threonyl-L-seryl-L-methionyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 83: PN: WO02055665 SEQID: 83 unclaimed sequence
CN 87: PN: WO0012679 SEQID: 83 unclaimed sequence
SQL **25**
SQL **25**

SEQ 1 CESSFSLNMN FSSKRTKFKI TTSMQ
= ====
HITS AT: 10-14

REFERENCE 1: 137:106028

REFERENCE 2: 132:204851

L2 ANSWER 44 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 204440-33-5 REGISTRY
CN L-Lysine, L-threonyl-L-tyrosyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)
SQL **5**
SQL **5**

SEQ 1 TYSAK

```
          =====
HITS AT:    1-5

REFERENCE   1:  128:228247

L2   ANSWER 45 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   185557-76-0  REGISTRY
CN   Glycine, L-tyrosyl-L-serylglycyl-L-cysteinylglycylglycyl-L-asparaginyl-L-
     .alpha.-glutamyl-L-asparaginyl-L-asparaginyl-L-phenylalanyl-L-threonyl-L-
     seryl-L-lysyl-L-glutaminyl-L-.alpha.-glutamyl-L-cysteinyl-L-leucyl-L-
     arginyl-L-alanyl-L-cysteinyl-L-lysyl-L-lysyl- (9CI)  (CA INDEX NAME)
SQL  24
SQL  24

SEQ      1 YSGCGGNENN FTSKQECLRA CKKG
                   = ====
HITS AT:    10-14

REFERENCE   1:  129:156937

REFERENCE   2:  126:84615

L2   ANSWER 46 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   171281-94-0  REGISTRY
CN   Glycine, glycyl-L-asparaginyl-L-.alpha.-glutamyl-L-asparaginyl-L-
     asparaginyl-L-phenylalanyl-L-threonyl-L-seryl-L-lysyl-L-glutaminyl-L-
     .alpha.-glutamyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-cysteinyl-L-
     lysyl-L-lysyl- (9CI)  (CA INDEX NAME)
SQL  19
SQL  19

SEQ      1 GNENNFTSKQ ECLRACKKG
               =====
HITS AT:    5-9

REFERENCE   1:  130:10630

REFERENCE   2:  127:104342

REFERENCE   3:  124:781

L2   ANSWER 47 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   161510-72-1  REGISTRY
CN   Hypertrehalosemic hormone (Blabera discoidalis), 7-[N6-[N-[N-(N-acetyl-L-
     seryl)-L-seryl]-L-seryl]-D-lysine]- (9CI)  (CA INDEX NAME)
NTE  multichain
     modified
-------------------------------------------------------------------------
 type            ------ location ------         description
-------------------------------------------------------------------------
terminal mod.    Thr-10          -          C-terminal amide
terminal mod.    Ser-1'          -          N-acetyl
bridge           Lys-7       - Ser-3'       amide bridge
uncommon         Glp-1           -          -
stereo           Lys-7           -          D
-------------------------------------------------------------------------
SQL  13,10,3
SQL  13,10,3

SEQ      1 XVNFSPKWGT
             =====
HITS AT:    3-7
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 122:183539

L2 ANSWER 48 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 161389-55-5 REGISTRY
CN Hypertrehalosemic hormone (Blabera discoidalis), 7-[N6-[N-[N-(N-acetyl-L-seryl)-L-seryl]-L-seryl]-L-lysine]- (9CI) (CA INDEX NAME)
NTE multichain
modified

type	location		description
terminal mod.	Thr-10	-	C-terminal amide
terminal mod.	Ser-1'	-	N-acetyl
bridge	Lys-7	- Ser-3'	amide bridge
uncommon	Glp-1	-	-

SQL **13,10,3**
SQL **13,10,3**

SEQ 1 XVNFSPKWGT
=====
HITS AT: 3-7

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 122:183539

L2 ANSWER 49 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 161389-51-1 REGISTRY
CN Hypertrehalosemic hormone (Blabera discoidalis), 7-[N6-[3-[4-hydroxy-3-(iodo-125I)phenyl]-1-oxopropyl]-L-lysine]- (9CI) (CA INDEX NAME)
NTE modified

type	location		description
terminal mod.	Thr-10	-	C-terminal amide
uncommon	Glp-1	-	-
modification	Lys-7	-	undetermined modification

SQL **10**
SQL **10**

SEQ 1 XVNFSPKWGT
=====
HITS AT: 3-7

REFERENCE 1: 122:183539

L2 ANSWER 50 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 159928-16-2 REGISTRY
CN L-Glutamic acid, N-[N-[N2-[N2-[N2-[1-[N-[N-(N2-L-seryl-L-asparaginyl)-L-tyrosyl]-L-threonyl]-L-prolyl]-L-lysyl]-L-asparaginyl]-L-lysyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)
SQL **10**
SQL **10**

SEQ 1 SNYTPKNKIE
=====
HITS AT: 2-6

REFERENCE 1: 122:53472

L2 ANSWER 51 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 148693-21-4 REGISTRY
CN L-Alanine, N-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[O-(1,1-dimethylethyl)-N-[O-(1,1-dimethylethyl)-N-[O-(1,1-dimethylethyl)-N-[(phenylmethoxy)carbonyl]-L-threonyl]-L-tyrosyl]-L-threonyl]-L-alanyl]-L-lysyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
NTE modified

type	------ location ------		description
modification	Thr-1	-	(phenylmethoxy)carbonyl<Z>
modification	Thr-1	-	1,1-dimethylethyl<t-Bu>
modification	Tyr-2	-	1,1-dimethylethyl<t-Bu>
modification	Thr-3	-	1,1-dimethylethyl<t-Bu>
modification	Lys-5	-	(1,1-dimethylethoxy) carbonyl<Boc>

SQL **6**
SQL **6**

SEQ 1 TYTAKA
=====
HITS AT: 1-5

REFERENCE 1: 119:49901

L2 ANSWER 52 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 148693-03-2 REGISTRY
CN L-Alanine, N-[N2-[N-[N-[N-[N-(N2-glycyl-L-lysyl)-L-threonyl]-L-tyrosyl]-L-threonyl]-L-alanyl]-L-lysyl]- (9CI) (CA INDEX NAME)
SQL **8**
SQL **8**

SEQ 1 GKTYTAKA
======
HITS AT: 3-7

REFERENCE 1: 119:49901

L2 ANSWER 53 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 146646-03-9 REGISTRY
CN L-Lysine, N2-[N2-[N-[N-[N-[N-[1-[N2-[N2-[N-(1-L-lysyl-L-prolyl)-L-threonyl]-L-lysyl]-L-lysyl]-L-prolyl]-L-threonyl]-L-phenylalanyl]-L-threonyl]-L-threonyl]-L-lysyl]- (9CI) (CA INDEX NAME)
SQL **12**
SQL **12**

SEQ 1 KPTKKPTFTT KK
==== =
HITS AT: 7-11

REFERENCE 1: 118:166893

L2 ANSWER 54 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 143681-09-8 REGISTRY
CN L-Tyrosine, N-[N-[N2-[N2-[1-[N2-[N-[N-[N-[N2-(N-L-lysyl-L-threonyl)-L-asparaginyl]-L-tyrosyl]-L-seryl]-L-threonyl]-L-lysyl]-L-prolyl]-L-glutaminyl]-L-lysyl]-L-seryl]- (9CI) (CA INDEX NAME)
SQL **12**
SQL **12**

```
SEQ      1 KTNYSTKPQK SY
             ======
HITS AT:   3-7

REFERENCE   1:  117:185027

L2   ANSWER 55 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   141631-39-2  REGISTRY
CN   L-Lysine, L-tyrosyl-L-.alpha.-aspartyl-L-seryl-L-asparaginyl-L-tyrosyl-L-
     threonyl-L-prolyl-L-lysyl-L-asparaginyl-L-lysyl-L-isoleucyl-L-.alpha.-
     glutamyl-L-arginyl-L-asparaginyl-L-histidyl-L-lysyl-L-tyrosyl-L-.alpha.-
     aspartyl-L-isoleucyl- (9CI)  (CA INDEX NAME)
SQL  20
SQL  20

SEQ      1 YDSNYTPKNK IERNHKYDIK
             ======
HITS AT:   4-8

REFERENCE   1:  116:252016

L2   ANSWER 56 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   141631-38-1  REGISTRY
CN   L-Lysine, L-tyrosyl-L-prolyl-L-valyl-L-leucyl-L-valyl-L-asparaginyl-L-
     phenylalanyl-L-asparaginyl-L-seryl-L-asparaginyl-L-asparaginyl-L-tyrosyl-L-
     threonyl-L-tyrosyl-L-.alpha.-aspartyl-L-seryl-L-asparaginyl-L-tyrosyl-L-
     threonyl-L-prolyl- (9CI)  (CA INDEX NAME)
SQL  21
SQL  21

SEQ      1 YPVLVNFNSN NYTYDSNYTP K
                          ==== =
HITS AT:   17-21

REFERENCE   1:  125:151136

REFERENCE   2:  116:252016

L2   ANSWER 57 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   138166-46-8  REGISTRY
CN   L-Isoleucine, L-asparaginyl-L-tyrosyl-L-threonyl-L-prolyl-L-lysyl-L-
     asparaginyl-L-lysyl-L-isoleucyl-L-.alpha.-glutamyl-L-arginyl-L-asparaginyl-
     L-histidyl-L-lysyl-L-tyrosyl-L-.alpha.-aspartyl-L-isoleucyl-L-lysyl-L-
     leucyl-L-threonyl- (9CI)  (CA INDEX NAME)
SQL  20
SQL  20

SEQ      1 NYTPKNKIER NHKYDIKLTI
           =====
HITS AT:   1-5

REFERENCE   1:  126:250187

REFERENCE   2:  121:203095

REFERENCE   3:  116:19422

L2   ANSWER 58 OF 59  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   138038-10-5  REGISTRY
CN   Somatostatin (sheep reduced), 3-L-glutamic acid-14-L-lysine-, cyclic
     (3.fwdarw.14)-peptide (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1,4,7,10,13,16,19,22,25,28,31,37-Dodecaazacyclodotetracontane,
```

somatostatin deriv.
NTE

type	location		description
bridge	Glu-3	- Lys-14	lactam

SQL **14**
SQL **14**

SEQ 1 AGEKNFFWKT FTSK
= ====

HITS AT: 10-14

REFERENCE 1: 116:21468

L2 ANSWER 59 OF 59 REGISTRY COPYRIGHT 2003 ACS on STN
RN 71645-27-7 REGISTRY
CN Somatostatin (sheep reduced), 1-de-L-alanine-2-deglycine-3-de-L-cysteine-14-de-L-cysteine-, cyclic (13.fwdarw.4)-peptide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,4,7,10,13,16,19,22,25,28-Decaazacyclotriacontane, cyclic peptide deriv.
NTE cyclic
SQL **10**
SQL **10**

SEQ 1 NFFWKTFTSK
=====

HITS AT: 6-10

REFERENCE 1: 91:211830